<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="review-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Pharmaceutics</journal-id>
<journal-id journal-id-type="iso-abbrev">Pharmaceutics</journal-id>
<journal-id journal-id-type="publisher-id">pharmaceutics</journal-id>
<journal-title-group>
<journal-title>Pharmaceutics</journal-title>
</journal-title-group>
<issn pub-type="epub">1999-4923</issn>
<publisher>
<publisher-name>MDPI</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">31877761</article-id>
<article-id pub-id-type="pmc">7022469</article-id>
<article-id pub-id-type="doi">10.3390/pharmaceutics12010013</article-id>
<article-id pub-id-type="publisher-id">pharmaceutics-12-00013</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Review</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Pharmacogenomic Characterization in Bipolar Spectrum Disorders</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-6111-332X</contrib-id>
<name>
<surname>Fortinguerra</surname>
<given-names>Stefano</given-names>
</name>
<xref ref-type="aff" rid="af1-pharmaceutics-12-00013">1</xref>
<xref ref-type="aff" rid="af2-pharmaceutics-12-00013">2</xref>
</contrib>
<contrib contrib-type="author">
<contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-4716-7401</contrib-id>
<name>
<surname>Sorrenti</surname>
<given-names>Vincenzo</given-names>
</name>
<xref ref-type="aff" rid="af1-pharmaceutics-12-00013">1</xref>
<xref ref-type="aff" rid="af2-pharmaceutics-12-00013">2</xref>
<xref ref-type="aff" rid="af3-pharmaceutics-12-00013">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Giusti</surname>
<given-names>Pietro</given-names>
</name>
<xref ref-type="aff" rid="af2-pharmaceutics-12-00013">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Zusso</surname>
<given-names>Morena</given-names>
</name>
<xref ref-type="aff" rid="af2-pharmaceutics-12-00013">2</xref>
</contrib>
<contrib contrib-type="author">
<contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-9742-8991</contrib-id>
<name>
<surname>Buriani</surname>
<given-names>Alessandro</given-names>
</name>
<xref ref-type="aff" rid="af1-pharmaceutics-12-00013">1</xref>
<xref ref-type="aff" rid="af2-pharmaceutics-12-00013">2</xref>
<xref ref-type="corresp" rid="c1-pharmaceutics-12-00013">*</xref>
</contrib>
</contrib-group>
<aff id="af1-pharmaceutics-12-00013"><label>1</label>Maria Paola Belloni Center for Personalized Medicine, Data Medica Group (Synlab Limited), 35131 Padova, Italy; <email>stefano.fortinguerra@gmail.com</email> (S.F.); <email>vincenzosorrenti88@gmail.com</email> (V.S.)</aff>
<aff id="af2-pharmaceutics-12-00013"><label>2</label>Department of Pharmaceutical &amp; Pharmacological Sciences, University of Padova, 35131 Padova, Italy; <email>pietro.giusti@unipd.it</email> (P.G.); <email>morena.zusso@unipd.it</email> (M.Z.)</aff>
<aff id="af3-pharmaceutics-12-00013"><label>3</label>Bendessere™ Study Center, Solgar Italia Multinutrient S.p.A., 35131 Padova, Italy</aff>
<author-notes>
<corresp id="c1-pharmaceutics-12-00013"><label>*</label>Correspondence: <email>alessandro.buriani@gmail.com</email></corresp>
</author-notes>
<pub-date pub-type="epub">
<day>21</day>
<month>12</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="collection">
<month>1</month>
<year>2020</year>
</pub-date>
<volume>12</volume>
<issue>1</issue>
<elocation-id>13</elocation-id>
<history>
<date date-type="received">
<day>25</day>
<month>11</month>
<year>2019</year>
</date>
<date date-type="accepted">
<day>19</day>
<month>12</month>
<year>2019</year>
</date>
</history>
<permissions>
<copyright-statement>© 2019 by the authors.</copyright-statement>
<copyright-year>2019</copyright-year>
<license license-type="open-access">
<license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p>
</license>
</permissions>
<abstract>
<p>The holistic approach of personalized medicine, merging clinical and molecular characteristics to tailor the diagnostic and therapeutic path to each individual, is steadily spreading in clinical practice. Psychiatric disorders represent one of the most difficult diagnostic challenges, given their frequent mixed nature and intrinsic variability, as in bipolar disorders and depression. Patients misdiagnosed as depressed are often initially prescribed serotonergic antidepressants, a treatment that can exacerbate a previously unrecognized bipolar condition. Thanks to the use of the patient’s genomic profile, it is possible to recognize such risk and at the same time characterize specific genetic assets specifically associated with bipolar spectrum disorder, as well as with the individual response to the various therapeutic options. This provides the basis for molecular diagnosis and the definition of pharmacogenomic profiles, thus guiding therapeutic choices and allowing a safer and more effective use of psychotropic drugs. Here, we report the pharmacogenomics state of the art in bipolar disorders and suggest an algorithm for therapeutic regimen choice.</p>
</abstract>
<kwd-group>
<kwd>personalized medicine</kwd>
<kwd>bipolar disorder</kwd>
<kwd>antipsychotics</kwd>
<kwd>mood stabilizers</kwd>
<kwd>pharmacogenomics</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="sec1-pharmaceutics-12-00013" sec-type="intro">
<title>1. Introduction</title>
<p>One important and recent development in the area of mood disorders is the recognition that many patients initially suspected suffering from major depressive disorder suffer instead from a form of bipolar disorder (BD) [<xref ref-type="bibr" rid="B1-pharmaceutics-12-00013">1</xref>]. Symptomatic bipolar disorder patients are more frequently in the depressive condition rather than in hypomanic, manic, or mixed states [<xref ref-type="bibr" rid="B1-pharmaceutics-12-00013">1</xref>,<xref ref-type="bibr" rid="B2-pharmaceutics-12-00013">2</xref>,<xref ref-type="bibr" rid="B3-pharmaceutics-12-00013">3</xref>]. As a consequence, such patients can be improperly diagnosed as suffering from major depression and prescribed antidepressants instead of the lithium, atypical antipsychotics, or antiepileptic-type mood stabilizers normally used to treat bipolar spectrum disorders [<xref ref-type="bibr" rid="B2-pharmaceutics-12-00013">2</xref>,<xref ref-type="bibr" rid="B3-pharmaceutics-12-00013">3</xref>]. Up to 50% of the patients once identified as suffering from unipolar depression are now recognized to be suffering from a bipolar spectrum disorder [<xref ref-type="bibr" rid="B1-pharmaceutics-12-00013">1</xref>,<xref ref-type="bibr" rid="B2-pharmaceutics-12-00013">2</xref>,<xref ref-type="bibr" rid="B3-pharmaceutics-12-00013">3</xref>]. Antidepressant treatment of unrecognized bipolar patients can increase the cyclical nature of the mood disorder, mixed states, and conversion to hypomania and mania, and can also contribute to increase suicide in younger patients (&lt;25 years) [<xref ref-type="bibr" rid="B4-pharmaceutics-12-00013">4</xref>,<xref ref-type="bibr" rid="B5-pharmaceutics-12-00013">5</xref>,<xref ref-type="bibr" rid="B6-pharmaceutics-12-00013">6</xref>]. The World Mental Health Survey Initiative estimated a 12 month and total lifetime prevalence of 1.5% and 2.4%, respectively, for bipolar disorder I, bipolar disorder II, and subthreshold BD [<xref ref-type="bibr" rid="B5-pharmaceutics-12-00013">5</xref>,<xref ref-type="bibr" rid="B7-pharmaceutics-12-00013">7</xref>]. Most people are in their teens or early twenties when bipolar disorder symptoms begin. The diagnosis of one of the various bipolar spectrum disorders is very complex, especially during the early disease stages. It is estimated that only 20% of patients with one of the bipolar spectrum disorders associated with depressive episodes are diagnosed and treated correctly within one year, with a 5–10 years delay typical between the onset of symptoms and a BD diagnosis [<xref ref-type="bibr" rid="B8-pharmaceutics-12-00013">8</xref>]. The main problem in making a diagnosis is distinguishing between bipolar I and II disorders from unipolar depression, especially when patients do not have a clear history of episodes of hypomania or mania.</p>
<p>The physiopathology of manic–depressive illness (MDI), or bipolar disorders (BPD) has not been completely clarified. No objective biological marker is available to determine with precision the state of the disease. However, twins, family, and adoption studies have highlighted the association of genetic components with the condition. First-degree relatives of subjects suffering from bipolar disorders are about seven times more likely to develop the disease compared to the general population, while the heritability of bipolar I disorder has been recently estimated at 0.73 [<xref ref-type="bibr" rid="B9-pharmaceutics-12-00013">9</xref>]. Unipolar depression has been reported as the main misdiagnosis in patients affected by bipolar II disorder, as these patients do not have episodes of complete mania and have mainly depressive episodes, as opposed to hypomania [<xref ref-type="bibr" rid="B5-pharmaceutics-12-00013">5</xref>,<xref ref-type="bibr" rid="B7-pharmaceutics-12-00013">7</xref>]. According to the current diagnostic criteria, the distinction of a depressed patient between unipolar major depressive disorder and bipolar spectrum disorder is not simple and is solely entrusted to the clinic. As for other psychiatric conditions, biological parameters are lacking, although some molecular processes conceivably associated with bipolar conditions have been suggested, particularly CNS serotonergic pathway alterations [<xref ref-type="bibr" rid="B10-pharmaceutics-12-00013">10</xref>,<xref ref-type="bibr" rid="B11-pharmaceutics-12-00013">11</xref>]. <italic>HTR2A</italic> gene variations have been shown to affect serotonergic receptors, making them hypersensitive to serotonin. When triggered, these hypersensitive receptors could abnormally stimulate glutamatergic transmission <xref ref-type="fig" rid="pharmaceutics-12-00013-f001">Figure 1</xref> [<xref ref-type="bibr" rid="B12-pharmaceutics-12-00013">12</xref>,<xref ref-type="bibr" rid="B13-pharmaceutics-12-00013">13</xref>,<xref ref-type="bibr" rid="B14-pharmaceutics-12-00013">14</xref>], thus contributing to the induction of states of mania, agitation, and anxiety. Therefore, the use of serotonergic antidepressant therapies can lead to the degeneration of a bipolar disorder spectrum condition [<xref ref-type="bibr" rid="B2-pharmaceutics-12-00013">2</xref>,<xref ref-type="bibr" rid="B3-pharmaceutics-12-00013">3</xref>,<xref ref-type="bibr" rid="B7-pharmaceutics-12-00013">7</xref>]. Unrecognized bipolar patients carrying such genetic mutations have a higher risk of developing a full-blown bipolar condition when receiving serotonergic antidepressants, and should avoid the use of these drugs [<xref ref-type="bibr" rid="B15-pharmaceutics-12-00013">15</xref>].</p>
</sec>
<sec id="sec2-pharmaceutics-12-00013">
<title>2. Clinical Classification of Bipolar Spectrum Disorders</title>
<p>In general, bipolar disorders are mood disorders that, unlike depressive disorders, which are characterized by a single polarity, present manic or hypomanic episodes alternating with depressive episodes. They are generally divided into:<list list-type="bullet"><list-item><p>Bipolar I disorder (BDI): The characteristic that primarily characterizes this condition is alternating manic and depressive episodes. BDI is characterized by the appearance of one or more manic or mixed episodes (an overt phase of mania concomitant with a full-blown phase of depression) lasting at least a week. Patients with BDI can also experience episodes of major depression.</p></list-item><list-item><p>Bipolar II disorder (BDII): This condition is characterized by alternating depressive and hypomanic episodes. Type II bipolar disorder is a mental disease similar to type I bipolar disorder, with moods that cycle between highs and lows, although in BDII the “highs” never reach a complete mania state (hypomania). Subjects with bipolar II disorder suffer more frequently from depressive episodes than from hypomania. Given that hypomania can be confused with normal happiness or even normal functioning, bipolar II disorder can often be misdiagnosed as a unipolar depression.</p></list-item><list-item><p>Cyclothymia: This condition is characterized by the alternation of mild depressive episodes and mild hypomanic episodes. In cyclothymia, a person has hypomania (as in bipolar II disorder) that frequently alternates with short periods of mild depression. When present, however, the symptoms of depression do not last long.</p></list-item><list-item><p>Bipolar disorder not otherwise specified (more recently labeled “not elsewhere classified”): in bipolar disorder not elsewhere classified, people have symptoms of mania or hypomania that are too low or too brief to meet the diagnostic criteria for a syndrome.</p></list-item></list></p>
<p>Currently, the diagnostic characterization of bipolar spectrum disorders is based mostly on clinical observations, family history, and collection of personal information from those closest to the patient [<xref ref-type="bibr" rid="B2-pharmaceutics-12-00013">2</xref>]. Symptoms suggesting that depression may be part of a bipolar disorder include increased sleep duration, psychomotor retardation, hyperphagia, psychotic symptoms, anxiety, suicidal ideation, and emotional lability during episodes [<xref ref-type="bibr" rid="B2-pharmaceutics-12-00013">2</xref>,<xref ref-type="bibr" rid="B3-pharmaceutics-12-00013">3</xref>]. Other signs that may orient diagnosis towards a bipolar depression are related to the course of the disease, including a high frequency of depressive symptoms, an early age of onset, a high number of sick days, and a sudden symptomatic reduction or disappearance [<xref ref-type="bibr" rid="B2-pharmaceutics-12-00013">2</xref>,<xref ref-type="bibr" rid="B5-pharmaceutics-12-00013">5</xref>]. The response to antidepressant treatment can also suggest a bipolar depression, such as a sequence of failures with antidepressants and the appearance of side effects like anxiety, agitation, and insomnia [<xref ref-type="bibr" rid="B2-pharmaceutics-12-00013">2</xref>,<xref ref-type="bibr" rid="B3-pharmaceutics-12-00013">3</xref>,<xref ref-type="bibr" rid="B5-pharmaceutics-12-00013">5</xref>].</p>
<p>In the DSM-5 [<xref ref-type="bibr" rid="B16-pharmaceutics-12-00013">16</xref>], bipolar disorders and related conditions have been distinguished from depressive disorders and relocated between psychotic and depressive disorders, as an intermediate group of conditions in terms of genetics, family history, and symptomatology. Conditions classified as bipolar disorders comprise a range of diagnostic subgroups that can be characterized by the severity of the mood alterations experienced in the acute phase [<xref ref-type="bibr" rid="B5-pharmaceutics-12-00013">5</xref>].</p>
</sec>
<sec id="sec3-pharmaceutics-12-00013">
<title>3. Pharmacological Treatments of Bipolar Spectrum Disorders</title>
<p>Before the advent of lithium, common treatments for bipolar patients were solanaceae alkaloids, bromides, and, starting from the early 1900s, barbiturates. The efficacy of lithium salts in the treatment of mania was postulated in 1800s [<xref ref-type="bibr" rid="B17-pharmaceutics-12-00013">17</xref>]. The antimanic effect was later demonstrated in the 1950s, and it was only in the late 1960s that its effectiveness was demonstrated in bipolar disorder for the prophylaxis of manic–depressive episodes [<xref ref-type="bibr" rid="B18-pharmaceutics-12-00013">18</xref>]. However, the FDA (US Food and Drug Administration) only released the authorization for its antimanic use in 1978 [<xref ref-type="bibr" rid="B19-pharmaceutics-12-00013">19</xref>], limited to maintenance/prophylaxis of manic–depressive episodes. In 1995, the FDA approved the anticonvulsant valproic acid for its antimanic use. At the same time, the antiepileptic carbamazepine was introduced for the treatment of bipolar disorder, with approval from both the FDA and NICE (National Institute for Health and Care Excellence). Since 2000, the FDA has approved several atypical antipsychotic drugs (AADs) for their antimanic action (quetiapine, aripiprazole, olanzapine, risperidone, ziprasidone, etc.), or for their antidepressant action (lurasidone, quetiapine). Finally, lamotrigine, a more recent antiepileptic drug, has been approved in bipolar disorder for the prevention of depressive episodes [<xref ref-type="bibr" rid="B20-pharmaceutics-12-00013">20</xref>,<xref ref-type="bibr" rid="B21-pharmaceutics-12-00013">21</xref>,<xref ref-type="bibr" rid="B22-pharmaceutics-12-00013">22</xref>].</p>
<sec id="sec3dot1-pharmaceutics-12-00013">
<title>3.1. Lithium</title>
<p>Lithium is used to decrease the recurrence of manic episodes, but it is also indicated for depressive episodes, although to a lesser extent [<xref ref-type="bibr" rid="B5-pharmaceutics-12-00013">5</xref>]. Even though lithium has been used in the treatment of bipolar disorders for almost 60 years, its mechanism of action has not been fully clarified [<xref ref-type="bibr" rid="B23-pharmaceutics-12-00013">23</xref>]. Some molecular steps have been implicated along the signal transduction cascade activated by neurotransmitter receptors, such as G proteins and phosphatidyl inositol. More recently, gene expression regulation of growth factors and neuronal plasticity has been associated with lithium activity via components of signal transduction, including protein kinase C and GSK3 [<xref ref-type="bibr" rid="B5-pharmaceutics-12-00013">5</xref>,<xref ref-type="bibr" rid="B23-pharmaceutics-12-00013">23</xref>,<xref ref-type="bibr" rid="B24-pharmaceutics-12-00013">24</xref>]. Based on these and other putative molecular associations of the lithium pathways, several studies have been carried out in order to identify potential genetic lithium response predictors [<xref ref-type="bibr" rid="B25-pharmaceutics-12-00013">25</xref>].</p>
</sec>
<sec id="sec3dot2-pharmaceutics-12-00013">
<title>3.2. Antiepileptics as Mood Stabilizers</title>
<p>Based on the theory that the recurrence of manic episodes can expose the subject to further manic episodes (kindling), a logical parallelism has been drawn with epilepsy, where the appearance of repeated epileptic seizures exposes the subject to further seizures [<xref ref-type="bibr" rid="B5-pharmaceutics-12-00013">5</xref>,<xref ref-type="bibr" rid="B26-pharmaceutics-12-00013">26</xref>,<xref ref-type="bibr" rid="B27-pharmaceutics-12-00013">27</xref>]. Several antiepileptics are often prescribed to treat bipolar disorders, some more effectively than others [<xref ref-type="bibr" rid="B26-pharmaceutics-12-00013">26</xref>,<xref ref-type="bibr" rid="B27-pharmaceutics-12-00013">27</xref>].</p>
<sec id="sec3dot2dot1-pharmaceutics-12-00013">
<title>3.2.1. Valproic Acid</title>
<p>Valproate is recommended in long-term treatment to prevent mania recurrence in bipolar disorder. It is also used in the acute phase of mania, although its preventive activity has not been adequately clarified in this context [<xref ref-type="bibr" rid="B28-pharmaceutics-12-00013">28</xref>]. Like lithium, valproic acid can be administered once a day with other mood stabilizers at doses that correspond to the lower limit of the therapeutic range, to enhance tolerability and therapeutic compliance [<xref ref-type="bibr" rid="B29-pharmaceutics-12-00013">29</xref>]. As with all antiepileptics, its precise mechanism of action is uncertain. At least three hypotheses have been proposed: inhibition of the voltage-dependent sodium channel, enhancement of GABAergic neurotransmission, and regulation of downstream signal transduction cascades [<xref ref-type="bibr" rid="B28-pharmaceutics-12-00013">28</xref>,<xref ref-type="bibr" rid="B29-pharmaceutics-12-00013">29</xref>]. To explain its mood-stabilizing activity in mania, it has been hypothesized that valproate acts by reducing the excessive stimulation of neurotransmission, inhibiting the ionic flow through the voltage-dependent sodium channels (VSSC) [<xref ref-type="bibr" rid="B28-pharmaceutics-12-00013">28</xref>]. No specific molecular site has been identified, but the drug may alter the phosphorylation of sodium channels, thus modifying their sensitivity. When less sodium enters the neuron, there is a reduction in glutamate release and therefore excitatory neurotransmission [<xref ref-type="bibr" rid="B28-pharmaceutics-12-00013">28</xref>,<xref ref-type="bibr" rid="B29-pharmaceutics-12-00013">29</xref>,<xref ref-type="bibr" rid="B30-pharmaceutics-12-00013">30</xref>]. Others have hypothesized that valproate could enhance GABA activity by decreasing its re-uptake, increasing its release, or slowing its metabolic degradation. Although it remains unknown exactly how the enhancement of GABAergic tone is achieved, it is believed that this may explain the antimanic effect of valproic acid [<xref ref-type="bibr" rid="B28-pharmaceutics-12-00013">28</xref>]. More recently, further mechanisms have been proposed for valproate that could explain its activity. Valproate can inhibit GSK3, but it can act on other molecular targets too; it can inhibit MARCKS (substrate of miranolated kinase C rich in alanine) as well as protein kinase C (PKC), and can activate various signals that promote long-term neuroprotection, such as BCL2, GAP43, ERK, and others [<xref ref-type="bibr" rid="B28-pharmaceutics-12-00013">28</xref>,<xref ref-type="bibr" rid="B29-pharmaceutics-12-00013">29</xref>,<xref ref-type="bibr" rid="B30-pharmaceutics-12-00013">30</xref>].</p>
</sec>
<sec id="sec3dot2dot2-pharmaceutics-12-00013">
<title>3.2.2. Carbamazepine</title>
<p>Carbamazepine was the first antiepileptic with demonstrated effectiveness for mania in bipolar disorder [<xref ref-type="bibr" rid="B5-pharmaceutics-12-00013">5</xref>,<xref ref-type="bibr" rid="B31-pharmaceutics-12-00013">31</xref>,<xref ref-type="bibr" rid="B32-pharmaceutics-12-00013">32</xref>], although it did not formally receive FDA approval. It is hypothesized that carbamazepine acts by blocking the voltage-dependent sodium channels (VSSC), possibly at the VSSC subunit level within the channel [<xref ref-type="bibr" rid="B33-pharmaceutics-12-00013">33</xref>].</p>
</sec>
<sec id="sec3dot2dot3-pharmaceutics-12-00013">
<title>3.2.3. Lamotrigine</title>
<p>Lamotrigine acts as a mood stabilizer and it is used in prevention of depression and mania, although this use has not been approved by FDA in bipolar depression. Nonetheless, in many guidelines on treatment of bipolar depression, this drug is preferred to antidepressants as a first-line drug [<xref ref-type="bibr" rid="B5-pharmaceutics-12-00013">5</xref>,<xref ref-type="bibr" rid="B34-pharmaceutics-12-00013">34</xref>]. The reduction of excitatory-type glutamatergic neurotransmission may represent the specific mechanism of action of lamotrigine [<xref ref-type="bibr" rid="B35-pharmaceutics-12-00013">35</xref>]. Some other antiepileptic drugs, like gabapentin, topiramate, oxcarbazepine/eslicarbazepine, and pregabalin, some calcium channel blockers of type L (e.g., dihydropyridine), and riluzole, are sometimes prescribed in “experimental” treatments for symptoms associated with bipolar disorder [<xref ref-type="bibr" rid="B5-pharmaceutics-12-00013">5</xref>].</p>
</sec>
</sec>
<sec id="sec3dot3-pharmaceutics-12-00013">
<title>3.3. Atypical Antipsychotics</title>
<p>Atypical antipsychotics have been shown to be effective for the main non-psychotic symptoms of mania and for the prevention of recurrence of mania. Currently, they are the most effective therapeutic option for bipolar disorder, along with most antiepileptics and lithium [<xref ref-type="bibr" rid="B5-pharmaceutics-12-00013">5</xref>,<xref ref-type="bibr" rid="B36-pharmaceutics-12-00013">36</xref>]. The mechanism of action of atypical antipsychotics in bipolar disorder is not yet fully understood, but the prevailing hypothesis is that antagonism or partial agonism of D2 receptors could explain the reduction of manic psychotic symptoms. Moreover, the 5HT2A receptor (5HT2AR) antagonism and partial agonism of 5HT1A receptors could be responsible for the reduction of manic and non-psychotic depressive symptoms observed with some atypical antipsychotics. This may be achieved through the downregulation of the glutamatergic system affecting pyramidal neurons. Given that hyperactivity of the glutamatergic system, depending on the neuronal circuit involved, can be associated with both manic and depressive symptoms, these antipsychotics can be effective in reducing both types of symptoms. Other mechanisms have also been hypothesized to explain why some atypical antipsychotics improve the symptomatic picture of the depressive phase of bipolar disorder. All these mechanisms are based on the ability of some atypical antipsychotics to increase serotonin, dopamine, and norepinephrine levels, while reducing those of glutamate [<xref ref-type="bibr" rid="B37-pharmaceutics-12-00013">37</xref>,<xref ref-type="bibr" rid="B38-pharmaceutics-12-00013">38</xref>]. Atypical antipsychotics are indicated in schizophrenia, and most of them also in mania, but quetiapine is the only one approved for bipolar conditions, while lurasidone has only been tested [<xref ref-type="bibr" rid="B39-pharmaceutics-12-00013">39</xref>,<xref ref-type="bibr" rid="B40-pharmaceutics-12-00013">40</xref>].</p>
</sec>
<sec id="sec3dot4-pharmaceutics-12-00013">
<title>3.4. Benzodiazepines</title>
<p>Although the use of these drugs as mood stabilizers has not been formally approved, benzodiazepines represent a treatment of considerable value, especially during emergencies. Their prompt administration can provide an immediate sedative effect and provide precious time, unlike mood stabilizers with a slower onset of action. Benzodiazepines are essential drugs for patients who suffer from intermittent episodes of agitation, insomnia, and incipient manic symptoms and require treatment as needed [<xref ref-type="bibr" rid="B41-pharmaceutics-12-00013">41</xref>].</p>
</sec>
<sec id="sec3dot5-pharmaceutics-12-00013">
<title>3.5. Antidepressants</title>
<p>Evidence is growing that antidepressants in these disorders not only do not work, but can even exacerbate the condition of some patients with bipolar disorder, leading to mania and hypomania states, destabilizing mood, and increasing cyclicality or even suicidality [<xref ref-type="bibr" rid="B2-pharmaceutics-12-00013">2</xref>,<xref ref-type="bibr" rid="B3-pharmaceutics-12-00013">3</xref>,<xref ref-type="bibr" rid="B42-pharmaceutics-12-00013">42</xref>,<xref ref-type="bibr" rid="B43-pharmaceutics-12-00013">43</xref>].</p>
<p>Evidence suggests that dysfunctions of glutamate neurotransmission may be implicated in various psychiatric conditions, including bipolar disorders [<xref ref-type="bibr" rid="B44-pharmaceutics-12-00013">44</xref>,<xref ref-type="bibr" rid="B45-pharmaceutics-12-00013">45</xref>]. The role of 5HT-mediated glutamatergic activation in BD could explain why the use of antidepressants can exacerbate manic symptoms in bipolar disorders. This hypothesis is still under study, but little doubt remains that antidepressants, tricyclic ones in particular, can trigger manic symptoms in subjects with bipolar spectrum disorders. 5HT2ARs are always postsynaptic and are located in many brain regions. In cortical neurons, they are coupled with Gαq/11 type G proteins. The latter activates membrane-bound phospholipase C beta, leading to cleavage of PIP2 into two messengers, IP3 and diacylglycerol (DAG). This stimulates protein kinase C (PKC), which in turn controls the function of the main glutamate transporter in CNS, Glutamate transporter-1 [<xref ref-type="bibr" rid="B46-pharmaceutics-12-00013">46</xref>,<xref ref-type="bibr" rid="B47-pharmaceutics-12-00013">47</xref>,<xref ref-type="bibr" rid="B48-pharmaceutics-12-00013">48</xref>]. In particular, PKC-mediated phosphorylation induces GLT1 transporter downregulation/endocytosis, thus increasing glutamatergic intersynaptic activity [<xref ref-type="bibr" rid="B49-pharmaceutics-12-00013">49</xref>,<xref ref-type="bibr" rid="B50-pharmaceutics-12-00013">50</xref>,<xref ref-type="bibr" rid="B51-pharmaceutics-12-00013">51</xref>,<xref ref-type="bibr" rid="B52-pharmaceutics-12-00013">52</xref>].</p>
</sec>
<sec id="sec3dot6-pharmaceutics-12-00013">
<title>3.6. Associations</title>
<p>In clinical practice, many subjects suffering from bipolar disorder need to be treated with more than one drug. Effective combinations include the association of valproate or lithium with an atypical antipsychotic. Evidence collected from clinical practice suggests more associations can be utilized, although such suggestions have not been adequately evaluated in controlled clinical trials. Examples include the combination of valproate and lithium, valproate and lamotrigine, lithium and lamotrigine, lithium with quetiapine, and lamotrigine with valproate and lithium. Expert opinions are very divergent when it comes to treating bipolar depression, particularly with antidepressants. Some believe that an antidepressant should not be given in any case, while others simply recommend caution when combining an antidepressant with a mood stabilizer.</p>
<p>In conclusion, current protocols and guidelines for acute mania recommend as first-line treatments lithium, quetiapine, divalproex, asenapine, aripiprazole, paliperidone, risperidone, and cariprazine in combination or alone. In bipolar I depression, recommended first-line treatments include quetiapine, lurasidone plus lithium or divalproex, lithium, lamotrigine, lurasidone, or adjunctive lamotrigine. Except for antidepressants, treatment with drugs that have shown efficacy in the acute phase is also recommended in the maintenance phase. For patients initiating or switching drugs in the maintenance phase, the use of monotherapy or combinations of lithium, quetiapine, divalproex, lamotrigine, asenapine, and aripiprazole can be suggested [<xref ref-type="bibr" rid="B5-pharmaceutics-12-00013">5</xref>,<xref ref-type="bibr" rid="B53-pharmaceutics-12-00013">53</xref>].</p>
</sec>
</sec>
<sec id="sec4-pharmaceutics-12-00013">
<title>4. Genetics of Bipolar Spectrum Disorders</title>
<p>Multiple genetic studies have pointed out that bipolar disorders (BPD) are often heritable conditions, with genetics accounting for 60–85% of the risk [<xref ref-type="bibr" rid="B54-pharmaceutics-12-00013">54</xref>,<xref ref-type="bibr" rid="B55-pharmaceutics-12-00013">55</xref>]. Studies indicate that the risk of recurrence of bipolar disorders in first-degree relatives is about 9%, almost 10-fold higher than in the general population [<xref ref-type="bibr" rid="B55-pharmaceutics-12-00013">55</xref>,<xref ref-type="bibr" rid="B56-pharmaceutics-12-00013">56</xref>]. Family studies have also indicated that bipolar I and II disorders have a genetic distinction; the risk of bipolar II disorder among relatives of patients with bipolar II disorder is greater than in relatives of patients with BDI [<xref ref-type="bibr" rid="B57-pharmaceutics-12-00013">57</xref>,<xref ref-type="bibr" rid="B58-pharmaceutics-12-00013">58</xref>,<xref ref-type="bibr" rid="B59-pharmaceutics-12-00013">59</xref>].</p>
<p>Research on genes that might influence bipolar disorders has been hampered by the phenotypic and genetic complexity of the syndrome, a limited knowledge on its pathogenesis, and by the scarcity of animal models. Linkage studies have highlighted different chromosomal regions as carriers of meaningful genes, but with inconsistent results. It is now generally recognized that the genetic associations of bipolar disorder are linked to many different genes [<xref ref-type="bibr" rid="B60-pharmaceutics-12-00013">60</xref>,<xref ref-type="bibr" rid="B61-pharmaceutics-12-00013">61</xref>]. Thus, genetic research in the field has been focused on genome-wide association studies. The application of this approach to BD since 2007 has allowed the identification of a sizable number of candidate genes, which have since been associated with the disorder in various studies (including <italic>DAOA</italic>, <italic>BDNF</italic>, <italic>GRIK4</italic>, <italic>DISC1</italic>, <italic>TPH2</italic>, and <italic>SLC6A4)</italic> [<xref ref-type="bibr" rid="B62-pharmaceutics-12-00013">62</xref>]. More recently, the first major BD genome-wide association study by the Psychiatric Genomics Consortium (PGC) Bipolar Disorder Working Group led to the identification of four significant loci at the genomic level. The study analyzed 7481 BD patients and compared them to 9250 controls. Three subsequent meta-analyses that included PGC BD data identified five more loci [<xref ref-type="bibr" rid="B63-pharmaceutics-12-00013">63</xref>]. In one of the most important studies on the subject, a genome-wide association study was conducted with 20,352 cases compared to 31,358 controls. A total of 822 sentinel variants were followed up independently in 9412 cases versus 137,760 controls. As a result, 30 loci (with 20 new ones) achieved significant genomic association evidence and contained genes coding for synaptic components (<italic>ANK3</italic>, <italic>RIMS1</italic>) and transporters, neurotransmitters and ion channels (<italic>SLC4A1</italic>, <italic>CACNA1C</italic>, <italic>SCN2A</italic>, <italic>GRIN2A</italic>). Interestingly type I BD is genetically highly correlated with schizophrenia, while type II bipolar disorder correlates more with major depressive disorder [<xref ref-type="bibr" rid="B62-pharmaceutics-12-00013">62</xref>,<xref ref-type="bibr" rid="B63-pharmaceutics-12-00013">63</xref>]. In summary, the results of the broader genomic analysis on BD have revealed that these conditions have an extensive polygenic architecture, implicating in their etiology neurotransmitter and calcium channel functions, confirming that BD falls within a spectrum of highly related psychiatric disorders [<xref ref-type="bibr" rid="B55-pharmaceutics-12-00013">55</xref>]. The detailed genetic dissection of the disorder, rationalized using a systems biology approach, could allow the identification of functional connections between the different molecular effectors identified, leading to the construction of a molecular network underlying the pathogenesis of the disease. This could also represent a valuable tool to guide, optimize, and personalize the therapeutic choice of molecular targets.</p>
</sec>
<sec id="sec5-pharmaceutics-12-00013">
<title>5. Pharmacogenomics of Bipolar Spectrum Disorder</title>
<p>The study of pharmacogenomics in the field of mental health is rapidly growing. Most data on genomics of bipolar spectrum disorders concentrate on the variability (response, side effects) of the pharmacological response when using atypical antipsychotics and/or antidepressants [<xref ref-type="bibr" rid="B36-pharmaceutics-12-00013">36</xref>,<xref ref-type="bibr" rid="B64-pharmaceutics-12-00013">64</xref>]. The genetic assets used in clinical settings are based mostly on the pharmacogenomic studies associating gene polymorphisms with treatment outcomes. In particular, genetic polymorphisms can affect pharmacodynamic and pharmacokinetic aspects of medications, thus influencing efficacy and susceptibility to side effects.</p>
<p>With the increased accessibility of individual DNA chip analysis, WES (whole-exome sequencing,) and WGS (whole-genome sequencing) for diagnostic studies [<xref ref-type="bibr" rid="B65-pharmaceutics-12-00013">65</xref>], pharmacogenomics is entering a phase of regular clinical use. The analysis of some key point mutations is actually required before specific drugs can be administered, in order to personalize the treatment according to the predicted efficacy or sensitivity to side effects [<xref ref-type="bibr" rid="B66-pharmaceutics-12-00013">66</xref>]. Genetic variants to be analyzed for each class of drugs are selected according to available evidence-based medicine data and clinical validations, and several dedicated databases are available and freely accessible on the web today (e.g., pharmGKB [<xref ref-type="bibr" rid="B67-pharmaceutics-12-00013">67</xref>], drugbank [<xref ref-type="bibr" rid="B68-pharmaceutics-12-00013">68</xref>], genecards [<xref ref-type="bibr" rid="B69-pharmaceutics-12-00013">69</xref>]).</p>
<p>Several factors can increase the possibility of a genetic diathesis in the treatment of bipolar spectrum disorders. Some meaningful SNPs are used in clinical settings to predict therapeutic response or potential toxicity. Polygenic determinants of drug effects have become more and more important in pharmacogenomics and are now used in clinical diagnostics to prevent adverse reactions to medications and to optimize therapy. Certain aspects of pharmacogenomic testing have entered the clinical routine. For example, FDA recommends testing for <italic>HLA-B</italic>*<italic>1502</italic> when using carbamazepine. Carriers of this mutation are estimated to have a 10-fold higher risk for Stevens–Johnson syndrome when assuming the drug [<xref ref-type="bibr" rid="B70-pharmaceutics-12-00013">70</xref>]. Today, the majority of tests available include both pharmacodynamic (PD) and pharmacokinetic (PK) genomic analytical panels.</p>
<sec id="sec5dot1-pharmaceutics-12-00013">
<title>5.1. Pharmacogenomics of Pharmacodynamic Pathways</title>
<p>Examples of genes implicated in the pharmacodynamics of neuropsychiatric drugs include <italic>COMT</italic>, <italic>DRD2</italic> dopamine receptor, <italic>HTR2C</italic> and <italic>HTR2A</italic> serotonin receptors, and <italic>SLC6A4</italic> serotonin transporter [<xref ref-type="bibr" rid="B71-pharmaceutics-12-00013">71</xref>,<xref ref-type="bibr" rid="B72-pharmaceutics-12-00013">72</xref>,<xref ref-type="bibr" rid="B73-pharmaceutics-12-00013">73</xref>,<xref ref-type="bibr" rid="B74-pharmaceutics-12-00013">74</xref>].</p>
<p>Serotonergic pathways have been the focus of most pharmacogenetic studies on clinical response to psychotropic drugs in BD patients. Alterations of these pathways have been implicated in bipolar disorders. The serotonin transporter <italic>SLC6A4</italic> gene has been extensively investigated. <italic>5-HTTLPR</italic> is a functional polymorphism of <italic>SLC6A4</italic>, with a short (s) and a long (l) allele variant that have been suggested to be related to stress and psychiatric disorders. There have been reports associating the (s) allele with poor response to serotonergic drugs in BD. On the other hand, genetic studies on the (l) allele and SSRI response have not been able to clearly demonstrate a functional association between gene expression and pharmacological effect. For example, rs25531, a SNP located in the same <italic>SLC6A4</italic> region as <italic>5-HTTLPR</italic>, although associated with increased transporter expression, does not affect the response to SSRIs [<xref ref-type="bibr" rid="B75-pharmaceutics-12-00013">75</xref>,<xref ref-type="bibr" rid="B76-pharmaceutics-12-00013">76</xref>].</p>
<p>The <italic>HTR2A</italic> gene for 5HT-2A receptors (5HT2ARs) has been associated with antidepressant effect. Patients with specific polymorphisms of this gene (rs6313 and rs7997012) have been found to respond better to antidepressants. The same mutations have also been associated with an increased sensitivity of 5HT2ARs to serotonin [<xref ref-type="bibr" rid="B77-pharmaceutics-12-00013">77</xref>,<xref ref-type="bibr" rid="B78-pharmaceutics-12-00013">78</xref>]. 5HT2ARs hypersensitivity found in rs6313 and rs7997012 genetic mutations has been associated with the occurrence of pharmacologically induced dysphoric conditions in misdiagnosed bipolar spectrum disorders [<xref ref-type="bibr" rid="B15-pharmaceutics-12-00013">15</xref>]. Several studies have shown an association between a good response to drugs that act on the serotonergic pathway in BD patients, and the rs6295 C/C genotype in the <italic>HTR1A</italic> gene [<xref ref-type="bibr" rid="B79-pharmaceutics-12-00013">79</xref>,<xref ref-type="bibr" rid="B80-pharmaceutics-12-00013">80</xref>,<xref ref-type="bibr" rid="B81-pharmaceutics-12-00013">81</xref>]. The <italic>HTR2C</italic> gene for the 5HT-2C receptor has been shown to be associated with adverse drug reactions when using neuroleptic drugs. There is evidence indicating an association of specific polymorphisms like variant rs3813929 with a higher risk of extrapyramidal side effects. Another polymorphism, rs1414334, has been associated with higher risk of developing metabolic syndrome in subjects treated with olanzapine [<xref ref-type="bibr" rid="B82-pharmaceutics-12-00013">82</xref>,<xref ref-type="bibr" rid="B83-pharmaceutics-12-00013">83</xref>].</p>
<p>Dopamine 2 receptors have been associated with antipsychotic effect and are coded by the highly polymorphic <italic>DRD2</italic> gene, located on chromosome 11q22. An extensively studied variant is -141C Ins/Del (rs1799732). When the Ins/Ins genotype is present, patients respond better to antipsychotic drugs than subjects carrying one or two copies of the Del allele. Subjects carrying the homozygous C allele with rs2514218 have been shown to respond better to antipsychotics than those homozygous for T allele, but they also present more side effects [<xref ref-type="bibr" rid="B84-pharmaceutics-12-00013">84</xref>,<xref ref-type="bibr" rid="B85-pharmaceutics-12-00013">85</xref>,<xref ref-type="bibr" rid="B86-pharmaceutics-12-00013">86</xref>].</p>
<p>Little evidence is available on genes encoding for glutamate receptors. Research has been focused on the <italic>Gβ3</italic> gene, with studies reporting an association between a good response to drugs that act on the serotoninergic pathway in BD patients, and the T/T genotype in the rs5443 polymorphism [<xref ref-type="bibr" rid="B79-pharmaceutics-12-00013">79</xref>,<xref ref-type="bibr" rid="B87-pharmaceutics-12-00013">87</xref>].</p>
<p><xref ref-type="table" rid="pharmaceutics-12-00013-t001">Table 1</xref> shows some of the most important pharmacodynamic mutations that can modify the pharmacotoxicological outcomes of drugs in bipolar disorder.</p>
</sec>
<sec id="sec5dot2-pharmaceutics-12-00013">
<title>5.2. Pharmacogenomics of Pharmacokinetic Pathways</title>
<p>CYP enzyme polymorphisms (cytochrome P450) may result in increased or decreased enzymatic activity. Such variations can thus determine a wide variety of drug metabolic patterns that, depending on the resulting metabolic activity, characterize the subject as a normal metabolizer, ultra-rapid metabolizer, intermediate metabolizer, or poor metabolizer. Poor metabolizers are subjects that have poor to no enzymatic activity, usually associated with having two copies of non-functioning alleles. Medications targeted by these enzymes are not metabolized effectively, thus increasing the risk of adverse drug reactions. In the case of pro-drugs, this condition can result in therapeutic failure, since the medication will not be transformed into the active form. Intermediate metabolizers have a slight functional impairment of drug metabolic activity due to at least one non-functioning allele. Normal metabolizers have a regular drug metabolic activity, while ultra-rapid metabolizers have enhanced enzyme activity that leads to an increased ability to metabolize drugs, decreasing the effectiveness of drugs, or increasing the risk of adverse drug reactions of prodrugs. For reference, the Clinical Pharmacogenetics Implementation Consortium (CPIC) published a review on pharmacogenomics nomenclature [<xref ref-type="bibr" rid="B161-pharmaceutics-12-00013">161</xref>,<xref ref-type="bibr" rid="B162-pharmaceutics-12-00013">162</xref>].</p>
<p>The drug metabolism (phase I) of psychiatric medications involves CYP 1 to three families, including CYP1A2, CYP2B6, CYP3A4/5, CYP2C9, CYP2C19, and CYP2D6. These CYP enzymes can be analyzed to personalize drug prescription and administration [<xref ref-type="bibr" rid="B163-pharmaceutics-12-00013">163</xref>].</p>
<p>The FDA labeling (US Food and Drug Administration) of about 200 drugs specify their pharmacogenomic characterization. Neuropsychiatric medications represent one fourth of all these drugs. With pharmacogenomic information on the type of metabolizer, it is possible to choose the most effective drug for a patient, and identify the dose range and the administration strategy.</p>
<p><xref ref-type="table" rid="pharmaceutics-12-00013-t002">Table 2</xref> shows some of the most important pharmacokinetic mutations that can modify the pharmacotoxicological outcome of the drugs in bipolar disorder.</p>
</sec>
</sec>
<sec id="sec6-pharmaceutics-12-00013" sec-type="conclusions">
<title>6. Conclusions</title>
<p>Bipolar spectrum disorder diagnosis is usually not based on the identification of pathogenetic mechanism, but on symptoms and signs, while the identification and association of traditional biological markers with bipolar disorder is still under investigation. The advent of genomics has allowed the identification of genetic assets associated with bipolar spectrum disorders, providing the basis for the identification of genetic risk factors and the definition of personalized pharmacotoxicological profiles. These can guide the initial therapeutic choice, or suggest corrections according to the individual’s biological networks implicated in the disease pathways or in the relevant pharmacological aspects.</p>
<p>Even before they are diagnosed with a bipolar condition, patients usually claim a depressive symptomatology of some degree. Using the patient’s molecular information can be helpful for the initial therapeutic orientation when a decision needs to be made on whether to use serotonergic antidepressants, given that mutations in their <italic>HTR2A</italic> gene would suggest a risk of manic state induction.</p>
<p>Once the bipolar condition is diagnosed, pharmacogenomic information can be used to guide the choice of the class of drugs to be used. In particular, the analysis of pharmacodynamically relevant SNPs can support the identification of the type of drugs with most chance of being effective and/or least likelihood of causing side effects. This information should be combined with a complete family history and medical information, as well as regular clinical risk factor profiling for bipolar disorder.</p>
<p>When the type of drug class to be used has been identified, pharmacogenomic information can help to drive the choice of the best molecule according to the individual pharmacokinetic asset, and at the same time indicate the dose and the therapeutic strategy that should be used to optimize effectiveness and minimize the risks of side effects.</p>
<p>A proposed algorithm is shown in <xref ref-type="fig" rid="pharmaceutics-12-00013-f002">Figure 2</xref>.</p>
<p>In summary, the genomic knowledge available today can support a personalized medicine approach to bipolar disorders, suggesting the most suitable pharmacological therapy for each patient. Together with the basic clinical information, a pharmacogenomic analysis should always be recommended to verify how one or more drugs might effectively act in a given subject, foreseeing the efficacy profile and safety of each drug, in order to increase therapeutic success and decrease unwanted adverse effects. Although more evidence is required before genomic data can be fully used to assist the clinician with a molecular diagnosis, when dealing with bipolar spectrum disorders, pharmacogenomics can provide orientation towards a safer use of drugs, particularly antidepressant drugs, based on the polymorphisms on the <italic>HTR2A</italic> gene. Once a bipolar disorder is diagnosed, drugs can be chosen based on the molecular targets identified by the pharmacodynamic SNPs, optimizing the doses and the pharmacological combinations based on the pharmacokinetic SNPs.</p>
</sec>
</body>
<back>
<notes>
<title>Funding</title>
<p>This research received no external funding.</p>
</notes>
<notes notes-type="COI-statement">
<title>Conflicts of Interest</title>
<p>The founding sponsors had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, and in the decision to publish the results.</p>
</notes>
<ref-list>
<title>References</title>
<ref id="B1-pharmaceutics-12-00013">
<label>1.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bobo</surname>
<given-names>W.V.</given-names>
</name>
</person-group>
<article-title>The diagnosis and management of bipolar I and II disorders: Clinical practice update</article-title>
<source/>Mayo Clin. Proc.
          <year>2017</year>
<volume>92</volume>
<fpage>1532</fpage>
<lpage>1551</lpage>
<pub-id pub-id-type="doi">10.1016/j.mayocp.2017.06.022</pub-id>
<pub-id pub-id-type="pmid">28888714</pub-id>
</element-citation>
</ref>
<ref id="B2-pharmaceutics-12-00013">
<label>2.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ghaemi</surname>
<given-names>S.N.</given-names>
</name>
<name>
<surname>Sachs</surname>
<given-names>G.S.</given-names>
</name>
<name>
<surname>Chiou</surname>
<given-names>A.M.</given-names>
</name>
<name>
<surname>Pandurangi</surname>
<given-names>A.K.</given-names>
</name>
<name>
<surname>Goodwin</surname>
<given-names>F.K.</given-names>
</name>
</person-group>
<article-title>Is bipolar disorder still underdiagnosed? Are antidepressants overutilized?</article-title>
<source/>J. Affect. Disord.
          <year>1999</year>
<volume>52</volume>
<fpage>135</fpage>
<lpage>144</lpage>
<pub-id pub-id-type="doi">10.1016/S0165-0327(98)00076-7</pub-id>
<pub-id pub-id-type="pmid">10357026</pub-id>
</element-citation>
</ref>
<ref id="B3-pharmaceutics-12-00013">
<label>3.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ghaemi</surname>
<given-names>S.N.</given-names>
</name>
<name>
<surname>Hsu</surname>
<given-names>D.J.</given-names>
</name>
<name>
<surname>Soldani</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Goodwin</surname>
<given-names>F.K.</given-names>
</name>
</person-group>
<article-title>Antidepressants in bipolar disorder: The case for caution</article-title>
<source/>Bipolar Disord.
          <year>2003</year>
<volume>5</volume>
<fpage>421</fpage>
<lpage>433</lpage>
<pub-id pub-id-type="doi">10.1046/j.1399-5618.2003.00074.x</pub-id>
<pub-id pub-id-type="pmid">14636365</pub-id>
</element-citation>
</ref>
<ref id="B4-pharmaceutics-12-00013">
<label>4.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Grande</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Berk</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Birmaher</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Vieta</surname>
<given-names>E.</given-names>
</name>
</person-group>
<article-title>Bipolar disorder</article-title>
<source/>Lancet
          <year>2016</year>
<volume>387</volume>
<fpage>1561</fpage>
<lpage>1572</lpage>
<pub-id pub-id-type="doi">10.1016/S0140-6736(15)00241-X</pub-id>
<pub-id pub-id-type="pmid">26388529</pub-id>
</element-citation>
</ref>
<ref id="B5-pharmaceutics-12-00013">
<label>5.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yatham</surname>
<given-names>L.N.</given-names>
</name>
<name>
<surname>Kennedy</surname>
<given-names>S.H.</given-names>
</name>
<name>
<surname>Parikh</surname>
<given-names>S.V.</given-names>
</name>
<name>
<surname>Schaffer</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Bond</surname>
<given-names>D.J.</given-names>
</name>
<name>
<surname>Frey</surname>
<given-names>B.N.</given-names>
</name>
<name>
<surname>Sharma</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Goldstein</surname>
<given-names>B.I.</given-names>
</name>
<name>
<surname>Rej</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Beaulieu</surname>
<given-names>S.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder</article-title>
<source/>Bipolar Disord.
          <year>2018</year>
<volume>20</volume>
<fpage>97</fpage>
<lpage>170</lpage>
<pub-id pub-id-type="doi">10.1111/bdi.12609</pub-id>
<pub-id pub-id-type="pmid">29536616</pub-id>
</element-citation>
</ref>
<ref id="B6-pharmaceutics-12-00013">
<label>6.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Benazzi</surname>
<given-names>F.</given-names>
</name>
</person-group>
<article-title>Bipolar disorder—Focus on bipolar II disorder and mixed depression</article-title>
<source/>Lancet
          <year>2018</year>
<volume>369</volume>
<fpage>935</fpage>
<lpage>945</lpage>
<pub-id pub-id-type="doi">10.1016/S0140-6736(07)60453-X</pub-id>
</element-citation>
</ref>
<ref id="B7-pharmaceutics-12-00013">
<label>7.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Phillips</surname>
<given-names>M.L.</given-names>
</name>
<name>
<surname>Kupfer</surname>
<given-names>D.J.</given-names>
</name>
</person-group>
<article-title>Bipolar disorder diagnosis: Challenges and future directions</article-title>
<source/>Lancet
          <year>2013</year>
<volume>381</volume>
<fpage>1663</fpage>
<lpage>1671</lpage>
<pub-id pub-id-type="doi">10.1016/S0140-6736(13)60989-7</pub-id>
<pub-id pub-id-type="pmid">23663952</pub-id>
</element-citation>
</ref>
<ref id="B8-pharmaceutics-12-00013">
<label>8.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Scott</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Leboyer</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Consequences of delayed diagnosis of bipolar disorders</article-title>
<source/>Encephale
          <year>2011</year>
<volume>37</volume>
<fpage>S173</fpage>
<lpage>S175</lpage>
<pub-id pub-id-type="doi">10.1016/S0013-7006(11)70048-3</pub-id>
<pub-id pub-id-type="pmid">22212870</pub-id>
</element-citation>
</ref>
<ref id="B9-pharmaceutics-12-00013">
<label>9.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Edvardsen</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Torgersen</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Røysamb</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Lygren</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Skre</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Onstad</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Oien</surname>
<given-names>P.A.</given-names>
</name>
</person-group>
<article-title>Heritability of bipolar spectrum disorders. Unity or heterogeneity?</article-title>
<source/>J. Affect Disord.
          <year>2008</year>
<volume>106</volume>
<fpage>229</fpage>
<lpage>240</lpage>
<pub-id pub-id-type="doi">10.1016/j.jad.2007.07.001</pub-id>
<pub-id pub-id-type="pmid">17692389</pub-id>
</element-citation>
</ref>
<ref id="B10-pharmaceutics-12-00013">
<label>10.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Angst</surname>
<given-names>J.</given-names>
</name>
</person-group>
<article-title>The bipolar spectrum</article-title>
<source/>Br. J. Psychiatry
          <year>2007</year>
<volume>190</volume>
<fpage>189</fpage>
<lpage>191</lpage>
<pub-id pub-id-type="doi">10.1192/bjp.bp.106.030957</pub-id>
<pub-id pub-id-type="pmid">17329735</pub-id>
</element-citation>
</ref>
<ref id="B11-pharmaceutics-12-00013">
<label>11.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dias</surname>
<given-names>V.V.</given-names>
</name>
<name>
<surname>Balanzá-Martinez</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Soeiro-de-Souza</surname>
<given-names>M.G.</given-names>
</name>
<name>
<surname>Moreno</surname>
<given-names>R.A.</given-names>
</name>
<name>
<surname>Figueira</surname>
<given-names>M.L.</given-names>
</name>
<name>
<surname>Machado-Vieira</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Vieta</surname>
<given-names>E.</given-names>
</name>
</person-group>
<article-title>Pharmacological approaches in bipolar disorders and the impact on cognition: A critical overview</article-title>
<source/>Acta Psychiatr. Scand.
          <year>2012</year>
<volume>126</volume>
<fpage>315</fpage>
<lpage>331</lpage>
<pub-id pub-id-type="doi">10.1111/j.1600-0447.2012.01910.x</pub-id>
<pub-id pub-id-type="pmid">22881296</pub-id>
</element-citation>
</ref>
<ref id="B12-pharmaceutics-12-00013">
<label>12.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Manji</surname>
<given-names>H.K.</given-names>
</name>
<name>
<surname>Quiroz</surname>
<given-names>J.A.</given-names>
</name>
<name>
<surname>Payne</surname>
<given-names>J.L.</given-names>
</name>
<name>
<surname>Singh</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Lopes</surname>
<given-names>B.P.</given-names>
</name>
<name>
<surname>Viegas</surname>
<given-names>J.S.</given-names>
</name>
<name>
<surname>Zarate</surname>
<given-names>C.A.</given-names>
</name>
</person-group>
<article-title>The underlying neurobiology of bipolar disorder</article-title>
<source/>World Psychiatry
          <year>2003</year>
<volume>2</volume>
<fpage>136</fpage>
<pub-id pub-id-type="pmid">16946919</pub-id>
</element-citation>
</ref>
<ref id="B13-pharmaceutics-12-00013">
<label>13.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chee</surname>
<given-names>I.S.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>S.W.</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>J.L.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>S.K.</given-names>
</name>
<name>
<surname>Shin</surname>
<given-names>Y.O.</given-names>
</name>
<name>
<surname>Shin</surname>
<given-names>S.C.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>Y.H.</given-names>
</name>
<name>
<surname>Hwang</surname>
<given-names>H.M.</given-names>
</name>
<name>
<surname>Lim</surname>
<given-names>M.R.</given-names>
</name>
</person-group>
<article-title>5-HT2A receptor gene promoter polymorphism–1438A/G and bipolar disorder</article-title>
<source/>Psychiatric Genet.
          <year>2001</year>
<volume>11</volume>
<fpage>111</fpage>
<lpage>114</lpage>
<pub-id pub-id-type="doi">10.1097/00041444-200109000-00001</pub-id>
</element-citation>
</ref>
<ref id="B14-pharmaceutics-12-00013">
<label>14.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Du</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Bakish</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Lapierre</surname>
<given-names>Y.D.</given-names>
</name>
<name>
<surname>Ravindran</surname>
<given-names>A.V.</given-names>
</name>
<name>
<surname>Hrdina</surname>
<given-names>P.D.</given-names>
</name>
</person-group>
<article-title>Association of polymorphism of serotonin 2A receptor gene with suicidal ideation in major depressive disorder</article-title>
<source/>Am. J. Med. Genet.
          <year>2000</year>
<volume>96</volume>
<fpage>56</fpage>
<lpage>60</lpage>
<pub-id pub-id-type="doi">10.1002/(SICI)1096-8628(20000207)96:1&lt;56::AID-AJMG12&gt;3.0.CO;2-L</pub-id>
<pub-id pub-id-type="pmid">10686553</pub-id>
</element-citation>
</ref>
<ref id="B15-pharmaceutics-12-00013">
<label>15.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fortinguerra</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Buriani</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Sorrenti</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Lenzi</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Giusti</surname>
<given-names>P.</given-names>
</name>
</person-group>
<article-title>Molecular network-selected pharmacogenomics in a case of bipolar spectrum disorder</article-title>
<source/>Pharmacogenomics
          <year>2017</year>
<volume>18</volume>
<fpage>1631</fpage>
<lpage>1642</lpage>
<pub-id pub-id-type="doi">10.2217/pgs-2017-0133</pub-id>
<pub-id pub-id-type="pmid">29173093</pub-id>
</element-citation>
</ref>
<ref id="B16-pharmaceutics-12-00013">
<label>16.</label>
<element-citation publication-type="book">
<person-group person-group-type="author">
<collab>American Psychiatric Association</collab>
</person-group>
<source/>Diagnostic and Statistical Manual of Mental Disorders: Diagnostic and Statistical Manual of Mental Disorders
          <edition>5th ed.</edition>
<publisher-name>American Psychiatric Association</publisher-name>
<publisher-loc>Arlington, VA, USA</publisher-loc>
<year>2013</year>
</element-citation>
</ref>
<ref id="B17-pharmaceutics-12-00013">
<label>17.</label>
<element-citation publication-type="book">
<person-group person-group-type="author">
<name>
<surname>Henderson</surname>
<given-names>D.K.</given-names>
</name>
<name>
<surname>Gillespie</surname>
<given-names>R.D.</given-names>
</name>
</person-group>
<source/>Textbook of Psychiatry
          <edition>6th ed.</edition>
<publisher-name>Humphrey Milford Oxford University Press</publisher-name>
<publisher-loc>London, UK</publisher-loc>
<year>1944</year>
<fpage>3</fpage>
</element-citation>
</ref>
<ref id="B18-pharmaceutics-12-00013">
<label>18.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Baastrup</surname>
<given-names>P.C.</given-names>
</name>
<name>
<surname>Schou</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Lithium as a prophylactic agent: Its effect against recurring depression and manic depressive psychosis</article-title>
<source/>Arch. Gen. Psychiatry
          <year>1967</year>
<volume>16</volume>
<fpage>162</fpage>
<lpage>172</lpage>
<pub-id pub-id-type="doi">10.1001/archpsyc.1967.01730200030005</pub-id>
<pub-id pub-id-type="pmid">6019331</pub-id>
</element-citation>
</ref>
<ref id="B19-pharmaceutics-12-00013">
<label>19.</label>
<element-citation publication-type="book">
<person-group person-group-type="author">
<name>
<surname>Shen</surname>
<given-names>W.W.</given-names>
</name>
</person-group>
<source/>Clinical Psychopharmacology in the Twenty-First Century
          <edition>Revised Edition</edition>
<publisher-name>Hochi Publishing Company</publisher-name>
<publisher-loc>Taipei, Taiwan</publisher-loc>
<year>2004</year>
<comment>(In Mandarin)</comment>
</element-citation>
</ref>
<ref id="B20-pharmaceutics-12-00013">
<label>20.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ramachandraiah</surname>
<given-names>C.T.</given-names>
</name>
<name>
<surname>Subramaniam</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Tancer</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>The story of antipsychotics: Past and present</article-title>
<source/>Indian J. Psychiatry
          <year>2009</year>
<volume>51</volume>
<fpage>324</fpage>
<pub-id pub-id-type="doi">10.4103/0019-5545.58304</pub-id>
<pub-id pub-id-type="pmid">20048463</pub-id>
</element-citation>
</ref>
<ref id="B21-pharmaceutics-12-00013">
<label>21.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shen</surname>
<given-names>W.W.</given-names>
</name>
</person-group>
<article-title>A history of antipsychotic drug development</article-title>
<source/>Compr. Psychiatry
          <year>1999</year>
<volume>40</volume>
<fpage>407</fpage>
<lpage>414</lpage>
<pub-id pub-id-type="doi">10.1016/S0010-440X(99)90082-2</pub-id>
<pub-id pub-id-type="pmid">10579370</pub-id>
</element-citation>
</ref>
<ref id="B22-pharmaceutics-12-00013">
<label>22.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Seeman</surname>
<given-names>P.</given-names>
</name>
</person-group>
<article-title>Atypical antipsychotics: Mechanism of action</article-title>
<source/>Focus
          <year>2004</year>
<volume>47</volume>
<fpage>27</fpage>
<lpage>58</lpage>
<pub-id pub-id-type="doi">10.1177/070674370204700106</pub-id>
</element-citation>
</ref>
<ref id="B23-pharmaceutics-12-00013">
<label>23.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Malhi</surname>
<given-names>G.S.</given-names>
</name>
<name>
<surname>Tanious</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Das</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Coulston</surname>
<given-names>C.M.</given-names>
</name>
<name>
<surname>Berk</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Potential mechanisms of action of lithium in bipolar disorder</article-title>
<source/>CNS Drugs
          <year>2013</year>
<volume>27</volume>
<fpage>135</fpage>
<lpage>153</lpage>
<pub-id pub-id-type="doi">10.1007/s40263-013-0039-0</pub-id>
<pub-id pub-id-type="pmid">23371914</pub-id>
</element-citation>
</ref>
<ref id="B24-pharmaceutics-12-00013">
<label>24.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Marmol</surname>
<given-names>F.</given-names>
</name>
</person-group>
<article-title>Lithium: Bipolar disorder and neurodegenerative diseases Possible cellular mechanisms of the therapeutic effects of lithium</article-title>
<source/>Prog. Neuropsychopharmacol. Biol. Psychiatry
          <year>2008</year>
<volume>32</volume>
<fpage>1761</fpage>
<lpage>1771</lpage>
<pub-id pub-id-type="doi">10.1016/j.pnpbp.2008.08.012</pub-id>
<pub-id pub-id-type="pmid">18789369</pub-id>
</element-citation>
</ref>
<ref id="B25-pharmaceutics-12-00013">
<label>25.</label>
<element-citation publication-type="book">
<person-group person-group-type="author">
<name>
<surname>Pisanu</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Squassina</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Alda</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Severino</surname>
<given-names>G.</given-names>
</name>
</person-group>
<article-title>Pharmacogenomics of bipolar disorder</article-title>
<source/>Personalized Psychiatry
          <edition>1st ed.</edition>
<person-group person-group-type="editor">
<name>
<surname>Baune</surname>
<given-names>B.</given-names>
</name>
</person-group>
<publisher-name>Elsevier Academic Press</publisher-name>
<publisher-loc>Amsterdam, The Netherlands</publisher-loc>
<year>2019</year>
<comment>Chapter 32</comment>
<isbn>9780128131763</isbn>
</element-citation>
</ref>
<ref id="B26-pharmaceutics-12-00013">
<label>26.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Spina</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Perugi</surname>
<given-names>G.</given-names>
</name>
</person-group>
<article-title>Antiepileptic drugs: Indications other than epilepsy</article-title>
<source/>Epileptic Disord.
          <year>2004</year>
<volume>6</volume>
<fpage>57</fpage>
<lpage>75</lpage>
<pub-id pub-id-type="pmid">15246950</pub-id>
</element-citation>
</ref>
<ref id="B27-pharmaceutics-12-00013">
<label>27.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Landmark</surname>
<given-names>C.J.</given-names>
</name>
</person-group>
<article-title>Antiepileptic drugs in non-epilepsy disorders</article-title>
<source/>CNS Drugs
          <year>2008</year>
<volume>22</volume>
<fpage>27</fpage>
<lpage>47</lpage>
<pub-id pub-id-type="doi">10.2165/00023210-200822010-00003</pub-id>
<pub-id pub-id-type="pmid">18072813</pub-id>
</element-citation>
</ref>
<ref id="B28-pharmaceutics-12-00013">
<label>28.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Friedman</surname>
<given-names>S.D.</given-names>
</name>
<name>
<surname>Dager</surname>
<given-names>S.R.</given-names>
</name>
<name>
<surname>Parow</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Hirashima</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Demopulos</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Stoll</surname>
<given-names>A.L.</given-names>
</name>
<name>
<surname>Lyoo</surname>
<given-names>I.K.</given-names>
</name>
<name>
<surname>Dunner</surname>
<given-names>D.L.</given-names>
</name>
<name>
<surname>Renshaw</surname>
<given-names>P.F.</given-names>
</name>
</person-group>
<article-title>Lithium and valproic acid treatment effects on brain chemistry in bipolar disorder</article-title>
<source/>Biol. Psychiatry
          <year>2004</year>
<volume>56</volume>
<fpage>340</fpage>
<lpage>348</lpage>
<pub-id pub-id-type="doi">10.1016/j.biopsych.2004.06.012</pub-id>
<pub-id pub-id-type="pmid">15336516</pub-id>
</element-citation>
</ref>
<ref id="B29-pharmaceutics-12-00013">
<label>29.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chiu</surname>
<given-names>C.T.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Hunsberger</surname>
<given-names>J.G.</given-names>
</name>
<name>
<surname>Chuang</surname>
<given-names>D.M.</given-names>
</name>
</person-group>
<article-title>Therapeutic potential of mood stabilizers lithium and valproic acid: Beyond bipolar disorder</article-title>
<source/>Pharmacol. Rev.
          <year>2013</year>
<volume>65</volume>
<fpage>105</fpage>
<lpage>142</lpage>
<pub-id pub-id-type="doi">10.1124/pr.111.005512</pub-id>
<pub-id pub-id-type="pmid">23300133</pub-id>
</element-citation>
</ref>
<ref id="B30-pharmaceutics-12-00013">
<label>30.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Macritchie</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Geddes</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Scott</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Haslam</surname>
<given-names>D.R.</given-names>
</name>
<name>
<surname>Goodwin</surname>
<given-names>G.</given-names>
</name>
</person-group>
<article-title>Valproic acid, valproate and divalproex in the maintenance treatment of bipolar disorder</article-title>
<source/>Cochrane Database Syst. Rev.
          <year>2001</year>
<pub-id pub-id-type="doi">10.1002/14651858.CD003196.pub2</pub-id>
</element-citation>
</ref>
<ref id="B31-pharmaceutics-12-00013">
<label>31.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Denicoff</surname>
<given-names>K.D.</given-names>
</name>
<name>
<surname>Smith-Jackson</surname>
<given-names>E.E.</given-names>
</name>
<name>
<surname>Disney</surname>
<given-names>E.R.</given-names>
</name>
<name>
<surname>Ali</surname>
<given-names>S.O.</given-names>
</name>
<name>
<surname>Leverich</surname>
<given-names>G.S.</given-names>
</name>
<name>
<surname>Post</surname>
<given-names>R.M.</given-names>
</name>
</person-group>
<article-title>Comparative prophylactic efficacy of lithium, carbamazepine, and the combination in bipolar disorder</article-title>
<source/>J. Clin. Psychiatry
          <year>1997</year>
<volume>58</volume>
<fpage>470</fpage>
<lpage>478</lpage>
<pub-id pub-id-type="doi">10.4088/JCP.v58n1102</pub-id>
<pub-id pub-id-type="pmid">9413412</pub-id>
</element-citation>
</ref>
<ref id="B32-pharmaceutics-12-00013">
<label>32.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kowatch</surname>
<given-names>R.A.</given-names>
</name>
<name>
<surname>Suppes</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Carmody</surname>
<given-names>T.J.</given-names>
</name>
<name>
<surname>Bucci</surname>
<given-names>J.P.</given-names>
</name>
<name>
<surname>Hume</surname>
<given-names>J.H.</given-names>
</name>
<name>
<surname>Kromelis</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Emslie</surname>
<given-names>G.J.</given-names>
</name>
<name>
<surname>Weinberg</surname>
<given-names>W.A.</given-names>
</name>
<name>
<surname>Rush</surname>
<given-names>A.J.</given-names>
</name>
</person-group>
<article-title>Effect size of lithium, divalproex sodium, and carbamazepine in children and adolescents with bipolar disorder</article-title>
<source/>J. Am. Acad. Child. Adolesc. Psychiatry
          <year>2000</year>
<volume>39</volume>
<fpage>713</fpage>
<lpage>720</lpage>
<pub-id pub-id-type="doi">10.1097/00004583-200006000-00009</pub-id>
<pub-id pub-id-type="pmid">10846305</pub-id>
</element-citation>
</ref>
<ref id="B33-pharmaceutics-12-00013">
<label>33.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tohen</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Castillo</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Pope</surname>
<given-names>H.G.</given-names>
</name>
<name>
<surname>Herbstein</surname>
<given-names>J.</given-names>
</name>
</person-group>
<article-title>Concomitant use of valproate and carbamazepine in bipolar and schizoaffective disorders</article-title>
<source/>J. Clin. Psychopharmacol.
          <year>1994</year>
<volume>14</volume>
<fpage>67</fpage>
<lpage>70</lpage>
<pub-id pub-id-type="doi">10.1097/00004714-199402000-00009</pub-id>
<pub-id pub-id-type="pmid">8151006</pub-id>
</element-citation>
</ref>
<ref id="B34-pharmaceutics-12-00013">
<label>34.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Calabrese</surname>
<given-names>J.R.</given-names>
</name>
<name>
<surname>Bowden</surname>
<given-names>C.L.</given-names>
</name>
<name>
<surname>Sachs</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Yatham</surname>
<given-names>L.N.</given-names>
</name>
<name>
<surname>Behnke</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Mehtonen</surname>
<given-names>O.P.</given-names>
</name>
<name>
<surname>Montgomery</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Ascher</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Paska</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Earl</surname>
<given-names>N.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently depressed patients with bipolar I disorder</article-title>
<source/>J. Clin. Psychiatry
          <year>2003</year>
<volume>64</volume>
<fpage>1013</fpage>
<lpage>1024</lpage>
<pub-id pub-id-type="doi">10.4088/JCP.v64n0906</pub-id>
<pub-id pub-id-type="pmid">14628976</pub-id>
</element-citation>
</ref>
<ref id="B35-pharmaceutics-12-00013">
<label>35.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lee</surname>
<given-names>C.Y.</given-names>
</name>
<name>
<surname>Fu</surname>
<given-names>W.M.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>C.C.</given-names>
</name>
<name>
<surname>Su</surname>
<given-names>M.J.</given-names>
</name>
<name>
<surname>Liou</surname>
<given-names>H.H.</given-names>
</name>
</person-group>
<article-title>Lamotrigine inhibits postsynaptic AMPA receptor and glutamate release in the dentate gyrus</article-title>
<source/>Epilepsia
          <year>2008</year>
<volume>49</volume>
<fpage>888</fpage>
<lpage>897</lpage>
<pub-id pub-id-type="doi">10.1111/j.1528-1167.2007.01526.x</pub-id>
<pub-id pub-id-type="pmid">18248444</pub-id>
</element-citation>
</ref>
<ref id="B36-pharmaceutics-12-00013">
<label>36.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yatham</surname>
<given-names>L.N.</given-names>
</name>
<name>
<surname>Goldstein</surname>
<given-names>J.M.</given-names>
</name>
<name>
<surname>Vieta</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Bowden</surname>
<given-names>C.L.</given-names>
</name>
<name>
<surname>Grunze</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Post</surname>
<given-names>R.M.</given-names>
</name>
<name>
<surname>Suppes</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Calabrese</surname>
<given-names>J.R.</given-names>
</name>
</person-group>
<article-title>Atypical antipsychotics in bipolar depression: Potential mechanisms of action</article-title>
<source/>J. Clin. Psychiatry
          <year>2005</year>
<volume>66</volume>
<fpage>40</fpage>
<lpage>48</lpage>
<pub-id pub-id-type="pmid">16038601</pub-id>
</element-citation>
</ref>
<ref id="B37-pharmaceutics-12-00013">
<label>37.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Meltzer</surname>
<given-names>H.Y.</given-names>
</name>
<name>
<surname>Massey</surname>
<given-names>B.W.</given-names>
</name>
</person-group>
<article-title>The role of serotonin receptors in the action of atypical antipsychotic drugs</article-title>
<source/>Curr. Opin. Pharmacol.
          <year>2011</year>
<volume>11</volume>
<fpage>59</fpage>
<lpage>67</lpage>
<pub-id pub-id-type="doi">10.1016/j.coph.2011.02.007</pub-id>
<pub-id pub-id-type="pmid">21420906</pub-id>
</element-citation>
</ref>
<ref id="B38-pharmaceutics-12-00013">
<label>38.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Meltzer</surname>
<given-names>H.Y.</given-names>
</name>
</person-group>
<article-title>The mechanism of action of novel antipsychotic drugs</article-title>
<source/>Schizophr. Bull.
          <year>1991</year>
<volume>17</volume>
<fpage>263</fpage>
<lpage>287</lpage>
<pub-id pub-id-type="doi">10.1093/schbul/17.2.263</pub-id>
<pub-id pub-id-type="pmid">1679253</pub-id>
</element-citation>
</ref>
<ref id="B39-pharmaceutics-12-00013">
<label>39.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Thase</surname>
<given-names>M.E.</given-names>
</name>
<name>
<surname>Macfadden</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Weisler</surname>
<given-names>R.H.</given-names>
</name>
<name>
<surname>Chang</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Paulsson</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Khan</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Calabrese</surname>
<given-names>J.R.</given-names>
</name>
</person-group>
<article-title>BOLDER II Study Group. Efficacy of quetiapine monotherapy in bipolar I and II depression: A double-blind, placebo-controlled study (the BOLDER II study)</article-title>
<source/>J. Clin. Psychopharmacol.
          <year>2006</year>
<volume>26</volume>
<fpage>600</fpage>
<lpage>609</lpage>
<pub-id pub-id-type="doi">10.1097/01.jcp.0000248603.76231.b7</pub-id>
<pub-id pub-id-type="pmid">17110817</pub-id>
</element-citation>
</ref>
<ref id="B40-pharmaceutics-12-00013">
<label>40.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fornaro</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>De Berardis</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Perna</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Solmi</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Veronese</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Orsolini</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Buonaguro</surname>
<given-names>E.F.</given-names>
</name>
<name>
<surname>Iasevoli</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Köhler</surname>
<given-names>C.A.</given-names>
</name>
<name>
<surname>Carvalho</surname>
<given-names>A.F.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Lurasidone in the treatment of bipolar depression: Systematic review of systematic reviews</article-title>
<source/>Biomed Res. Int.
          <year>2017</year>
<volume>2017</volume>
<fpage>3084859</fpage>
<pub-id pub-id-type="doi">10.1155/2017/3084859</pub-id>
<pub-id pub-id-type="pmid">28573138</pub-id>
</element-citation>
</ref>
<ref id="B41-pharmaceutics-12-00013">
<label>41.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Freeman</surname>
<given-names>M.P.</given-names>
</name>
<name>
<surname>Freeman</surname>
<given-names>S.A.</given-names>
</name>
<name>
<surname>McElroy</surname>
<given-names>S.L.</given-names>
</name>
</person-group>
<article-title>The comorbidity of bipolar and anxiety disorders: Prevalence, psychobiology, and treatment issues</article-title>
<source/>J. Affect. Disord.
          <year>2002</year>
<volume>68</volume>
<fpage>1</fpage>
<lpage>23</lpage>
<pub-id pub-id-type="doi">10.1016/S0165-0327(00)00299-8</pub-id>
<pub-id pub-id-type="pmid">11869778</pub-id>
</element-citation>
</ref>
<ref id="B42-pharmaceutics-12-00013">
<label>42.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ghaemi</surname>
<given-names>S.N.</given-names>
</name>
<name>
<surname>Boiman</surname>
<given-names>E.E.</given-names>
</name>
<name>
<surname>Goodwin</surname>
<given-names>F.K.</given-names>
</name>
</person-group>
<article-title>Diagnosing bipolar disorder and the effect of antidepressants: A naturalistic study</article-title>
<source/>J. Clin. Psychiatry
          <year>2000</year>
<volume>61</volume>
<pub-id pub-id-type="doi">10.4088/JCP.v61n1013</pub-id>
</element-citation>
</ref>
<ref id="B43-pharmaceutics-12-00013">
<label>43.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>El-Mallakh</surname>
<given-names>R.S.</given-names>
</name>
<name>
<surname>Vöhringer</surname>
<given-names>P.A.</given-names>
</name>
<name>
<surname>Ostacher</surname>
<given-names>M.M.</given-names>
</name>
<name>
<surname>Baldassano</surname>
<given-names>C.F.</given-names>
</name>
<name>
<surname>Holtzman</surname>
<given-names>N.S.</given-names>
</name>
<name>
<surname>Whitham</surname>
<given-names>E.A.</given-names>
</name>
<name>
<surname>Thommi</surname>
<given-names>S.B.</given-names>
</name>
<name>
<surname>Goodwin</surname>
<given-names>F.K.</given-names>
</name>
<name>
<surname>Ghaemi</surname>
<given-names>S.N.</given-names>
</name>
</person-group>
<article-title>Antidepressants worsen rapid-cycling course in bipolar depression: A STEP-BD randomized clinical trial</article-title>
<source/>J. Affect. Disord.
          <year>2015</year>
<volume>184</volume>
<fpage>318</fpage>
<lpage>321</lpage>
<pub-id pub-id-type="doi">10.1016/j.jad.2015.04.054</pub-id>
<pub-id pub-id-type="pmid">26142612</pub-id>
</element-citation>
</ref>
<ref id="B44-pharmaceutics-12-00013">
<label>44.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>King</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Jelen</surname>
<given-names>L.A.</given-names>
</name>
<name>
<surname>Horne</surname>
<given-names>C.M.</given-names>
</name>
<name>
<surname>Cleare</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Pariante</surname>
<given-names>C.M.</given-names>
</name>
<name>
<surname>Young</surname>
<given-names>A.H.</given-names>
</name>
<name>
<surname>Stone</surname>
<given-names>J.M.</given-names>
</name>
</person-group>
<article-title>Inflammation, Glutamate, and Cognition in Bipolar Disorder Type II: A Proof of Concept Study</article-title>
<source/>Front. Psychiatry
          <year>2019</year>
<volume>10</volume>
<fpage>66</fpage>
<pub-id pub-id-type="doi">10.3389/fpsyt.2019.00066</pub-id>
<pub-id pub-id-type="pmid">30881316</pub-id>
</element-citation>
</ref>
<ref id="B45-pharmaceutics-12-00013">
<label>45.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jun</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Choi</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Lim</surname>
<given-names>S.M.</given-names>
</name>
<name>
<surname>Bae</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Hong</surname>
<given-names>Y.S.</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>J.E.</given-names>
</name>
<name>
<surname>Lyoo</surname>
<given-names>I.K.</given-names>
</name>
</person-group>
<article-title>Disturbance of the glutamatergic system in mood disorders</article-title>
<source/>Exp. Neurobiol.
          <year>2014</year>
<volume>23</volume>
<fpage>28</fpage>
<lpage>35</lpage>
<pub-id pub-id-type="doi">10.5607/en.2014.23.1.28</pub-id>
<pub-id pub-id-type="pmid">24737937</pub-id>
</element-citation>
</ref>
<ref id="B46-pharmaceutics-12-00013">
<label>46.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kalandadze</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Robinson</surname>
<given-names>M.B.</given-names>
</name>
</person-group>
<article-title>Protein Kinase C Activation Decreases Cell Surface Expression of the GLT-1 Subtype of Glutamate Transporter requirement of a carboxyl-terminal domain and partial dependence on serine 486</article-title>
<source/>J. Biol. Chem.
          <year>2002</year>
<volume>277</volume>
<fpage>45741</fpage>
<lpage>45750</lpage>
<pub-id pub-id-type="doi">10.1074/jbc.M203771200</pub-id>
<pub-id pub-id-type="pmid">12324450</pub-id>
</element-citation>
</ref>
<ref id="B47-pharmaceutics-12-00013">
<label>47.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Guillet</surname>
<given-names>B.A.</given-names>
</name>
<name>
<surname>Velly</surname>
<given-names>L.J.</given-names>
</name>
<name>
<surname>Canolle</surname>
<given-names>B.F.M.M.</given-names>
</name>
<name>
<surname>Masmejean</surname>
<given-names>F.M.</given-names>
</name>
<name>
<surname>Nieoullon</surname>
<given-names>A.L.</given-names>
</name>
<name>
<surname>Pisano</surname>
<given-names>P.</given-names>
</name>
</person-group>
<article-title>Differential regulation by protein kinases of activity and cell surface expression of glutamate transporters in neuron-enriched cultures</article-title>
<source/>Neurochem. Int.
          <year>2005</year>
<volume>46</volume>
<fpage>337</fpage>
<lpage>346</lpage>
<pub-id pub-id-type="doi">10.1016/j.neuint.2004.10.006</pub-id>
<pub-id pub-id-type="pmid">15707698</pub-id>
</element-citation>
</ref>
<ref id="B48-pharmaceutics-12-00013">
<label>48.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Boehmer</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Palmada</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Rajamanickam</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Schniepp</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Amara</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Lang</surname>
<given-names>F.</given-names>
</name>
</person-group>
<article-title>Post-translational regulation of EAAT2 function by co-expressed ubiquitin ligase Nedd4-2 is impacted by SGK kinases</article-title>
<source/>J. Neurochem.
          <year>2006</year>
<volume>97</volume>
<fpage>911</fpage>
<lpage>921</lpage>
<pub-id pub-id-type="doi">10.1111/j.1471-4159.2006.03629.x</pub-id>
<pub-id pub-id-type="pmid">16573659</pub-id>
</element-citation>
</ref>
<ref id="B49-pharmaceutics-12-00013">
<label>49.</label>
<element-citation publication-type="book">
<person-group person-group-type="author">
<name>
<surname>Sattler</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Rothstein</surname>
<given-names>J.D.</given-names>
</name>
</person-group>
<article-title>Regulation and dysregulation of glutamate transporters</article-title>
<source/>Neurotransmitter Transporters
          <publisher-name>Springer</publisher-name>
<publisher-loc>Berlin/Heidelberg, Germany</publisher-loc>
<year>2006</year>
<fpage>277</fpage>
<lpage>303</lpage>
</element-citation>
</ref>
<ref id="B50-pharmaceutics-12-00013">
<label>50.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Martínez-Villarreal</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>García Tardón</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Ibáñez</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Giménez</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Zafra</surname>
<given-names>F.</given-names>
</name>
</person-group>
<article-title>Cell surface turnover of the glutamate transporter GLT-1 is mediated by ubiquitination/deubiquitination</article-title>
<source/>Glia
          <year>2012</year>
<volume>60</volume>
<fpage>1356</fpage>
<lpage>1365</lpage>
<pub-id pub-id-type="doi">10.1002/glia.22354</pub-id>
<pub-id pub-id-type="pmid">22593014</pub-id>
</element-citation>
</ref>
<ref id="B51-pharmaceutics-12-00013">
<label>51.</label>
<element-citation publication-type="book">
<person-group person-group-type="author">
<name>
<surname>Rang</surname>
<given-names>H.P.</given-names>
</name>
<name>
<surname>Dale</surname>
<given-names>M.M.</given-names>
</name>
<name>
<surname>Ritter</surname>
<given-names>J.M.</given-names>
</name>
<name>
<surname>Moore</surname>
<given-names>P.K.</given-names>
</name>
</person-group>
<article-title>Ch. 10</article-title>
<source/>Pharmacology
          <edition>5th ed.</edition>
<publisher-name>Elsevier Churchill Livingstone</publisher-name>
<publisher-loc>London, UK</publisher-loc>
<year>2010</year>
<isbn>978-0-443-07145-4</isbn>
</element-citation>
</ref>
<ref id="B52-pharmaceutics-12-00013">
<label>52.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>González-gonzález</surname>
<given-names>I.M.</given-names>
</name>
<name>
<surname>García-tardón</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Giménez</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Zafra</surname>
<given-names>F.</given-names>
</name>
</person-group>
<article-title>PKC-dependent endocytosis of the GLT1 glutamate transporter depends on ubiquitylation of lysines located in a C-terminal cluster</article-title>
<source/>Glia
          <year>2008</year>
<volume>56</volume>
<fpage>963</fpage>
<lpage>974</lpage>
<pub-id pub-id-type="doi">10.1002/glia.20670</pub-id>
<pub-id pub-id-type="pmid">18381652</pub-id>
</element-citation>
</ref>
<ref id="B53-pharmaceutics-12-00013">
<label>53.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Reynolds</surname>
<given-names>G.P.</given-names>
</name>
</person-group>
<article-title>Receptor mechanisms of antipsychotic drug action in bipolar disorder—Focus on asenapine</article-title>
<source/>Ther. Adv. Psychopharm.
          <year>2011</year>
<volume>1</volume>
<fpage>197</fpage>
<lpage>204</lpage>
<pub-id pub-id-type="doi">10.1177/2045125311430112</pub-id>
</element-citation>
</ref>
<ref id="B54-pharmaceutics-12-00013">
<label>54.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Smoller</surname>
<given-names>J.W.</given-names>
</name>
<name>
<surname>Finn</surname>
<given-names>C.T.</given-names>
</name>
</person-group>
<article-title>Family, twin, and adoption studies of bipolar disorder</article-title>
<source/>Am. J. Med. Genet. Part C Semin. Med. Genet.
          <year>2003</year>
<volume>123</volume>
<fpage>48</fpage>
<lpage>58</lpage>
<pub-id pub-id-type="doi">10.1002/ajmg.c.20013</pub-id>
</element-citation>
</ref>
<ref id="B55-pharmaceutics-12-00013">
<label>55.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Stahl</surname>
<given-names>E.A.</given-names>
</name>
<name>
<surname>Breen</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Forstner</surname>
<given-names>A.J.</given-names>
</name>
<name>
<surname>McQuillin</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Ripke</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Trubetskoy</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Mattheisen</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Coleman</surname>
<given-names>J.R.</given-names>
</name>
<name>
<surname>Gaspar</surname>
<given-names>H.A.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Genome-wide association study identifies 30 loci associated with bipolar disorder</article-title>
<source/>Nature Genet.
          <year>2019</year>
<volume>51</volume>
<fpage>793</fpage>
<pub-id pub-id-type="doi">10.1038/s41588-019-0397-8</pub-id>
<pub-id pub-id-type="pmid">31043756</pub-id>
</element-citation>
</ref>
<ref id="B56-pharmaceutics-12-00013">
<label>56.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kessler</surname>
<given-names>R.C.</given-names>
</name>
<name>
<surname>Rubinow</surname>
<given-names>D.R.</given-names>
</name>
<name>
<surname>Holmes</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Abelson</surname>
<given-names>J.M.</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>S.</given-names>
</name>
</person-group>
<article-title>The epidemiology of DSM-III-R bipolar I disorder in a general population survey</article-title>
<source/>Psychol. Med.
          <year>1997</year>
<volume>27</volume>
<fpage>1079</fpage>
<lpage>1089</lpage>
<pub-id pub-id-type="doi">10.1017/S0033291797005333</pub-id>
<pub-id pub-id-type="pmid">9300513</pub-id>
</element-citation>
</ref>
<ref id="B57-pharmaceutics-12-00013">
<label>57.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gershon</surname>
<given-names>E.S.</given-names>
</name>
<name>
<surname>Hamovit</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Guroff</surname>
<given-names>J.J.</given-names>
</name>
<name>
<surname>Dibble</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Leckman</surname>
<given-names>J.F.</given-names>
</name>
<name>
<surname>Sceery</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Targum</surname>
<given-names>S.D.</given-names>
</name>
<name>
<surname>Nurnberger</surname>
<given-names>J.I.</given-names>
<suffix>Jr.</suffix>
</name>
<name>
<surname>Goldin</surname>
<given-names>L.R.</given-names>
</name>
<name>
<surname>Bunney</surname>
<given-names>W.E.</given-names>
<suffix>Jr.</suffix>
</name>
</person-group>
<article-title>A family study of schizoaffective, bipolar I, bipolar II, unipolar, and normal control probands</article-title>
<source/>Arch. Gen. Psychiatry
          <year>1982</year>
<volume>39</volume>
<fpage>1157</fpage>
<lpage>1167</lpage>
<pub-id pub-id-type="doi">10.1001/archpsyc.1982.04290100031006</pub-id>
<pub-id pub-id-type="pmid">7125846</pub-id>
</element-citation>
</ref>
<ref id="B58-pharmaceutics-12-00013">
<label>58.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Andreasen</surname>
<given-names>N.C.</given-names>
</name>
<name>
<surname>Rice</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Endicott</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Coryell</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Grove</surname>
<given-names>W.M.</given-names>
</name>
<name>
<surname>Reich</surname>
<given-names>T.</given-names>
</name>
</person-group>
<article-title>Familial rates of affective disorder: A report from the National Institute of Mental Health Collaborative Study</article-title>
<source/>Arch. Gen. Psychiatry
          <year>1987</year>
<volume>44</volume>
<fpage>461</fpage>
<lpage>469</lpage>
<pub-id pub-id-type="doi">10.1001/archpsyc.1987.01800170083011</pub-id>
<pub-id pub-id-type="pmid">3579497</pub-id>
</element-citation>
</ref>
<ref id="B59-pharmaceutics-12-00013">
<label>59.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Heun</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Maier</surname>
<given-names>W.</given-names>
</name>
</person-group>
<article-title>The distinction of bipolar II disorder from bipolar I and recurrent unipolar depression: Results of a controlled family study</article-title>
<source/>Acta Psychiatr. Scand.
          <year>1993</year>
<volume>87</volume>
<fpage>279</fpage>
<lpage>284</lpage>
<pub-id pub-id-type="doi">10.1111/j.1600-0447.1993.tb03372.x</pub-id>
<pub-id pub-id-type="pmid">8488750</pub-id>
</element-citation>
</ref>
<ref id="B60-pharmaceutics-12-00013">
<label>60.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Barnett</surname>
<given-names>J.H.</given-names>
</name>
<name>
<surname>Smoller</surname>
<given-names>J.W.</given-names>
</name>
</person-group>
<article-title>The genetics of bipolar disorder</article-title>
<source/>Neuroscience
          <year>2009</year>
<volume>164</volume>
<fpage>331</fpage>
<lpage>343</lpage>
<pub-id pub-id-type="doi">10.1016/j.neuroscience.2009.03.080</pub-id>
<pub-id pub-id-type="pmid">19358880</pub-id>
</element-citation>
</ref>
<ref id="B61-pharmaceutics-12-00013">
<label>61.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Craddock</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Sklar</surname>
<given-names>P.</given-names>
</name>
</person-group>
<article-title>Genetics of bipolar disorder</article-title>
<source/>Lancet
          <year>2013</year>
<volume>381</volume>
<fpage>1654</fpage>
<lpage>1662</lpage>
<pub-id pub-id-type="doi">10.1016/S0140-6736(13)60855-7</pub-id>
<pub-id pub-id-type="pmid">23663951</pub-id>
</element-citation>
</ref>
<ref id="B62-pharmaceutics-12-00013">
<label>62.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ferreira</surname>
<given-names>M.A.</given-names>
</name>
<name>
<surname>O’Donovan</surname>
<given-names>M.C.</given-names>
</name>
<name>
<surname>Meng</surname>
<given-names>Y.A.</given-names>
</name>
<name>
<surname>Jones</surname>
<given-names>I.R.</given-names>
</name>
<name>
<surname>Ruderfer</surname>
<given-names>D.M.</given-names>
</name>
<name>
<surname>Jones</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Fan</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Kirov</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Perlis</surname>
<given-names>R.H.</given-names>
</name>
<name>
<surname>Green</surname>
<given-names>E.K.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Collaborative genome-wide association analysis supports a role for ANK3 and CACNA1C in bipolar disorder</article-title>
<source/>Nature Genet.
          <year>2008</year>
<volume>40</volume>
<fpage>1056</fpage>
<pub-id pub-id-type="doi">10.1038/ng.209</pub-id>
<pub-id pub-id-type="pmid">18711365</pub-id>
</element-citation>
</ref>
<ref id="B63-pharmaceutics-12-00013">
<label>63.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<collab>Psychiatric GWAS Consortium Bipolar Disorder Working Group</collab>
</person-group>
<article-title>Large-scale genome-wide association analysis of bipolar disorder identifies a new susceptibility locus near ODZ4</article-title>
<source/>Nature Genet.
          <year>2011</year>
<volume>43</volume>
<fpage>977</fpage>
<pub-id pub-id-type="doi">10.1038/ng.943</pub-id>
<pub-id pub-id-type="pmid">21926972</pub-id>
</element-citation>
</ref>
<ref id="B64-pharmaceutics-12-00013">
<label>64.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Saiz-Rodríguez</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Belmonte</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Román</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Ochoa</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Jiang-Zheng</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Koller</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Mejía</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Zubiaur</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Wojnicz</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Abad-Santos</surname>
<given-names>F.</given-names>
</name>
</person-group>
<article-title>Effect of ABCB1 C3435T polymorphism on pharmacokinetics of antipsychotics and antidepressants</article-title>
<source/>Basic. Clin. Pharmacol. Toxicol.
          <year>2018</year>
<volume>123</volume>
<fpage>474</fpage>
<lpage>485</lpage>
<pub-id pub-id-type="doi">10.1111/bcpt.13031</pub-id>
<pub-id pub-id-type="pmid">29723928</pub-id>
</element-citation>
</ref>
<ref id="B65-pharmaceutics-12-00013">
<label>65.</label>
<element-citation publication-type="book">
<person-group person-group-type="author">
<name>
<surname>Buriani</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Fortinguerra</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Carrara</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Pelkonen</surname>
<given-names>O.</given-names>
</name>
</person-group>
<article-title>Systems network pharmaco-toxicology in the study of herbal medicines</article-title>
<source/>Toxicology of Herbal Products
          <publisher-name>Springer</publisher-name>
<publisher-loc>Cham, Germany</publisher-loc>
<year>2017</year>
<fpage>129</fpage>
<lpage>164</lpage>
</element-citation>
</ref>
<ref id="B66-pharmaceutics-12-00013">
<label>66.</label>
<element-citation publication-type="gov">
<article-title>Table of Pharmacogenomic Biomarkers in Drug Labeling (FDA)</article-title>
<comment>Available online: <ext-link ext-link-type="uri" xlink:href="https://www.fda.gov/drugs/science-and-research-drugs/table-pharmacogenomic-biomarkers-drug-labeling">https://www.fda.gov/drugs/science-and-research-drugs/table-pharmacogenomic-biomarkers-drug-labeling</ext-link></comment>
<date-in-citation content-type="access-date" iso-8601-date="2019-09-01">(accessed on 1 September 2019)</date-in-citation>
</element-citation>
</ref>
<ref id="B67-pharmaceutics-12-00013">
<label>67.</label>
<element-citation publication-type="web">
<article-title>Pharmgkb</article-title>
<comment>Available online: <ext-link ext-link-type="uri" xlink:href="https://www.pharmgkb.org">https://www.pharmgkb.org</ext-link></comment>
<date-in-citation content-type="access-date" iso-8601-date="2019-09-01">(accessed on 1 September 2019)</date-in-citation>
</element-citation>
</ref>
<ref id="B68-pharmaceutics-12-00013">
<label>68.</label>
<element-citation publication-type="web">
<article-title>The DrugBank database</article-title>
<comment>Available online: <ext-link ext-link-type="uri" xlink:href="https://www.drugbank.ca/">https://www.drugbank.ca/</ext-link></comment>
<date-in-citation content-type="access-date" iso-8601-date="2019-09-01">(accessed on 1 September 2019)</date-in-citation>
</element-citation>
</ref>
<ref id="B69-pharmaceutics-12-00013">
<label>69.</label>
<element-citation publication-type="web">
<article-title>GeneCards®: The Human Gene Database</article-title>
<comment>Available online: <ext-link ext-link-type="uri" xlink:href="https://www.genecards.org/">https://www.genecards.org/</ext-link></comment>
<date-in-citation content-type="access-date" iso-8601-date="2019-09-01">(accessed on 1 September 2019)</date-in-citation>
</element-citation>
</ref>
<ref id="B70-pharmaceutics-12-00013">
<label>70.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Phillips</surname>
<given-names>E.J.</given-names>
</name>
<name>
<surname>Sukasem</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Whirl-Carrillo</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Müller</surname>
<given-names>D.J.</given-names>
</name>
<name>
<surname>Dunnenberger</surname>
<given-names>H.M.</given-names>
</name>
<name>
<surname>Chantratita</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Goldspiel</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>Y.T.</given-names>
</name>
<name>
<surname>Carleton</surname>
<given-names>B.C.</given-names>
</name>
<name>
<surname>George</surname>
<given-names>A.L.</given-names>
<suffix>Jr.</suffix>
</name>
<etal></etal>
</person-group>
<article-title>Clinical pharmacogenetics implementation consortium guideline for HLA genotype and use of carbamazepine and oxcarbazepine: 2017 update</article-title>
<source/>Clin. Pharmacol. Ther.
          <year>2018</year>
<volume>103</volume>
<fpage>574</fpage>
<lpage>581</lpage>
<pub-id pub-id-type="doi">10.1002/cpt.1004</pub-id>
<pub-id pub-id-type="pmid">29392710</pub-id>
</element-citation>
</ref>
<ref id="B71-pharmaceutics-12-00013">
<label>71.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Smith</surname>
<given-names>R.M.</given-names>
</name>
</person-group>
<article-title>Advancing psychiatric pharmacogenomics using drug development paradigms</article-title>
<source/>Pharmacogenomics
          <year>2017</year>
<volume>18</volume>
<fpage>1459</fpage>
<lpage>1467</lpage>
<pub-id pub-id-type="doi">10.2217/pgs-2017-0104</pub-id>
<pub-id pub-id-type="pmid">28975860</pub-id>
</element-citation>
</ref>
<ref id="B72-pharmaceutics-12-00013">
<label>72.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Luzum</surname>
<given-names>J.A.</given-names>
</name>
<name>
<surname>Pakyz</surname>
<given-names>R.E.</given-names>
</name>
<name>
<surname>Elsey</surname>
<given-names>A.R.</given-names>
</name>
<name>
<surname>Haidar</surname>
<given-names>C.E.</given-names>
</name>
<name>
<surname>Peterson</surname>
<given-names>J.F.</given-names>
</name>
<name>
<surname>Whirl-Carrillo</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Handelman</surname>
<given-names>S.K.</given-names>
</name>
<name>
<surname>Palmer</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Pulley</surname>
<given-names>J.M.</given-names>
</name>
<name>
<surname>Beller</surname>
<given-names>M.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>The Pharmacogenomics Research Network Translational Pharmacogenetics Program: Outcomes and metrics of pharmacogenetic implementations across diverse healthcare systems</article-title>
<source/>Clin. Pharmacol. Ther.
          <year>2017</year>
<volume>102</volume>
<fpage>502</fpage>
<lpage>510</lpage>
<pub-id pub-id-type="doi">10.1002/cpt.630</pub-id>
<pub-id pub-id-type="pmid">28090649</pub-id>
</element-citation>
</ref>
<ref id="B73-pharmaceutics-12-00013">
<label>73.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mas</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Gassó</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Lafuente</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Bioque</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Lobo</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Gonzàlez-Pinto</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Olmeda</surname>
<given-names>M.S.</given-names>
</name>
<name>
<surname>Corripio</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Llerena</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Cabrera</surname>
<given-names>B.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Pharmacogenetic study of antipsychotic induced acute extrapyramidal symptoms in a first episode psychosis cohort: Role of dopamine, serotonin and glutamate candidate genes</article-title>
<source/>Pharmacogenom. J.
          <year>2016</year>
<volume>16</volume>
<fpage>439</fpage>
<pub-id pub-id-type="doi">10.1038/tpj.2016.44</pub-id>
</element-citation>
</ref>
<ref id="B74-pharmaceutics-12-00013">
<label>74.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Taylor</surname>
<given-names>S.</given-names>
</name>
</person-group>
<article-title>Association between COMT Val158Met and psychiatric disorders: A comprehensive meta-analysis</article-title>
<source/>Am. J. Med. Genet. B Neuropsychiatr. Genet.
          <year>2018</year>
<volume>177</volume>
<fpage>199</fpage>
<lpage>210</lpage>
<pub-id pub-id-type="doi">10.1002/ajmg.b.32556</pub-id>
<pub-id pub-id-type="pmid">28608575</pub-id>
</element-citation>
</ref>
<ref id="B75-pharmaceutics-12-00013">
<label>75.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Al Maruf</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Greenslade</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Arnold</surname>
<given-names>P.D.</given-names>
</name>
<name>
<surname>Bousman</surname>
<given-names>C.</given-names>
</name>
</person-group>
<article-title>Antidepressant pharmacogenetics in children and young adults: A systematic review</article-title>
<source/>J. Affect. Disord.
          <year>2019</year>
<volume>254</volume>
<fpage>98</fpage>
<lpage>108</lpage>
<pub-id pub-id-type="doi">10.1016/j.jad.2019.05.025</pub-id>
<pub-id pub-id-type="pmid">31112844</pub-id>
</element-citation>
</ref>
<ref id="B76-pharmaceutics-12-00013">
<label>76.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Serretti</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Calati</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Mandelli</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>De Ronchi</surname>
<given-names>D.</given-names>
</name>
</person-group>
<article-title>Serotonin transporter gene variants and behavior: A comprehensive review</article-title>
<source/>Curr. Drug Targets
          <year>2006</year>
<volume>7</volume>
<fpage>1659</fpage>
<lpage>1669</lpage>
<pub-id pub-id-type="doi">10.2174/138945006779025419</pub-id>
<pub-id pub-id-type="pmid">17168841</pub-id>
</element-citation>
</ref>
<ref id="B77-pharmaceutics-12-00013">
<label>77.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Qesseveur</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Petit</surname>
<given-names>A.C.</given-names>
</name>
<name>
<surname>Nguyen</surname>
<given-names>H.T.</given-names>
</name>
<name>
<surname>Dahan</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Colle</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Rotenberg</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Seif</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Robert</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>David</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Guilloux</surname>
<given-names>J.P.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Genetic dysfunction of serotonin 2A receptor hampers response to antidepressant drugs: A translational approach</article-title>
<source/>Neuropharmacology
          <year>2016</year>
<volume>105</volume>
<fpage>142</fpage>
<lpage>153</lpage>
<pub-id pub-id-type="doi">10.1016/j.neuropharm.2015.12.022</pub-id>
<pub-id pub-id-type="pmid">26764241</pub-id>
</element-citation>
</ref>
<ref id="B78-pharmaceutics-12-00013">
<label>78.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lin</surname>
<given-names>J.Y.</given-names>
</name>
<name>
<surname>Jiang</surname>
<given-names>M.Y.</given-names>
</name>
<name>
<surname>Kan</surname>
<given-names>Z.M.</given-names>
</name>
<name>
<surname>Chu</surname>
<given-names>Y.</given-names>
</name>
</person-group>
<article-title>Influence of 5-<italic>HTR2A</italic> genetic polymorphisms on the efficacy of antidepressants in the treatment of major depressive disorder: A meta-analysis</article-title>
<source/>J. Affect. Disord.
          <year>2014</year>
<volume>168</volume>
<fpage>430</fpage>
<lpage>438</lpage>
<pub-id pub-id-type="doi">10.1016/j.jad.2014.06.012</pub-id>
<pub-id pub-id-type="pmid">25108775</pub-id>
</element-citation>
</ref>
<ref id="B79-pharmaceutics-12-00013">
<label>79.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Niitsu</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Fabbri</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Bentini</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Serretti</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>Pharmacogenetics in major depression: A comprehensive meta-analysis</article-title>
<source/>Prog. Neuropsychopharmacol. Biol. Psychiatry
          <year>2013</year>
<volume>45</volume>
<fpage>183</fpage>
<lpage>194</lpage>
<pub-id pub-id-type="doi">10.1016/j.pnpbp.2013.05.011</pub-id>
<pub-id pub-id-type="pmid">23733030</pub-id>
</element-citation>
</ref>
<ref id="B80-pharmaceutics-12-00013">
<label>80.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kishi</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Yoshimura</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Fukuo</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Okochi</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Matsunaga</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Umene-Nakano</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Nakamura</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Serretti</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Correll</surname>
<given-names>C.U.</given-names>
</name>
<name>
<surname>Kane</surname>
<given-names>J.M.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>The serotonin 1A receptor gene confer susceptibility to mood disorders: Results from an extended meta-analysis of patients with major depression and bipolar disorder</article-title>
<source/>Eur. Arch. Psychiatry Clin. Neurosci.
          <year>2013</year>
<volume>263</volume>
<fpage>105</fpage>
<lpage>118</lpage>
<pub-id pub-id-type="doi">10.1007/s00406-012-0337-4</pub-id>
<pub-id pub-id-type="pmid">22752684</pub-id>
</element-citation>
</ref>
<ref id="B81-pharmaceutics-12-00013">
<label>81.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Illi</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Setälä-Soikkeli</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Viikki</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Poutanen</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>Huhtala</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Mononen</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Lehtimäki</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Leinonen</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Kampman</surname>
<given-names>O.</given-names>
</name>
</person-group>
<article-title><italic>HTR1A</italic>, 5-<italic>HTR2A</italic>, 5-<italic>HTR6</italic>, <italic>TPH1</italic> and <italic>TPH2</italic> polymorphisms and major depression</article-title>
<source/>Neuroreport
          <year>2009</year>
<volume>20</volume>
<fpage>1125</fpage>
<lpage>1128</lpage>
<pub-id pub-id-type="doi">10.1097/WNR.0b013e32832eb708</pub-id>
<pub-id pub-id-type="pmid">19590397</pub-id>
</element-citation>
</ref>
<ref id="B82-pharmaceutics-12-00013">
<label>82.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Risselada</surname>
<given-names>A.J.</given-names>
</name>
<name>
<surname>Vehof</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Bruggeman</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Wilffert</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Cohen</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Al Hadithy</surname>
<given-names>A.F.</given-names>
</name>
<name>
<surname>Arends</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Mulder</surname>
<given-names>H.</given-names>
</name>
</person-group>
<article-title>Association between HTR2C gene polymorphisms and the metabolic syndrome in patients using antipsychotics: A replication study</article-title>
<source/>Pharmacogenom. J.
          <year>2012</year>
<volume>12</volume>
<fpage>62</fpage>
<pub-id pub-id-type="doi">10.1038/tpj.2010.66</pub-id>
</element-citation>
</ref>
<ref id="B83-pharmaceutics-12-00013">
<label>83.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rico-Gomis</surname>
<given-names>J.M.</given-names>
</name>
<name>
<surname>Palazón-Bru</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Triano-García</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Mahecha-García</surname>
<given-names>L.F.</given-names>
</name>
<name>
<surname>García-Monsalve</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Navarro-Ruiz</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Villagordo-Peñalver</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Jiménez-Abril</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Martínez-Hortelano</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Francisco Gil-Guillén</surname>
<given-names>V.</given-names>
</name>
</person-group>
<article-title>Association between the HTR2C rs1414334 C/G gene polymorphism and the development of the metabolic syndrome in patients treated with atypical antipsychotics</article-title>
<source/>PeerJ
          <year>2016</year>
<volume>4</volume>
<fpage>e2163</fpage>
<pub-id pub-id-type="doi">10.7717/peerj.2163</pub-id>
<pub-id pub-id-type="pmid">27441116</pub-id>
</element-citation>
</ref>
<ref id="B84-pharmaceutics-12-00013">
<label>84.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>J.P.</given-names>
</name>
<name>
<surname>Robinson</surname>
<given-names>D.G.</given-names>
</name>
<name>
<surname>Gallego</surname>
<given-names>J.A.</given-names>
</name>
<name>
<surname>John</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Addington</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Tohen</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Kane</surname>
<given-names>J.M.</given-names>
</name>
<name>
<surname>Malhotra</surname>
<given-names>A.K.</given-names>
</name>
<name>
<surname>Lencz</surname>
<given-names>T.</given-names>
</name>
</person-group>
<article-title>Association of a schizophrenia risk variant at the DRD2 locus with antipsychotic treatment response in first-episode psychosis</article-title>
<source/>Schizophr. Bull.
          <year>2015</year>
<volume>41</volume>
<fpage>1248</fpage>
<lpage>1255</lpage>
<pub-id pub-id-type="doi">10.1093/schbul/sbv116</pub-id>
<pub-id pub-id-type="pmid">26320194</pub-id>
</element-citation>
</ref>
<ref id="B85-pharmaceutics-12-00013">
<label>85.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Eum</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Schneiderhan</surname>
<given-names>M.E.</given-names>
</name>
<name>
<surname>Brown</surname>
<given-names>J.T.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>A.M.</given-names>
</name>
<name>
<surname>Bishop</surname>
<given-names>J.R.</given-names>
</name>
</person-group>
<article-title>Pharmacogenetic evaluation to assess breakthrough psychosis with aripiprazole long-acting injection: A case report</article-title>
<source/>BMC Psychiatry
          <year>2017</year>
<volume>17</volume>
<elocation-id>238</elocation-id>
<pub-id pub-id-type="doi">10.1186/s12888-017-1396-x</pub-id>
<pub-id pub-id-type="pmid">28673279</pub-id>
</element-citation>
</ref>
<ref id="B86-pharmaceutics-12-00013">
<label>86.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>J.P.</given-names>
</name>
<name>
<surname>Lencz</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Malhotra</surname>
<given-names>A.K.</given-names>
</name>
</person-group>
<article-title>D2 receptor genetic variation and clinical response to antipsychotic drug treatment: A meta-analysis</article-title>
<source/>Am. J. Psychiatry
          <year>2010</year>
<volume>167</volume>
<fpage>763</fpage>
<lpage>772</lpage>
<pub-id pub-id-type="doi">10.1176/appi.ajp.2009.09040598</pub-id>
<pub-id pub-id-type="pmid">20194480</pub-id>
</element-citation>
</ref>
<ref id="B87-pharmaceutics-12-00013">
<label>87.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Keers</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Bonvicini</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Scassellati</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Uher</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Placentino</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Giovannini</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Rietschel</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Henigsberg</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Kozel</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Mors</surname>
<given-names>O.</given-names>
</name>
</person-group>
<article-title>Variation in GNB3 predicts response and adverse reactions to antidepressants</article-title>
<source/>J. Psychopharmacol.
          <year>2011</year>
<volume>25</volume>
<fpage>867</fpage>
<lpage>874</lpage>
<pub-id pub-id-type="doi">10.1177/0269881110376683</pub-id>
<pub-id pub-id-type="pmid">20826553</pub-id>
</element-citation>
</ref>
<ref id="B88-pharmaceutics-12-00013">
<label>88.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Amare</surname>
<given-names>A.T.</given-names>
</name>
<name>
<surname>Schubert</surname>
<given-names>K.O.</given-names>
</name>
<name>
<surname>Hou</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Clark</surname>
<given-names>S.R.</given-names>
</name>
<name>
<surname>Papiol</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Heilbronner</surname>
<given-names>U.</given-names>
</name>
<name>
<surname>Degenhardt</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Tekola-Ayele</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Hsu</surname>
<given-names>Y.H.</given-names>
</name>
<name>
<surname>Shekhtman</surname>
<given-names>T.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Association of polygenic score for schizophrenia and HLA antigen and inflammation genes with response to lithium in bipolar affective disorder: A genome-wide association study</article-title>
<source/>JAMA Psychiatry
          <year>2018</year>
<volume>75</volume>
<fpage>65</fpage>
<lpage>74</lpage>
<pub-id pub-id-type="pmid">29121268</pub-id>
</element-citation>
</ref>
<ref id="B89-pharmaceutics-12-00013">
<label>89.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>van Huis-Tanja</surname>
<given-names>L.H.</given-names>
</name>
<name>
<surname>Ewing</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>van der Straaten</surname>
<given-names>R.J.H.M.</given-names>
</name>
<name>
<surname>Swen</surname>
<given-names>J.J.</given-names>
</name>
<name>
<surname>Baak-Pablo</surname>
<given-names>R.F.</given-names>
</name>
<name>
<surname>Punt</surname>
<given-names>C.J.A.</given-names>
</name>
<name>
<surname>Gelderblom</surname>
<given-names>A.J.</given-names>
</name>
<name>
<surname>Guchelaar</surname>
<given-names>H.J.</given-names>
</name>
</person-group>
<article-title>Clinical validation study of genetic markers for capecitabine efficacy in metastatic colorectal cancer patients</article-title>
<source/>Pharmacogenet. Genom.
          <year>2015</year>
<volume>25</volume>
<fpage>279</fpage>
<lpage>288</lpage>
<pub-id pub-id-type="doi">10.1097/FPC.0000000000000119</pub-id>
</element-citation>
</ref>
<ref id="B90-pharmaceutics-12-00013">
<label>90.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Clark</surname>
<given-names>S.L.</given-names>
</name>
<name>
<surname>Souza</surname>
<given-names>R.P.</given-names>
</name>
<name>
<surname>Adkins</surname>
<given-names>D.E.</given-names>
</name>
<name>
<surname>Åberg</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Bukszár</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>McClay</surname>
<given-names>J.L.</given-names>
</name>
<name>
<surname>Sullivan</surname>
<given-names>P.F.</given-names>
</name>
<name>
<surname>van den Oord</surname>
<given-names>E.J.</given-names>
</name>
</person-group>
<article-title>Genome-wide association study of patient and clinician rated global impression severity during antipsychotic treatment</article-title>
<source/>Pharmacogenet. Genom.
          <year>2013</year>
<volume>23</volume>
<fpage>69</fpage>
<pub-id pub-id-type="doi">10.1097/FPC.0b013e32835ca260</pub-id>
</element-citation>
</ref>
<ref id="B91-pharmaceutics-12-00013">
<label>91.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Almoguera</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Riveiro-Alvarez</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>López-Castromán</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Dorado</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Vaquero-Lorenzo</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Fernandez-Piqueras</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Llerena</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Abad-Santos</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Baca-García</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Dal-Ré</surname>
<given-names>R.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Association of common genetic variants with risperidone adverse events in a Spanish schizophrenic population</article-title>
<source/>Pharmacogenom. J.
          <year>2013</year>
<volume>13</volume>
<fpage>197</fpage>
<pub-id pub-id-type="doi">10.1038/tpj.2011.57</pub-id>
</element-citation>
</ref>
<ref id="B92-pharmaceutics-12-00013">
<label>92.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ikeda</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Yamanouchi</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Kinoshita</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Kitajima</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Yoshimura</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Hashimoto</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>O’Donovan</surname>
<given-names>M.C.</given-names>
</name>
<name>
<surname>Nakamura</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Ozaki</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Iwata</surname>
<given-names>N.</given-names>
</name>
</person-group>
<article-title>Variants of dopamine and serotonin candidate genes as predictors of response to risperidone treatment in first-episode schizophrenia</article-title>
<source/>Pharmacogenomics
          <year>2008</year>
<volume>9</volume>
<fpage>1437</fpage>
<lpage>1443</lpage>
<pub-id pub-id-type="doi">10.2217/14622416.9.10.1437</pub-id>
<pub-id pub-id-type="pmid">18855532</pub-id>
</element-citation>
</ref>
<ref id="B93-pharmaceutics-12-00013">
<label>93.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>López-Rodríguez</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Cabaleiro</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Ochoa</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Román</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Borobia</surname>
<given-names>A.M.</given-names>
</name>
<name>
<surname>Carcas</surname>
<given-names>A.J.</given-names>
</name>
<name>
<surname>Ayuso</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Novalbos</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Abad-Santos</surname>
<given-names>F.</given-names>
</name>
</person-group>
<article-title>Pharmacodynamic genetic variants related to antipsychotic adverse reactions in healthy volunteers</article-title>
<source/>Pharmacogenomics
          <year>2013</year>
<volume>14</volume>
<fpage>1203</fpage>
<lpage>1214</lpage>
<pub-id pub-id-type="doi">10.2217/pgs.13.106</pub-id>
<pub-id pub-id-type="pmid">23859574</pub-id>
</element-citation>
</ref>
<ref id="B94-pharmaceutics-12-00013">
<label>94.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Squassina</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Manchia</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Borg</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Congiu</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Costa</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Georgitsi</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Chillotti</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Ardau</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Mitropoulos</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Severino</surname>
<given-names>G.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Evidence for association of an ACCN1 gene variant with response to lithium treatment in Sardinian patients with bipolar disorder</article-title>
<source/>Pharmacogenomics
          <year>2011</year>
<volume>12</volume>
<fpage>1559</fpage>
<lpage>1569</lpage>
<pub-id pub-id-type="doi">10.2217/pgs.11.102</pub-id>
<pub-id pub-id-type="pmid">21961650</pub-id>
</element-citation>
</ref>
<ref id="B95-pharmaceutics-12-00013">
<label>95.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lane</surname>
<given-names>H.Y.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>Y.C.</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>C.L.</given-names>
</name>
<name>
<surname>Chang</surname>
<given-names>Y.C.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>P.L.</given-names>
</name>
<name>
<surname>Lu</surname>
<given-names>C.T.</given-names>
</name>
<name>
<surname>Chang</surname>
<given-names>W.H.</given-names>
</name>
</person-group>
<article-title>Risperidone-related weight gain: Genetic and nongenetic predictors</article-title>
<source/>J. Clin. Psychopharmacol.
          <year>2006</year>
<volume>26</volume>
<fpage>128</fpage>
<lpage>134</lpage>
<pub-id pub-id-type="doi">10.1097/01.jcp.0000203196.65710.2b</pub-id>
<pub-id pub-id-type="pmid">16633140</pub-id>
</element-citation>
</ref>
<ref id="B96-pharmaceutics-12-00013">
<label>96.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Anttila</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Winsvold</surname>
<given-names>B.S.</given-names>
</name>
<name>
<surname>Gormley</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Kurth</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Bettella</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>McMahon</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Kallela</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Malik</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>de Vries</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Terwindt</surname>
<given-names>G.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Genome-wide meta-analysis identifies new susceptibility loci for migraine</article-title>
<source/>Nat. Genet.
          <year>2013</year>
<volume>45</volume>
<fpage>912</fpage>
<pub-id pub-id-type="doi">10.1038/ng.2676</pub-id>
<pub-id pub-id-type="pmid">23793025</pub-id>
</element-citation>
</ref>
<ref id="B97-pharmaceutics-12-00013">
<label>97.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Silberberg</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Levit</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Collier</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Clair</surname>
<given-names>D.S.</given-names>
</name>
<name>
<surname>Munro</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Kerwin</surname>
<given-names>R.W.</given-names>
</name>
<name>
<surname>Tondo</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Floris</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Breen</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Navon</surname>
<given-names>R.</given-names>
</name>
</person-group>
<article-title>Stargazin involvement with bipolar disorder and response to lithium treatment</article-title>
<source/>Pharmacogenet. Genom.
          <year>2008</year>
<volume>18</volume>
<fpage>403</fpage>
<lpage>412</lpage>
<pub-id pub-id-type="doi">10.1097/FPC.0b013e3282f974ca</pub-id>
</element-citation>
</ref>
<ref id="B98-pharmaceutics-12-00013">
<label>98.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Xiong</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Wei</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Huo</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Shen</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Shao</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Zeng</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>T.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>A pharmacogenetic study of risperidone on chemokine (C-C motif) ligand 2 (CCL2) in Chinese Han schizophrenia patients</article-title>
<source/>Prog. Neuropsychopharmacol. Biol. Psychiatry
          <year>2014</year>
<volume>51</volume>
<fpage>153</fpage>
<lpage>158</lpage>
<pub-id pub-id-type="doi">10.1016/j.pnpbp.2014.01.017</pub-id>
<pub-id pub-id-type="pmid">24495780</pub-id>
</element-citation>
</ref>
<ref id="B99-pharmaceutics-12-00013">
<label>99.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nurmi</surname>
<given-names>E.L.</given-names>
</name>
<name>
<surname>Spilman</surname>
<given-names>S.L.</given-names>
</name>
<name>
<surname>Whelan</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Scahill</surname>
<given-names>L.L.</given-names>
</name>
<name>
<surname>Aman</surname>
<given-names>M.G.</given-names>
</name>
<name>
<surname>McDougle</surname>
<given-names>C.J.</given-names>
</name>
<name>
<surname>Arnold</surname>
<given-names>L.E.</given-names>
</name>
<name>
<surname>Handen</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Johnson</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Sukhodolsky</surname>
<given-names>D.G.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Moderation of antipsychotic-induced weight gain by energy balance gene variants in the RUPP autism network risperidone studies</article-title>
<source/>Transl. Psychiatry
          <year>2013</year>
<volume>3</volume>
<fpage>e274</fpage>
<pub-id pub-id-type="doi">10.1038/tp.2013.26</pub-id>
<pub-id pub-id-type="pmid">23799528</pub-id>
</element-citation>
</ref>
<ref id="B100-pharmaceutics-12-00013">
<label>100.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vázquez-Bourgon</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Arranz</surname>
<given-names>M.J.</given-names>
</name>
<name>
<surname>Mata</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Pelayo-Terán</surname>
<given-names>J.M.</given-names>
</name>
<name>
<surname>Pérez-Iglesias</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Medina-González</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Carrasco-Marín</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Vázquez-Barquero</surname>
<given-names>J.L.</given-names>
</name>
<name>
<surname>Crespo-Facorro</surname>
<given-names>B.</given-names>
</name>
</person-group>
<article-title>Serotonin transporter polymorphisms and early response to antipsychotic treatment in first episode of psychosis</article-title>
<source/>Psychiatr. Res.
          <year>2010</year>
<volume>175</volume>
<fpage>189</fpage>
<lpage>194</lpage>
<pub-id pub-id-type="doi">10.1016/j.psychres.2008.12.011</pub-id>
</element-citation>
</ref>
<ref id="B101-pharmaceutics-12-00013">
<label>101.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Xu</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Minica</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Yi</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Shen</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Xing</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Shi</surname>
<given-names>Y.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Association studies of genomic variants with treatment response to risperidone, clozapine, quetiapine and chlorpromazine in the Chinese Han population</article-title>
<source/>Pharmacogenom. J.
          <year>2016</year>
<volume>16</volume>
<fpage>357</fpage>
<pub-id pub-id-type="doi">10.1038/tpj.2015.61</pub-id>
</element-citation>
</ref>
<ref id="B102-pharmaceutics-12-00013">
<label>102.</label>
<element-citation publication-type="gov">
<article-title>Drugs@FDA: Drug Product Depakene (Valproic Acid), NDA018081, REMEDYREPACK INC</article-title>
<comment>Available online: <ext-link ext-link-type="uri" xlink:href="https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&amp;varApplNo=018081">https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&amp;varApplNo=018081</ext-link></comment>
<date-in-citation content-type="access-date" iso-8601-date="2019-09-01">(accessed on 1 September 2019)</date-in-citation>
</element-citation>
</ref>
<ref id="B103-pharmaceutics-12-00013">
<label>103.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Terzić</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Kastelic</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Dolžan</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Kores Plesničar</surname>
<given-names>B.</given-names>
</name>
</person-group>
<article-title>Genetic polymorphisms in dopaminergic system and treatment-resistant schizophrenia</article-title>
<source/>Psychiatr. Danub.
          <year>2016</year>
<volume>28</volume>
<fpage>127</fpage>
<lpage>131</lpage>
<pub-id pub-id-type="pmid">27287786</pub-id>
</element-citation>
</ref>
<ref id="B104-pharmaceutics-12-00013">
<label>104.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hong</surname>
<given-names>C.J.</given-names>
</name>
<name>
<surname>Liou</surname>
<given-names>Y.J.</given-names>
</name>
<name>
<surname>Bai</surname>
<given-names>Y.M.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>T.T.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Y.C.</given-names>
</name>
<name>
<surname>Tsai</surname>
<given-names>S.J.</given-names>
</name>
</person-group>
<article-title>Dopamine receptor D2 gene is associated with weight gain in schizophrenic patients under long-term atypical antipsychotic treatment</article-title>
<source/>Pharmacogenet. Genom.
          <year>2010</year>
<volume>20</volume>
<fpage>359</fpage>
<lpage>366</lpage>
<pub-id pub-id-type="doi">10.1097/FPC.0b013e3283397d06</pub-id>
</element-citation>
</ref>
<ref id="B105-pharmaceutics-12-00013">
<label>105.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lencz</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Robinson</surname>
<given-names>D.G.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Ekholm</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Sevy</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Gunduz-Bruce</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Woerner</surname>
<given-names>M.G.</given-names>
</name>
<name>
<surname>Kane</surname>
<given-names>J.M.</given-names>
</name>
<name>
<surname>Goldman</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Malhotra</surname>
<given-names>A.K.</given-names>
</name>
</person-group>
<article-title>DRD2 promoter region variation as a predictor of sustained response to antipsychotic medication in first-episode schizophrenia patients</article-title>
<source/>Am. J. Psychiatry
          <year>2006</year>
<volume>163</volume>
<fpage>529</fpage>
<lpage>531</lpage>
<pub-id pub-id-type="doi">10.1176/appi.ajp.163.3.529</pub-id>
<pub-id pub-id-type="pmid">16513877</pub-id>
</element-citation>
</ref>
<ref id="B106-pharmaceutics-12-00013">
<label>106.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cabaleiro</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>López-Rodríguez</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Román</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Ochoa</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Novalbos</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Borobia</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Carcas</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Abad-Santos</surname>
<given-names>F.</given-names>
</name>
</person-group>
<article-title>Pharmacogenetics of quetiapine in healthy volunteers: Association with pharmacokinetics, pharmacodynamics, and adverse effects</article-title>
<source/>Int. Clin. Psychopharmacol.
          <year>2015</year>
<volume>30</volume>
<fpage>82</fpage>
<lpage>88</lpage>
<pub-id pub-id-type="doi">10.1097/YIC.0000000000000047</pub-id>
<pub-id pub-id-type="pmid">25025989</pub-id>
</element-citation>
</ref>
<ref id="B107-pharmaceutics-12-00013">
<label>107.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Perlis</surname>
<given-names>R.H.</given-names>
</name>
<name>
<surname>Fijal</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Dharia</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Houston</surname>
<given-names>J.P.</given-names>
</name>
</person-group>
<article-title>Pharmacogenetic investigation of response to duloxetine treatment in generalized anxiety disorder</article-title>
<source/>Pharmacogenom. J.
          <year>2013</year>
<volume>13</volume>
<fpage>280</fpage>
<pub-id pub-id-type="doi">10.1038/tpj.2011.62</pub-id>
</element-citation>
</ref>
<ref id="B108-pharmaceutics-12-00013">
<label>108.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Porcelli</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Balzarro</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>S.J.</given-names>
</name>
<name>
<surname>Han</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Patkar</surname>
<given-names>A.A.</given-names>
</name>
<name>
<surname>Pae</surname>
<given-names>C.U.</given-names>
</name>
<name>
<surname>Serretti</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>PDE7B, NMBR and EPM2A variants and schizophrenia: A case-control and pharmacogenetics study</article-title>
<source/>Neuropsychobiology
          <year>2016</year>
<volume>73</volume>
<fpage>160</fpage>
<lpage>168</lpage>
<pub-id pub-id-type="doi">10.1159/000445295</pub-id>
<pub-id pub-id-type="pmid">27092952</pub-id>
</element-citation>
</ref>
<ref id="B109-pharmaceutics-12-00013">
<label>109.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Monteleone</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Milano</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Petrella</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Canestrelli</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Maj</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Endocannabinoid Pro129Thr FAAH functional polymorphism but not 1359G/A CNR1 polymorphism is associated with antipsychotic-induced weight gain</article-title>
<source/>J. Clin. Psychopharmacol.
          <year>2010</year>
<volume>30</volume>
<fpage>441</fpage>
<lpage>445</lpage>
<pub-id pub-id-type="doi">10.1097/JCP.0b013e3181e742c5</pub-id>
<pub-id pub-id-type="pmid">20631561</pub-id>
</element-citation>
</ref>
<ref id="B110-pharmaceutics-12-00013">
<label>110.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mao</surname>
<given-names>Y.M.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>Z.Q.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>B.L.</given-names>
</name>
<name>
<surname>Guo</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Han</surname>
<given-names>C.T.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>L.J.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>S.Y.</given-names>
</name>
<name>
<surname>Fan</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>H.H.</given-names>
</name>
</person-group>
<article-title>Effect of 393T&gt; C polymorphism of GNAS1 gene on dobutamine response in Chinese healthy subjects</article-title>
<source/>J. Clin. Pharmacol.
          <year>2009</year>
<volume>49</volume>
<fpage>929</fpage>
<lpage>936</lpage>
<pub-id pub-id-type="doi">10.1177/0091270009337945</pub-id>
<pub-id pub-id-type="pmid">19542315</pub-id>
</element-citation>
</ref>
<ref id="B111-pharmaceutics-12-00013">
<label>111.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Alakus</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Warnecke-Eberz</surname>
<given-names>U.</given-names>
</name>
<name>
<surname>Bollschweiler</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Mönig</surname>
<given-names>S.P.</given-names>
</name>
<name>
<surname>Vallböhmer</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Brabender</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Drebber</surname>
<given-names>U.</given-names>
</name>
<name>
<surname>Baldus</surname>
<given-names>S.E.</given-names>
</name>
<name>
<surname>Riemann</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Siffert</surname>
<given-names>W.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>GNAS1 T393C polymorphism is associated with histopathological response to neoadjuvant radiochemotherapy in esophageal cancer</article-title>
<source/>Pharmacogenom. J.
          <year>2009</year>
<volume>9</volume>
<fpage>202</fpage>
<pub-id pub-id-type="doi">10.1038/tpj.2009.5</pub-id>
</element-citation>
</ref>
<ref id="B112-pharmaceutics-12-00013">
<label>112.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Noordam</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Direk</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Sitlani</surname>
<given-names>C.M.</given-names>
</name>
<name>
<surname>Aarts</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Tiemeier</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Hofman</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>Identifying genetic loci associated with antidepressant drug response with drug-gene interaction models in a population-based study</article-title>
<source/>J. Psychiatr. Res.
          <year>2015</year>
<volume>62</volume>
<fpage>31</fpage>
<lpage>37</lpage>
<pub-id pub-id-type="doi">10.1016/j.jpsychires.2015.01.005</pub-id>
<pub-id pub-id-type="pmid">25649181</pub-id>
</element-citation>
</ref>
<ref id="B113-pharmaceutics-12-00013">
<label>113.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Balan</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Sathyan</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Radha</surname>
<given-names>S.K.</given-names>
</name>
<name>
<surname>Joseph</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Radhakrishnan</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Banerjee</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>GABRG2, rs211037 is associated with epilepsy susceptibility, but not with antiepileptic drug resistance and febrile seizures</article-title>
<source/>Pharmacogenet. Genom.
          <year>2013</year>
<volume>23</volume>
<fpage>605</fpage>
<lpage>610</lpage>
<pub-id pub-id-type="doi">10.1097/FPC.0000000000000000</pub-id>
</element-citation>
</ref>
<ref id="B114-pharmaceutics-12-00013">
<label>114.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname>
<given-names>C.H.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>C.S.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>M.T.M.</given-names>
</name>
<name>
<surname>Ouyang</surname>
<given-names>W.C.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>C.C.</given-names>
</name>
<name>
<surname>Chong</surname>
<given-names>M.Y.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>J.Y.</given-names>
</name>
<name>
<surname>Tan</surname>
<given-names>H.K.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>Y.C.</given-names>
</name>
<name>
<surname>Chuo</surname>
<given-names>L.J.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Variant GADL1 and response to lithium therapy in bipolar I disorder</article-title>
<source/>N. Engl. J. Med.
          <year>2014</year>
<volume>370</volume>
<fpage>119</fpage>
<lpage>128</lpage>
<pub-id pub-id-type="doi">10.1056/NEJMoa1212444</pub-id>
<pub-id pub-id-type="pmid">24369049</pub-id>
</element-citation>
</ref>
<ref id="B115-pharmaceutics-12-00013">
<label>115.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Fang</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Du</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Ma</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Feng</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Xing</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>He</surname>
<given-names>L.</given-names>
</name>
</person-group>
<article-title>The—1019 C/G polymorphism of the 5-HT1A receptor gene is associated with negative symptom response to risperidone treatment in schizophrenia patients</article-title>
<source/>J. Clin. Psychopharmacol.
          <year>2008</year>
<volume>22</volume>
<fpage>904</fpage>
<lpage>909</lpage>
<pub-id pub-id-type="doi">10.1177/0269881107081522</pub-id>
</element-citation>
</ref>
<ref id="B116-pharmaceutics-12-00013">
<label>116.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Stevenson</surname>
<given-names>J.M.</given-names>
</name>
<name>
<surname>Reilly</surname>
<given-names>J.L.</given-names>
</name>
<name>
<surname>Harris</surname>
<given-names>M.S.H.</given-names>
</name>
<name>
<surname>Patel</surname>
<given-names>S.R.</given-names>
</name>
<name>
<surname>Weiden</surname>
<given-names>P.J.</given-names>
</name>
<name>
<surname>Prasad</surname>
<given-names>K.M.</given-names>
</name>
<name>
<surname>Badner</surname>
<given-names>J.A.</given-names>
</name>
<name>
<surname>Nimgaonkar</surname>
<given-names>V.L.</given-names>
</name>
<name>
<surname>Keshavan</surname>
<given-names>M.S.</given-names>
</name>
<name>
<surname>Sweeney</surname>
<given-names>J.A.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Antipsychotic pharmacogenomics in first episode psychosis: A role for glutamate genes</article-title>
<source/>Transl. Psychiatry
          <year>2016</year>
<volume>6</volume>
<fpage>e739</fpage>
<pub-id pub-id-type="doi">10.1038/tp.2016.10</pub-id>
<pub-id pub-id-type="pmid">26905411</pub-id>
</element-citation>
</ref>
<ref id="B117-pharmaceutics-12-00013">
<label>117.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hung</surname>
<given-names>C.C.</given-names>
</name>
<name>
<surname>Ho</surname>
<given-names>J.L.</given-names>
</name>
<name>
<surname>Chang</surname>
<given-names>W.L.</given-names>
</name>
<name>
<surname>Tai</surname>
<given-names>J.J.</given-names>
</name>
<name>
<surname>Hsieh</surname>
<given-names>T.J.</given-names>
</name>
<name>
<surname>Hsieh</surname>
<given-names>Y.W.</given-names>
</name>
<name>
<surname>Liou</surname>
<given-names>H.H.</given-names>
</name>
</person-group>
<article-title>Association of genetic variants in six candidate genes with valproic acid therapy optimization</article-title>
<source/>Pharmacogenomics
          <year>2011</year>
<volume>12</volume>
<fpage>1107</fpage>
<lpage>1117</lpage>
<pub-id pub-id-type="doi">10.2217/pgs.11.64</pub-id>
<pub-id pub-id-type="pmid">21806385</pub-id>
</element-citation>
</ref>
<ref id="B118-pharmaceutics-12-00013">
<label>118.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fijal</surname>
<given-names>B.A.</given-names>
</name>
<name>
<surname>Kinon</surname>
<given-names>B.J.</given-names>
</name>
<name>
<surname>Kapur</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Stauffer</surname>
<given-names>V.L.</given-names>
</name>
<name>
<surname>Conley</surname>
<given-names>R.R.</given-names>
</name>
<name>
<surname>Jamal</surname>
<given-names>H.H.</given-names>
</name>
<name>
<surname>Kane</surname>
<given-names>J.M.</given-names>
</name>
<name>
<surname>Witte</surname>
<given-names>M.M.</given-names>
</name>
<name>
<surname>Houston</surname>
<given-names>J.P.</given-names>
</name>
</person-group>
<article-title>Candidate-gene association analysis of response to risperidone in African-American and white patients with schizophrenia</article-title>
<source/>Pharmacogenom. J.
          <year>2009</year>
<volume>9</volume>
<fpage>311</fpage>
<pub-id pub-id-type="doi">10.1038/tpj.2009.24</pub-id>
</element-citation>
</ref>
<ref id="B119-pharmaceutics-12-00013">
<label>119.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lin</surname>
<given-names>Y.F.</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>M.C.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>H.C.</given-names>
</name>
</person-group>
<article-title>Glycogen synthase kinase 3β gene polymorphisms may be associated with bipolar I disorder and the therapeutic response to lithium</article-title>
<source/>J. Affect. Disord.
          <year>2013</year>
<volume>147</volume>
<fpage>401</fpage>
<lpage>406</lpage>
<pub-id pub-id-type="doi">10.1016/j.jad.2012.08.025</pub-id>
<pub-id pub-id-type="pmid">23021822</pub-id>
</element-citation>
</ref>
<ref id="B120-pharmaceutics-12-00013">
<label>120.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>L.J.</given-names>
</name>
<name>
<surname>Hu</surname>
<given-names>F.Y.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>X.T.</given-names>
</name>
<name>
<surname>An</surname>
<given-names>D.M.</given-names>
</name>
<name>
<surname>Yan</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>D.</given-names>
</name>
</person-group>
<article-title>Predictive markers for carbamazepine and lamotrigine-induced maculopapular exanthema in Han Chinese</article-title>
<source/>Epilepsy Res.
          <year>2013</year>
<volume>106</volume>
<fpage>296</fpage>
<lpage>300</lpage>
<pub-id pub-id-type="doi">10.1016/j.eplepsyres.2013.05.004</pub-id>
<pub-id pub-id-type="pmid">23830818</pub-id>
</element-citation>
</ref>
<ref id="B121-pharmaceutics-12-00013">
<label>121.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Koomdee</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Pratoomwun</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Jantararoungtong</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Theeramoke</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Tassaneeyakul</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Klaewsongkram</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Rerkpattanapipat</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Santon</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Puangpetch</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Intusoma</surname>
<given-names>U.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Association of HLA-A and HLA-B alleles with lamotrigine-induced cutaneous adverse drug reactions in the Thai population</article-title>
<source/>Front. Pharmacol.
          <year>2017</year>
<volume>8</volume>
<fpage>879</fpage>
<pub-id pub-id-type="doi">10.3389/fphar.2017.00879</pub-id>
<pub-id pub-id-type="pmid">29238301</pub-id>
</element-citation>
</ref>
<ref id="B122-pharmaceutics-12-00013">
<label>122.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kazeem</surname>
<given-names>G.R.</given-names>
</name>
<name>
<surname>Cox</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Aponte</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Messenheimer</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Brazell</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Nelsen</surname>
<given-names>A.C.</given-names>
</name>
</person-group>
<article-title>High-resolution HLA genotyping and severe cutaneous adverse reactions in lamotrigine-treated patients</article-title>
<source/>Pharmacogenet. Genom.
          <year>2009</year>
<volume>19</volume>
<fpage>661</fpage>
<lpage>665</lpage>
<pub-id pub-id-type="doi">10.1097/FPC.0b013e32832c347d</pub-id>
</element-citation>
</ref>
<ref id="B123-pharmaceutics-12-00013">
<label>123.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Liew</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Kwan</surname>
<given-names>P.</given-names>
</name>
</person-group>
<article-title>Real-world cost-effectiveness of pharmacogenetic screening for epilepsy treatment</article-title>
<source/>Neurology
          <year>2016</year>
<volume>86</volume>
<fpage>1086</fpage>
<lpage>1094</lpage>
<pub-id pub-id-type="doi">10.1212/WNL.0000000000002484</pub-id>
<pub-id pub-id-type="pmid">26888992</pub-id>
</element-citation>
</ref>
<ref id="B124-pharmaceutics-12-00013">
<label>124.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ramírez</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Bellón</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Tong</surname>
<given-names>H.Y.</given-names>
</name>
<name>
<surname>Borobia</surname>
<given-names>A.M.</given-names>
</name>
<name>
<surname>de Abajo</surname>
<given-names>F.J.</given-names>
</name>
<name>
<surname>Lerma</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Hidalgo</surname>
<given-names>M.A.</given-names>
</name>
<name>
<surname>Castañer</surname>
<given-names>J.L.</given-names>
</name>
<name>
<surname>Cabañas</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Fiandor</surname>
<given-names>A.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Significant HLA class I type associations with aromatic antiepileptic drug (AED)-induced SJS/TEN are different from those found for the same AED-induced DRESS in the Spanish population</article-title>
<source/>Pharmacol. Res.
          <year>2017</year>
<volume>115</volume>
<fpage>168</fpage>
<lpage>178</lpage>
<pub-id pub-id-type="doi">10.1016/j.phrs.2016.11.027</pub-id>
<pub-id pub-id-type="pmid">27888155</pub-id>
</element-citation>
</ref>
<ref id="B125-pharmaceutics-12-00013">
<label>125.</label>
<element-citation publication-type="gov">
<article-title>Drugs@FDA: Drug Product Tegretol (Carbamazepine), NDA016608, REMEDYREPACK INC</article-title>
<comment>Available online: <ext-link ext-link-type="uri" xlink:href="https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&amp;varApplNo=016608">https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&amp;varApplNo=016608</ext-link></comment>
<date-in-citation content-type="access-date" iso-8601-date="2019-09-01">(accessed on 1 September 2019)</date-in-citation>
</element-citation>
</ref>
<ref id="B126-pharmaceutics-12-00013">
<label>126.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wei</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Xuan</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Shao</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Zeng</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>T.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>A pharmacogenetic study of risperidone on histamine H3 receptor gene (HRH3) in Chinese Han schizophrenia patients</article-title>
<source/>J. Psychopharmacol.
          <year>2012</year>
<volume>26</volume>
<fpage>813</fpage>
<lpage>818</lpage>
<pub-id pub-id-type="doi">10.1177/0269881111405358</pub-id>
<pub-id pub-id-type="pmid">21652606</pub-id>
</element-citation>
</ref>
<ref id="B127-pharmaceutics-12-00013">
<label>127.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wei</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Sun</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Huo</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Qin</surname>
<given-names>S.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Histamine H4 receptor polymorphism: A potential predictor of risperidone efficacy</article-title>
<source/>J. Clin. Psychopharmacol.
          <year>2013</year>
<volume>33</volume>
<fpage>221</fpage>
<lpage>225</lpage>
<pub-id pub-id-type="doi">10.1097/JCP.0b013e318283963b</pub-id>
<pub-id pub-id-type="pmid">23422377</pub-id>
</element-citation>
</ref>
<ref id="B128-pharmaceutics-12-00013">
<label>128.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Crisafulli</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Chiesa</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Han</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>S.J.</given-names>
</name>
<name>
<surname>Park</surname>
<given-names>M.H.</given-names>
</name>
<name>
<surname>Balzarro</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Andrisano</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Patkar</surname>
<given-names>A.A.</given-names>
</name>
<name>
<surname>Pae</surname>
<given-names>C.U.</given-names>
</name>
<name>
<surname>Serretti</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>Case-control association study for 10 genes in patients with schizophrenia: Influence of 5HTR1A variation rs10042486 on schizophrenia and response to antipsychotics</article-title>
<source/>Eur. Arch. Psychiatry Clin. Neurosci.
          <year>2012</year>
<volume>262</volume>
<fpage>199</fpage>
<lpage>205</lpage>
<pub-id pub-id-type="doi">10.1007/s00406-011-0278-3</pub-id>
<pub-id pub-id-type="pmid">22120873</pub-id>
</element-citation>
</ref>
<ref id="B129-pharmaceutics-12-00013">
<label>129.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kato</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Fukuda</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Wakeno</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Okugawa</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Takekita</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Watanabe</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Yamashita</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Hosoi</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Azuma</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Kinoshita</surname>
<given-names>T.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Effect of 5-HT1A gene polymorphisms on antidepressant response in major depressive disorder</article-title>
<source/>Am. J. Med. Genet. B Neuropsychiatr. Genet.
          <year>2009</year>
<volume>150</volume>
<fpage>115</fpage>
<lpage>123</lpage>
<pub-id pub-id-type="doi">10.1002/ajmg.b.30783</pub-id>
</element-citation>
</ref>
<ref id="B130-pharmaceutics-12-00013">
<label>130.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Correia</surname>
<given-names>C.T.</given-names>
</name>
<name>
<surname>Almeida</surname>
<given-names>J.P.</given-names>
</name>
<name>
<surname>Santos</surname>
<given-names>P.E.</given-names>
</name>
<name>
<surname>Sequeira</surname>
<given-names>A.F.</given-names>
</name>
<name>
<surname>Marques</surname>
<given-names>C.E.</given-names>
</name>
<name>
<surname>Miguel</surname>
<given-names>T.S.</given-names>
</name>
<name>
<surname>Abreu</surname>
<given-names>R.L.</given-names>
</name>
<name>
<surname>Oliveira</surname>
<given-names>G.G.</given-names>
</name>
<name>
<surname>Vicente</surname>
<given-names>A.M.</given-names>
</name>
</person-group>
<article-title>Pharmacogenetics of risperidone therapy in autism: Association analysis of eight candidate genes with drug efficacy and adverse drug reactions</article-title>
<source/>Pharmacogenom. J.
          <year>2010</year>
<volume>10</volume>
<fpage>418</fpage>
<pub-id pub-id-type="doi">10.1038/tpj.2009.63</pub-id>
</element-citation>
</ref>
<ref id="B131-pharmaceutics-12-00013">
<label>131.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Opgen-Rhein</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Brandl</surname>
<given-names>E.J.</given-names>
</name>
<name>
<surname>Müller</surname>
<given-names>D.J.</given-names>
</name>
<name>
<surname>Neuhaus</surname>
<given-names>A.H.</given-names>
</name>
<name>
<surname>Tiwari</surname>
<given-names>A.K.</given-names>
</name>
<name>
<surname>Sander</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Dettling</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Association of HTR2C, but not LEP or INSIG2, genes with antipsychotic-induced weight gain in a German sample</article-title>
<source/>Pharmacogenomics
          <year>2010</year>
<volume>11</volume>
<fpage>773</fpage>
<lpage>780</lpage>
<pub-id pub-id-type="doi">10.2217/pgs.10.50</pub-id>
<pub-id pub-id-type="pmid">20504252</pub-id>
</element-citation>
</ref>
<ref id="B132-pharmaceutics-12-00013">
<label>132.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Puangpetch</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Unaharassamee</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Jiratjintana</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Koomdee</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Sukasem</surname>
<given-names>C.</given-names>
</name>
</person-group>
<article-title>Genetic polymorphisms of HTR 2C, LEP and LEPR on metabolic syndromes in patients treated with atypical antipsychotic drugs</article-title>
<source/>J. Pharm. Pharmacol.
          <year>2018</year>
<volume>70</volume>
<fpage>536</fpage>
<lpage>542</lpage>
<pub-id pub-id-type="doi">10.1111/jphp.12892</pub-id>
<pub-id pub-id-type="pmid">29441581</pub-id>
</element-citation>
</ref>
<ref id="B133-pharmaceutics-12-00013">
<label>133.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rico-Gomis</surname>
<given-names>J.M.</given-names>
</name>
<name>
<surname>Palazón-Bru</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Triano-García</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Fabián</surname>
<given-names>L.</given-names>
</name>
</person-group>
<article-title>Relationship between the rs1414334 C/G polymorphism in the HTR2C gene and smoking in patients treated with atypical antipsychotics</article-title>
<source/>Adicciones
          <year>2018</year>
<volume>30</volume>
<fpage>123</fpage>
<lpage>130</lpage>
<pub-id pub-id-type="doi">10.20882/adicciones.876</pub-id>
<pub-id pub-id-type="pmid">28492956</pub-id>
</element-citation>
</ref>
<ref id="B134-pharmaceutics-12-00013">
<label>134.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname>
<given-names>B.C.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>X.W.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Wei</surname>
<given-names>Z.Y.</given-names>
</name>
<name>
<surname>Ji</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>F.P.</given-names>
</name>
<name>
<surname>Wan</surname>
<given-names>C.L.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>Y.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>FHTR2C promoter polymorphisms are associated with risperidone efficacy in Chinese female patients</article-title>
<source/>Pharmacogenomics
          <year>2010</year>
<volume>11</volume>
<fpage>685</fpage>
<lpage>692</lpage>
<pub-id pub-id-type="doi">10.2217/pgs.10.23</pub-id>
<pub-id pub-id-type="pmid">20415561</pub-id>
</element-citation>
</ref>
<ref id="B135-pharmaceutics-12-00013">
<label>135.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ruaño</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Thompson</surname>
<given-names>P.D.</given-names>
</name>
<name>
<surname>Windemuth</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Seip</surname>
<given-names>R.L.</given-names>
</name>
<name>
<surname>Dande</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Sorokin</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Kocherla</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Smith</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Holford</surname>
<given-names>T.R.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>A.H.</given-names>
</name>
</person-group>
<article-title>Physiogenomic association of statin-related myalgia to serotonin receptors</article-title>
<source/>Muscle Nerve
          <year>2007</year>
<volume>36</volume>
<fpage>329</fpage>
<lpage>335</lpage>
<pub-id pub-id-type="doi">10.1002/mus.20871</pub-id>
<pub-id pub-id-type="pmid">17600820</pub-id>
</element-citation>
</ref>
<ref id="B136-pharmaceutics-12-00013">
<label>136.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Jamba</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Patrick</surname>
<given-names>C.</given-names>
<suffix>III</suffix>
</name>
<name>
<surname>Padmanabhan</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Brennan</surname>
<given-names>M.D.</given-names>
</name>
</person-group>
<article-title>Targeted pharmacogenetic analysis of antipsychotic response in the CATIE study</article-title>
<source/>Pharmacogenomics
          <year>2012</year>
<volume>13</volume>
<fpage>1227</fpage>
<lpage>1237</lpage>
<pub-id pub-id-type="doi">10.2217/pgs.12.105</pub-id>
<pub-id pub-id-type="pmid">22920393</pub-id>
</element-citation>
</ref>
<ref id="B137-pharmaceutics-12-00013">
<label>137.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Srivastava</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Deshpande</surname>
<given-names>S.N.</given-names>
</name>
<name>
<surname>Nimgaonkar</surname>
<given-names>V.L.</given-names>
</name>
<name>
<surname>Lerer</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Thelma</surname>
<given-names>B.K.</given-names>
</name>
</person-group>
<article-title>Genetic correlates of olanzapine-induced weight gain in schizophrenia subjects from north India: Role of metabolic pathway genes</article-title>
<source/>Pharmacogenomics
          <year>2008</year>
<fpage>1055</fpage>
<lpage>1068</lpage>
<pub-id pub-id-type="doi">10.2217/14622416.9.8.1055</pub-id>
<pub-id pub-id-type="pmid">18681781</pub-id>
</element-citation>
</ref>
<ref id="B138-pharmaceutics-12-00013">
<label>138.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Calarge</surname>
<given-names>C.A.</given-names>
</name>
<name>
<surname>Ellingrod</surname>
<given-names>V.L.</given-names>
</name>
<name>
<surname>Zimmerman</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Acion</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Sivitz</surname>
<given-names>W.I.</given-names>
</name>
<name>
<surname>Schlechte</surname>
<given-names>J.A.</given-names>
</name>
</person-group>
<article-title>Leptin promoter-2548G/A variants predict risperidone-associated weight gain in children and adolescents</article-title>
<source/>Psychiat. Genet.
          <year>2009</year>
<volume>19</volume>
<fpage>320</fpage>
<pub-id pub-id-type="doi">10.1097/YPG.0b013e3283328e06</pub-id>
</element-citation>
</ref>
<ref id="B139-pharmaceutics-12-00013">
<label>139.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Ni</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Su</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Hou</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Xie</surname>
<given-names>W.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Association of LEPR and ANKK1 gene polymorphisms with weight gain in epilepsy patients receiving valproic acid</article-title>
<source/>Int. J. Neuropsychoph.
          <year>2015</year>
<volume>18</volume>
<pub-id pub-id-type="doi">10.1093/ijnp/pyv021</pub-id>
</element-citation>
</ref>
<ref id="B140-pharmaceutics-12-00013">
<label>140.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Malhotra</surname>
<given-names>A.K.</given-names>
</name>
<name>
<surname>Correll</surname>
<given-names>C.U.</given-names>
</name>
<name>
<surname>Chowdhury</surname>
<given-names>N.I.</given-names>
</name>
<name>
<surname>Müller</surname>
<given-names>D.J.</given-names>
</name>
<name>
<surname>Gregersen</surname>
<given-names>P.K.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>A.T.</given-names>
</name>
<name>
<surname>Tiwari</surname>
<given-names>A.K.</given-names>
</name>
<name>
<surname>Kane</surname>
<given-names>J.M.</given-names>
</name>
<name>
<surname>Fleischhacker</surname>
<given-names>W.W.</given-names>
</name>
<name>
<surname>Kahn</surname>
<given-names>R.S.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Association between common variants near the melanocortin 4 receptor gene and severe antipsychotic drug-induced weight gain</article-title>
<source/>Arch. Gen. Psychiatry
          <year>2012</year>
<volume>69</volume>
<fpage>904</fpage>
<lpage>912</lpage>
<pub-id pub-id-type="doi">10.1001/archgenpsychiatry.2012.191</pub-id>
<pub-id pub-id-type="pmid">22566560</pub-id>
</element-citation>
</ref>
<ref id="B141-pharmaceutics-12-00013">
<label>141.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Czerwensky</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Leucht</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Steimer</surname>
<given-names>W.</given-names>
</name>
</person-group>
<article-title>MC4R rs489693: A clinical risk factor for second generation antipsychotic-related weight gain?</article-title>
<source/>Int. J. Neuropsychopharmacol.
          <year>2013</year>
<volume>16</volume>
<fpage>2103</fpage>
<lpage>2109</lpage>
<pub-id pub-id-type="doi">10.1017/S1461145713000849</pub-id>
<pub-id pub-id-type="pmid">23920449</pub-id>
</element-citation>
</ref>
<ref id="B142-pharmaceutics-12-00013">
<label>142.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Campos-de-Sousa</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Guindalini</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Tondo</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Munro</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Osborne</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Floris</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Pedrazzoli</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Tufik</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Breen</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Collier</surname>
<given-names>D.</given-names>
</name>
</person-group>
<article-title>Nuclear receptor Rev-Erb-α circadian gene variants and lithium carbonate prophylaxis in bipolar affective disorder</article-title>
<source/>J. Biol. Rhythms
          <year>2010</year>
<volume>25</volume>
<fpage>132</fpage>
<lpage>137</lpage>
<pub-id pub-id-type="doi">10.1177/0748730410362713</pub-id>
<pub-id pub-id-type="pmid">20348464</pub-id>
</element-citation>
</ref>
<ref id="B143-pharmaceutics-12-00013">
<label>143.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>McCarthy</surname>
<given-names>M.J.</given-names>
</name>
<name>
<surname>Nievergelt</surname>
<given-names>C.M.</given-names>
</name>
<name>
<surname>Shekhtman</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Kripke</surname>
<given-names>D.F.</given-names>
</name>
<name>
<surname>Welsh</surname>
<given-names>D.K.</given-names>
</name>
<name>
<surname>Kelsoe</surname>
<given-names>J.R.</given-names>
</name>
</person-group>
<article-title>Functional genetic variation in the Rev-Erbα pathway and lithium response in the treatment of bipolar disorder</article-title>
<source/>Genes Brain Behav.
          <year>2011</year>
<volume>10</volume>
<fpage>852</fpage>
<lpage>861</lpage>
<pub-id pub-id-type="doi">10.1111/j.1601-183X.2011.00725.x</pub-id>
<pub-id pub-id-type="pmid">21781277</pub-id>
</element-citation>
</ref>
<ref id="B144-pharmaceutics-12-00013">
<label>144.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Choong</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Polari</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Kamdem</surname>
<given-names>R.H.</given-names>
</name>
<name>
<surname>Gervasoni</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Spisla</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Sirot</surname>
<given-names>E.J.</given-names>
</name>
<name>
<surname>Bickel</surname>
<given-names>G.G.</given-names>
</name>
<name>
<surname>Bondolfi</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Conus</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Eap</surname>
<given-names>C.B.</given-names>
</name>
</person-group>
<article-title>Pharmacogenetic study on risperidone long-acting injection: Influence of cytochrome P450 2D6 and pregnane X receptor on risperidone exposure and drug-induced side-effects</article-title>
<source/>J. Clin. Psychopharmacol.
          <year>2013</year>
<volume>33</volume>
<fpage>289</fpage>
<lpage>298</lpage>
<pub-id pub-id-type="doi">10.1097/JCP.0b013e31828f62cd</pub-id>
<pub-id pub-id-type="pmid">23609392</pub-id>
</element-citation>
</ref>
<ref id="B145-pharmaceutics-12-00013">
<label>145.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vandenberghe</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Guidi</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Choong</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>von Gunten</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Conus</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Csajka</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Eap</surname>
<given-names>C.B.</given-names>
</name>
</person-group>
<article-title>Genetics-based population pharmacokinetics and pharmacodynamics of risperidone in a psychiatric cohort</article-title>
<source/>Clin. Pharmacokinet.
          <year>2015</year>
<volume>54</volume>
<fpage>1259</fpage>
<lpage>1272</lpage>
<pub-id pub-id-type="doi">10.1007/s40262-015-0289-8</pub-id>
<pub-id pub-id-type="pmid">26129906</pub-id>
</element-citation>
</ref>
<ref id="B146-pharmaceutics-12-00013">
<label>146.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Fan</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Gao</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Yi</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Yuan</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Hong</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>S.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Neurotrophic tyrosine kinase receptor type 2 (NTRK2) gene associated with treatment response to mood stabilizers in patients with bipolar I disorder</article-title>
<source/>J. Mol. Neurosci.
          <year>2013</year>
<volume>50</volume>
<fpage>305</fpage>
<lpage>310</lpage>
<pub-id pub-id-type="doi">10.1007/s12031-013-9956-0</pub-id>
<pub-id pub-id-type="pmid">23315174</pub-id>
</element-citation>
</ref>
<ref id="B147-pharmaceutics-12-00013">
<label>147.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lane</surname>
<given-names>H.Y.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>Y.C.</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>C.L.</given-names>
</name>
<name>
<surname>Chang</surname>
<given-names>Y.C.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>P.L.</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>C.H.</given-names>
</name>
<name>
<surname>Tsai</surname>
<given-names>G.E.</given-names>
</name>
</person-group>
<article-title>RGS4 polymorphisms predict clinical manifestations and responses to risperidone treatment in patients with schizophrenia</article-title>
<source/>J. Clin. Psychopharmacol.
          <year>2008</year>
<volume>28</volume>
<fpage>64</fpage>
<lpage>68</lpage>
<pub-id pub-id-type="doi">10.1097/jcp.0b013e3181603f5a</pub-id>
<pub-id pub-id-type="pmid">18204343</pub-id>
</element-citation>
</ref>
<ref id="B148-pharmaceutics-12-00013">
<label>148.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Campbell</surname>
<given-names>D.B.</given-names>
</name>
<name>
<surname>Ebert</surname>
<given-names>P.J.</given-names>
</name>
<name>
<surname>Skelly</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Stroup</surname>
<given-names>T.S.</given-names>
</name>
<name>
<surname>Lieberman</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Levitt</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Sullivan</surname>
<given-names>P.F.</given-names>
</name>
</person-group>
<article-title>Ethnic stratification of the association of RGS4 variants with antipsychotic treatment response in schizophrenia</article-title>
<source/>Biol. Psychiatry
          <year>2008</year>
<volume>63</volume>
<fpage>32</fpage>
<lpage>41</lpage>
<pub-id pub-id-type="doi">10.1016/j.biopsych.2007.04.018</pub-id>
<pub-id pub-id-type="pmid">17588543</pub-id>
</element-citation>
</ref>
<ref id="B149-pharmaceutics-12-00013">
<label>149.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Need</surname>
<given-names>A.C.</given-names>
</name>
<name>
<surname>Keefe</surname>
<given-names>R.S.</given-names>
</name>
<name>
<surname>Ge</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Grossman</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Dickson</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>McEvoy</surname>
<given-names>J.P.</given-names>
</name>
<name>
<surname>Goldstein</surname>
<given-names>D.B.</given-names>
</name>
</person-group>
<article-title>Pharmacogenetics of antipsychotic response in the CATIE trial: A candidate gene analysis</article-title>
<source/>Eur. J. Hum. Genet.
          <year>2009</year>
<volume>17</volume>
<fpage>946</fpage>
<pub-id pub-id-type="doi">10.1038/ejhg.2008.264</pub-id>
<pub-id pub-id-type="pmid">19156168</pub-id>
</element-citation>
</ref>
<ref id="B150-pharmaceutics-12-00013">
<label>150.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kumari</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Lakhan</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Garg</surname>
<given-names>R.K.</given-names>
</name>
<name>
<surname>Kalita</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Misra</surname>
<given-names>U.K.</given-names>
</name>
<name>
<surname>Mittal</surname>
<given-names>B.</given-names>
</name>
</person-group>
<article-title>Pharmacogenomic association study on the role of drug metabolizing, drug transporters and drug target gene polymorphisms in drug-resistant epilepsy in a north Indian population</article-title>
<source/>Indian J. Hum. Genet.
          <year>2011</year>
<volume>17</volume>
<issue>Suppl. 1</issue>
<fpage>S32</fpage>
<pub-id pub-id-type="pmid">21747585</pub-id>
</element-citation>
</ref>
<ref id="B151-pharmaceutics-12-00013">
<label>151.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Daci</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Beretta</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Vllasaliu</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Shala</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Govori</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Norata</surname>
<given-names>G.D.</given-names>
</name>
<name>
<surname>Krasniqi</surname>
<given-names>S.</given-names>
</name>
</person-group>
<article-title>Polymorphic variants of SCN1A and EPHX1 influence plasma carbamazepine concentration, metabolism and pharmacoresistance in a population of Kosovar Albanian epileptic patients</article-title>
<source/>PLoS ONE
          <year>2015</year>
<volume>10</volume>
<elocation-id>e0142408</elocation-id>
<pub-id pub-id-type="doi">10.1371/journal.pone.0142408</pub-id>
<pub-id pub-id-type="pmid">26555147</pub-id>
</element-citation>
</ref>
<ref id="B152-pharmaceutics-12-00013">
<label>152.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Thompson</surname>
<given-names>C.H.</given-names>
</name>
<name>
<surname>Kahlig</surname>
<given-names>K.M.</given-names>
</name>
<name>
<surname>George</surname>
<given-names>A.L.</given-names>
<suffix>Jr.</suffix>
</name>
</person-group>
<article-title>SCN1A splice variants exhibit divergent sensitivity to commonly used antiepileptic drugs</article-title>
<source/>Epilepsia
          <year>2011</year>
<volume>52</volume>
<fpage>1000</fpage>
<lpage>1009</lpage>
<pub-id pub-id-type="doi">10.1111/j.1528-1167.2011.03040.x</pub-id>
<pub-id pub-id-type="pmid">21453355</pub-id>
</element-citation>
</ref>
<ref id="B153-pharmaceutics-12-00013">
<label>153.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Haerian</surname>
<given-names>B.S.</given-names>
</name>
<name>
<surname>Baum</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Kwan</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Tan</surname>
<given-names>H.J.</given-names>
</name>
<name>
<surname>Raymond</surname>
<given-names>A.A.</given-names>
</name>
<name>
<surname>Mohamed</surname>
<given-names>Z.</given-names>
</name>
</person-group>
<article-title>SCN1A, SCN2A and SCN3A gene polymorphisms and responsiveness to antiepileptic drugs: A multicenter cohort study and meta-analysis</article-title>
<source/>Pharmacogenomics
          <year>2013</year>
<volume>14</volume>
<fpage>1153</fpage>
<lpage>1166</lpage>
<pub-id pub-id-type="doi">10.2217/pgs.13.104</pub-id>
<pub-id pub-id-type="pmid">23859570</pub-id>
</element-citation>
</ref>
<ref id="B154-pharmaceutics-12-00013">
<label>154.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kwan</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Poon</surname>
<given-names>W.S.</given-names>
</name>
<name>
<surname>Ng</surname>
<given-names>H.K.</given-names>
</name>
<name>
<surname>Kang</surname>
<given-names>D.E.</given-names>
</name>
<name>
<surname>Wong</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Ng</surname>
<given-names>P.W.</given-names>
</name>
<name>
<surname>Lui</surname>
<given-names>C.H.</given-names>
</name>
<name>
<surname>Sin</surname>
<given-names>N.C.</given-names>
</name>
<name>
<surname>Wong</surname>
<given-names>K.S.</given-names>
</name>
<name>
<surname>Baum</surname>
<given-names>L.</given-names>
</name>
</person-group>
<article-title>Multidrug resistance in epilepsy and polymorphisms in the voltage-gated sodium channel genes SCN1A, SCN2A, and SCN3A: Correlation among phenotype, genotype, and mRNA expression</article-title>
<source/>Pharmacogenet. Genom.
          <year>2008</year>
<volume>18</volume>
<fpage>989</fpage>
<lpage>998</lpage>
<pub-id pub-id-type="doi">10.1097/FPC.0b013e3283117d67</pub-id>
</element-citation>
</ref>
<ref id="B155-pharmaceutics-12-00013">
<label>155.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kwon</surname>
<given-names>J.S.</given-names>
</name>
<name>
<surname>Joo</surname>
<given-names>Y.H.</given-names>
</name>
<name>
<surname>Nam</surname>
<given-names>H.J.</given-names>
</name>
<name>
<surname>Lim</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Cho</surname>
<given-names>E.Y.</given-names>
</name>
<name>
<surname>Jung</surname>
<given-names>M.H.</given-names>
</name>
<name>
<surname>Choi</surname>
<given-names>J.S.</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Kang</surname>
<given-names>D.H.</given-names>
</name>
<name>
<surname>Oh</surname>
<given-names>S.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Association of the glutamate transporter gene slc1a1 with atypical antipsychotics—Induced obsessive-compulsive symptoms</article-title>
<source/>Arch. Gen. Psychiatry
          <year>2009</year>
<volume>66</volume>
<fpage>1233</fpage>
<lpage>1241</lpage>
<pub-id pub-id-type="doi">10.1001/archgenpsychiatry.2009.155</pub-id>
<pub-id pub-id-type="pmid">19884611</pub-id>
</element-citation>
</ref>
<ref id="B156-pharmaceutics-12-00013">
<label>156.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zai</surname>
<given-names>C.C.</given-names>
</name>
<name>
<surname>Tiwari</surname>
<given-names>A.K.</given-names>
</name>
<name>
<surname>Mazzoco</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>de Luca</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Müller</surname>
<given-names>D.J.</given-names>
</name>
<name>
<surname>Shaikh</surname>
<given-names>S.A.</given-names>
</name>
<name>
<surname>Lohoff</surname>
<given-names>F.W.</given-names>
</name>
<name>
<surname>Freeman</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Voineskos</surname>
<given-names>A.N.</given-names>
</name>
<name>
<surname>Potkin</surname>
<given-names>S.G.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Association study of the vesicular monoamine transporter gene SLC18A2 with tardive dyskinesia</article-title>
<source/>J. Psychiatr. Res.
          <year>2013</year>
<volume>47</volume>
<fpage>1760</fpage>
<lpage>1765</lpage>
<pub-id pub-id-type="doi">10.1016/j.jpsychires.2013.07.025</pub-id>
<pub-id pub-id-type="pmid">24018103</pub-id>
</element-citation>
</ref>
<ref id="B157-pharmaceutics-12-00013">
<label>157.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hongkaew</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Medhasi</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Pasomsub</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Ngamsamut</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Puangpetch</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Vanwong</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Chamnanphon</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Limsila</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Suthisisang</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Wilffert</surname>
<given-names>B.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>UGT1A1 polymorphisms associated with prolactin response in risperidone-treated children and adolescents with autism spectrum disorder</article-title>
<source/>Pharmacogenom. J.
          <year>2018</year>
<volume>18</volume>
<fpage>740</fpage>
<pub-id pub-id-type="doi">10.1038/s41397-018-0031-7</pub-id>
</element-citation>
</ref>
<ref id="B158-pharmaceutics-12-00013">
<label>158.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Serretti</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Pae</surname>
<given-names>C.U.</given-names>
</name>
<name>
<surname>Chiesa</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Mandelli</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>De Ronchi</surname>
<given-names>D.</given-names>
</name>
</person-group>
<article-title>Influence of TAAR6 polymorphisms on response to aripiprazole</article-title>
<source/>Prog. Neuropsychopharmacol. Biol. Psychiatry
          <year>2009</year>
<volume>33</volume>
<fpage>822</fpage>
<lpage>826</lpage>
<pub-id pub-id-type="doi">10.1016/j.pnpbp.2009.03.032</pub-id>
<pub-id pub-id-type="pmid">19345712</pub-id>
</element-citation>
</ref>
<ref id="B159-pharmaceutics-12-00013">
<label>159.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ma</surname>
<given-names>J.Z.</given-names>
</name>
<name>
<surname>Beuten</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Payne</surname>
<given-names>T.J.</given-names>
</name>
<name>
<surname>Dupont</surname>
<given-names>R.T.</given-names>
</name>
<name>
<surname>Elston</surname>
<given-names>R.C.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>M.D.</given-names>
</name>
</person-group>
<article-title>Haplotype analysis indicates an association between the DOPA decarboxylase (DDC) gene and nicotine dependence</article-title>
<source/>Hum. Mol. Genet.
          <year>2005</year>
<volume>14</volume>
<fpage>1691</fpage>
<lpage>1698</lpage>
<pub-id pub-id-type="doi">10.1093/hmg/ddi177</pub-id>
<pub-id pub-id-type="pmid">15879433</pub-id>
</element-citation>
</ref>
<ref id="B160-pharmaceutics-12-00013">
<label>160.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tzvetkov</surname>
<given-names>M.V.</given-names>
</name>
<name>
<surname>Brockmöller</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Roots</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Kirchheiner</surname>
<given-names>J.</given-names>
</name>
</person-group>
<article-title>Common genetic variations in human brain-specific tryptophan hydroxylase-2 and response to antidepressant treatment</article-title>
<source/>Pharmacogenet. Genom.
          <year>2008</year>
<volume>18</volume>
<fpage>495</fpage>
<lpage>506</lpage>
<pub-id pub-id-type="doi">10.1097/FPC.0b013e3282fb02cb</pub-id>
</element-citation>
</ref>
<ref id="B161-pharmaceutics-12-00013">
<label>161.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Relling</surname>
<given-names>M.V.</given-names>
</name>
<name>
<surname>Klein</surname>
<given-names>T.E.</given-names>
</name>
</person-group>
<article-title>CPIC: Clinical pharmacogenetics implementation consortium of the pharmacogenomics research network</article-title>
<source/>Clin. Pharmacol. Ther.
          <year>2011</year>
<volume>89</volume>
<fpage>464</fpage>
<lpage>467</lpage>
<pub-id pub-id-type="doi">10.1038/clpt.2010.279</pub-id>
<pub-id pub-id-type="pmid">21270786</pub-id>
</element-citation>
</ref>
<ref id="B162-pharmaceutics-12-00013">
<label>162.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hicks</surname>
<given-names>J.K.</given-names>
</name>
<name>
<surname>Swen</surname>
<given-names>J.J.</given-names>
</name>
<name>
<surname>Thorn</surname>
<given-names>C.F.</given-names>
</name>
<name>
<surname>Sangkuhl</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Kharasch</surname>
<given-names>E.D.</given-names>
</name>
<name>
<surname>Ellingrod</surname>
<given-names>V.L.</given-names>
</name>
<name>
<surname>Skaar</surname>
<given-names>T.C.</given-names>
</name>
<name>
<surname>Müller</surname>
<given-names>D.J.</given-names>
</name>
<name>
<surname>Gaedigk</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Sting</surname>
<given-names>J.C.</given-names>
</name>
</person-group>
<article-title>Clinical Pharmacogenetics Implementation Consortium. Clinical Pharmacogenetics Implementation Consortium guideline for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants</article-title>
<source/>Clin. Pharmacol. Ther.
          <year>2013</year>
<volume>93</volume>
<fpage>402</fpage>
<lpage>408</lpage>
<pub-id pub-id-type="doi">10.1038/clpt.2013.2</pub-id>
<pub-id pub-id-type="pmid">23486447</pub-id>
</element-citation>
</ref>
<ref id="B163-pharmaceutics-12-00013">
<label>163.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gross</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Daniel</surname>
<given-names>J.</given-names>
</name>
</person-group>
<article-title>Overview of pharmacogenomic testing in clinical practice</article-title>
<source/>Ment. Health Clin.
          <year>2018</year>
<volume>8</volume>
<fpage>235</fpage>
<lpage>241</lpage>
<pub-id pub-id-type="doi">10.9740/mhc.2018.09.235</pub-id>
<pub-id pub-id-type="pmid">30206507</pub-id>
</element-citation>
</ref>
<ref id="B164-pharmaceutics-12-00013">
<label>164.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Grover</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Bala</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Sharma</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Gourie-Devi</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Baghel</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Kaur</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Gupta</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Talwar</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Kukreti</surname>
<given-names>R.</given-names>
</name>
</person-group>
<article-title>Absence of a general association between ABCB1 genetic variants and response to antiepileptic drugs in epilepsy patients</article-title>
<source/>Biochimie
          <year>2010</year>
<volume>92</volume>
<fpage>1207</fpage>
<lpage>1212</lpage>
<pub-id pub-id-type="doi">10.1016/j.biochi.2010.04.008</pub-id>
<pub-id pub-id-type="pmid">20417680</pub-id>
</element-citation>
</ref>
<ref id="B165-pharmaceutics-12-00013">
<label>165.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kuzman</surname>
<given-names>M.R.</given-names>
</name>
<name>
<surname>Medved</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Bozina</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Hotujac</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Sain</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Bilusic</surname>
<given-names>H.</given-names>
</name>
</person-group>
<article-title>The influence of 5-HT2C and MDR1 genetic polymorphisms on antipsychotic-induced weight gain in female schizophrenic patients</article-title>
<source/>Psychiatry Res.
          <year>2008</year>
<volume>160</volume>
<fpage>308</fpage>
<lpage>315</lpage>
<pub-id pub-id-type="doi">10.1016/j.psychres.2007.06.006</pub-id>
<pub-id pub-id-type="pmid">18718676</pub-id>
</element-citation>
</ref>
<ref id="B166-pharmaceutics-12-00013">
<label>166.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Suzuki</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Tsuneyama</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Fukui</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Sugai</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Watanabe</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Ono</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Saito</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Inoue</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Someya</surname>
<given-names>T.</given-names>
</name>
</person-group>
<article-title>Effect of risperidone metabolism and P-glycoprotein gene polymorphism on QT interval in patients with schizophrenia</article-title>
<source/>Pharmacogenom. J.
          <year>2014</year>
<volume>14</volume>
<fpage>452</fpage>
<pub-id pub-id-type="doi">10.1038/tpj.2014.6</pub-id>
</element-citation>
</ref>
<ref id="B167-pharmaceutics-12-00013">
<label>167.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Sun</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Deng</surname>
<given-names>Y.S.</given-names>
</name>
<name>
<surname>Qiu</surname>
<given-names>X.W.</given-names>
</name>
</person-group>
<article-title>ABCB1 1199G&gt; A Polymorphism impacts transport ability of P-gp-mediated antipsychotics</article-title>
<source/>DNA Cell Biol.
          <year>2018</year>
<volume>37</volume>
<fpage>325</fpage>
<lpage>329</lpage>
<pub-id pub-id-type="doi">10.1089/dna.2017.4096</pub-id>
<pub-id pub-id-type="pmid">29443543</pub-id>
</element-citation>
</ref>
<ref id="B168-pharmaceutics-12-00013">
<label>168.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mi</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Du</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Xiao</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Lu</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>He</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Shi</surname>
<given-names>L.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Association of ABCB1 gene polymorphisms with efficacy and adverse reaction to risperidone or paliperidone in Han Chinese schizophrenic patients</article-title>
<source/>Neurosci. Bull.
          <year>2016</year>
<volume>32</volume>
<fpage>547</fpage>
<lpage>549</lpage>
<pub-id pub-id-type="doi">10.1007/s12264-016-0050-9</pub-id>
<pub-id pub-id-type="pmid">27456824</pub-id>
</element-citation>
</ref>
<ref id="B169-pharmaceutics-12-00013">
<label>169.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhou</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Xie</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Polymorphisms of ABCG2, ABCB1 and HNF4α are associated with Lamotrigine trough concentrations in epilepsy patients</article-title>
<source/>Drug. Metab. Pharmacokinet.
          <year>2015</year>
<volume>30</volume>
<fpage>282</fpage>
<lpage>287</lpage>
<pub-id pub-id-type="doi">10.1016/j.dmpk.2015.05.002</pub-id>
<pub-id pub-id-type="pmid">26213157</pub-id>
</element-citation>
</ref>
<ref id="B170-pharmaceutics-12-00013">
<label>170.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rafaniello</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Sessa</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Bernardi</surname>
<given-names>F.F.</given-names>
</name>
<name>
<surname>Pozzi</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Cheli</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Cattaneo</surname>
<given-names>D.</given-names>
</name>
</person-group>
<article-title>The predictive value of ABCB1, ABCG2, CYP3A4/5 and CYP2D6 polymorphisms for risperidone and aripiprazole plasma concentrations and the occurrence of adverse drug reactions</article-title>
<source/>Pharmacogenom. J.
          <year>2018</year>
<volume>18</volume>
<fpage>422</fpage>
<pub-id pub-id-type="doi">10.1038/tpj.2017.38</pub-id>
</element-citation>
</ref>
<ref id="B171-pharmaceutics-12-00013">
<label>171.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wen</surname>
<given-names>Z.P.</given-names>
</name>
<name>
<surname>Fan</surname>
<given-names>S.S.</given-names>
</name>
<name>
<surname>Du</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Yin</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>B.T.</given-names>
</name>
<name>
<surname>Peng</surname>
<given-names>Z.F.</given-names>
</name>
<name>
<surname>Xie</surname>
<given-names>Y.Y.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Tang</surname>
<given-names>J.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Influence of acylpeptide hydrolase polymorphisms on valproic acid level in Chinese epilepsy patients</article-title>
<source/>Pharmacogenomics
          <year>2016</year>
<volume>17</volume>
<fpage>1219</fpage>
<lpage>1225</lpage>
<pub-id pub-id-type="doi">10.2217/pgs-2016-0030</pub-id>
<pub-id pub-id-type="pmid">27406852</pub-id>
</element-citation>
</ref>
<ref id="B172-pharmaceutics-12-00013">
<label>172.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Grover</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Talwar</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Gourie-Devi</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Gupta</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Bala</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Sharma</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Baghel</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Kaur</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Sharma</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Kukreti</surname>
<given-names>R.</given-names>
</name>
</person-group>
<article-title>Genetic polymorphisms in sex hormone metabolizing genes and drug response in women with epilepsy</article-title>
<source/>Pharmacogenomics
          <year>2010</year>
<volume>11</volume>
<fpage>1525</fpage>
<lpage>1534</lpage>
<pub-id pub-id-type="doi">10.2217/pgs.10.120</pub-id>
<pub-id pub-id-type="pmid">21121773</pub-id>
</element-citation>
</ref>
<ref id="B173-pharmaceutics-12-00013">
<label>173.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tan</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>J.T.</given-names>
</name>
<name>
<surname>Sun</surname>
<given-names>Y.P.</given-names>
</name>
<name>
<surname>Ou</surname>
<given-names>J.R.</given-names>
</name>
<name>
<surname>Song</surname>
<given-names>J.H.</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>Y.</given-names>
</name>
</person-group>
<article-title>The influence of cytochrome oxidase CYP2A6, CYP2B6, and CYP2C9 polymorphisms on the plasma concentrations of valproic acid in epileptic patients</article-title>
<source/>Clin. Neurol. Neurosurg.
          <year>2010</year>
<volume>112</volume>
<fpage>320</fpage>
<lpage>323</lpage>
<pub-id pub-id-type="doi">10.1016/j.clineuro.2010.01.002</pub-id>
<pub-id pub-id-type="pmid">20089352</pub-id>
</element-citation>
</ref>
<ref id="B174-pharmaceutics-12-00013">
<label>174.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tay</surname>
<given-names>J.K.</given-names>
</name>
<name>
<surname>Tan</surname>
<given-names>C.H.</given-names>
</name>
<name>
<surname>Chong</surname>
<given-names>S.A.</given-names>
</name>
<name>
<surname>Tan</surname>
<given-names>E.C.</given-names>
</name>
</person-group>
<article-title>Functional polymorphisms of the cytochrome P450 1A2 (CYP1A2) gene and prolonged QTc interval in schizophrenia</article-title>
<source/>Prog. Neuropsychopharmacol. Biol. Psychiatry
          <year>2007</year>
<volume>31</volume>
<fpage>1297</fpage>
<lpage>1302</lpage>
<pub-id pub-id-type="doi">10.1016/j.pnpbp.2007.05.013</pub-id>
<pub-id pub-id-type="pmid">17611010</pub-id>
</element-citation>
</ref>
<ref id="B175-pharmaceutics-12-00013">
<label>175.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hodgson</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Tansey</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Dernovšek</surname>
<given-names>M.Z.</given-names>
</name>
<name>
<surname>Hauser</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Henigsberg</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Maier</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Mors</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>Placentino</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Rietschel</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Souery</surname>
<given-names>D.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Genetic differences in cytochrome P450 enzymes and antidepressant treatment response</article-title>
<source/>J. Psychopharmacol.
          <year>2014</year>
<volume>28</volume>
<fpage>133</fpage>
<lpage>141</lpage>
<pub-id pub-id-type="doi">10.1177/0269881113512041</pub-id>
<pub-id pub-id-type="pmid">24257813</pub-id>
</element-citation>
</ref>
<ref id="B176-pharmaceutics-12-00013">
<label>176.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Grasmäder</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Verwohlt</surname>
<given-names>P.L.</given-names>
</name>
<name>
<surname>Rietschel</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Dragicevic</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Müller</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Hiemke</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Freymann</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Zobel</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Maier</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Rao</surname>
<given-names>M.L.</given-names>
</name>
</person-group>
<article-title>Impact of polymorphisms of cytochrome-P450 isoenzymes 2C9, 2C19 and 2D6 on plasma concentrations and clinical effects of antidepressants in a naturalistic clinical setting</article-title>
<source/>Eur. J. Clin. Pharmacol.
          <year>2004</year>
<volume>60</volume>
<fpage>329</fpage>
<lpage>336</lpage>
<pub-id pub-id-type="doi">10.1007/s00228-004-0766-8</pub-id>
<pub-id pub-id-type="pmid">15168101</pub-id>
</element-citation>
</ref>
<ref id="B177-pharmaceutics-12-00013">
<label>177.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yokono</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Morita</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Someya</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Hirokane</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Okawa</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Shimoda</surname>
<given-names>K.</given-names>
</name>
</person-group>
<article-title>The effect of CYP2C19 and CYP2D6 genotypes on the metabolism of clomipramine in Japanese psychiatric patients</article-title>
<source/>J. Clin. Psychopharmacol.
          <year>2001</year>
<volume>21</volume>
<fpage>549</fpage>
<lpage>555</lpage>
<pub-id pub-id-type="doi">10.1097/00004714-200112000-00002</pub-id>
<pub-id pub-id-type="pmid">11763000</pub-id>
</element-citation>
</ref>
<ref id="B178-pharmaceutics-12-00013">
<label>178.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Smith</surname>
<given-names>R.L.</given-names>
</name>
<name>
<surname>Haslemo</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Refsum</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Molden</surname>
<given-names>E.</given-names>
</name>
</person-group>
<article-title>Impact of age, gender and CYP2C9/2C19 genotypes on dose-adjusted steady-state serum concentrations of valproic acid—A large-scale study based on naturalistic therapeutic drug monitoring data</article-title>
<source/>Eur. J. Clin. Pharmacol.
          <year>2016</year>
<volume>72</volume>
<fpage>1099</fpage>
<lpage>1104</lpage>
<pub-id pub-id-type="doi">10.1007/s00228-016-2087-0</pub-id>
<pub-id pub-id-type="pmid">27353638</pub-id>
</element-citation>
</ref>
<ref id="B179-pharmaceutics-12-00013">
<label>179.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cabaleiro</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>López-Rodríguez</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Ochoa</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Román</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Novalbos</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Abad-Santos</surname>
<given-names>F.</given-names>
</name>
</person-group>
<article-title>Polymorphisms influencing olanzapine metabolism and adverse effects in healthy subjects</article-title>
<source/>Hum. Psychopharm. Clin.
          <year>2013</year>
<volume>28</volume>
<fpage>205</fpage>
<lpage>214</lpage>
<pub-id pub-id-type="doi">10.1002/hup.2308</pub-id>
</element-citation>
</ref>
<ref id="B180-pharmaceutics-12-00013">
<label>180.</label>
<element-citation publication-type="gov">
<article-title>Drugs@FDA: Drug Product ABILIFY (ARIPIPRAZOLE), NDA021436, Rebel Distributors Corp</article-title>
<comment>Available online: <ext-link ext-link-type="uri" xlink:href="https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&amp;varApplNo=021436">https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&amp;varApplNo=021436</ext-link></comment>
<date-in-citation content-type="access-date" iso-8601-date="2019-09-01">(accessed on 1 September 2019)</date-in-citation>
</element-citation>
</ref>
<ref id="B181-pharmaceutics-12-00013">
<label>181.</label>
<element-citation publication-type="gov">
<article-title>Drugs@FDA: Drug Product PERSERIS (Risperidone), NDA210655, Indivior Inc</article-title>
<comment>Available online: <ext-link ext-link-type="uri" xlink:href="https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&amp;varApplNo=210655">https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&amp;varApplNo=210655</ext-link></comment>
<date-in-citation content-type="access-date" iso-8601-date="2019-09-01">(accessed on 1 September 2019)</date-in-citation>
</element-citation>
</ref>
<ref id="B182-pharmaceutics-12-00013">
<label>182.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Findling</surname>
<given-names>R.L.</given-names>
</name>
<name>
<surname>Nucci</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Piergies</surname>
<given-names>A.A.</given-names>
</name>
<name>
<surname>Gomeni</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Bartolic</surname>
<given-names>E.I.</given-names>
</name>
<name>
<surname>Fong</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Carpenter</surname>
<given-names>D.J.</given-names>
</name>
<name>
<surname>Leeder</surname>
<given-names>J.S.</given-names>
</name>
<name>
<surname>Gaedigk</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Danoff</surname>
<given-names>T.M.</given-names>
</name>
</person-group>
<article-title>Multiple dose pharmacokinetics of paroxetine in children and adolescents with major depressive disorder or obsessive–compulsive disorder</article-title>
<source/>Neuropsychopharmacology
          <year>2006</year>
<volume>31</volume>
<fpage>1274</fpage>
<pub-id pub-id-type="doi">10.1038/sj.npp.1300960</pub-id>
<pub-id pub-id-type="pmid">16319918</pub-id>
</element-citation>
</ref>
<ref id="B183-pharmaceutics-12-00013">
<label>183.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Spigset</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>Granberg</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Hägg</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Norström</surname>
<given-names>Å.</given-names>
</name>
<name>
<surname>Dahlqvist</surname>
<given-names>R.</given-names>
</name>
</person-group>
<article-title>Relationship between fluvoxamine pharmacokinetics and CYP2D6/CYP2C19 phenotype polymorphisms</article-title>
<source/>Eur. J. Clin. Pharmacol.
          <year>1997</year>
<volume>52</volume>
<fpage>129</fpage>
<lpage>133</lpage>
<pub-id pub-id-type="doi">10.1007/s002280050261</pub-id>
<pub-id pub-id-type="pmid">9174682</pub-id>
</element-citation>
</ref>
<ref id="B184-pharmaceutics-12-00013">
<label>184.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gjestad</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Haslemo</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Andreassen</surname>
<given-names>O.A.</given-names>
</name>
<name>
<surname>Molden</surname>
<given-names>E.</given-names>
</name>
</person-group>
<article-title>4β-Hydroxycholesterol level significantly correlates with steady-state serum concentration of the CYP3A4 substrate quetiapine in psychiatric patients</article-title>
<source/>Br. J. Clin. Pharmacol.
          <year>2017</year>
<volume>83</volume>
<fpage>2398</fpage>
<lpage>2405</lpage>
<pub-id pub-id-type="doi">10.1111/bcp.13341</pub-id>
<pub-id pub-id-type="pmid">28585378</pub-id>
</element-citation>
</ref>
<ref id="B185-pharmaceutics-12-00013">
<label>185.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cuttle</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Munns</surname>
<given-names>A.J.</given-names>
</name>
<name>
<surname>Hogg</surname>
<given-names>N.A.</given-names>
</name>
<name>
<surname>Scott</surname>
<given-names>J.R.</given-names>
</name>
<name>
<surname>Hooper</surname>
<given-names>W.D.</given-names>
</name>
<name>
<surname>Dickinson</surname>
<given-names>R.G.</given-names>
</name>
<name>
<surname>Gillam</surname>
<given-names>E.M.</given-names>
</name>
</person-group>
<article-title>Phenytoin metabolism by human cytochrome P450: Involvement of P450 3A and 2C forms in secondary metabolism and drug-protein adduct formation</article-title>
<source/>Drug. Metab. Dispos.
          <year>2000</year>
<volume>28</volume>
<fpage>945</fpage>
<lpage>950</lpage>
<pub-id pub-id-type="pmid">10901705</pub-id>
</element-citation>
</ref>
<ref id="B186-pharmaceutics-12-00013">
<label>186.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Brandl</surname>
<given-names>E.J.</given-names>
</name>
<name>
<surname>Chowdhury</surname>
<given-names>N.I.</given-names>
</name>
<name>
<surname>Tiwari</surname>
<given-names>A.K.</given-names>
</name>
<name>
<surname>Lett</surname>
<given-names>T.A.</given-names>
</name>
<name>
<surname>Meltzer</surname>
<given-names>H.Y.</given-names>
</name>
<name>
<surname>Kennedy</surname>
<given-names>J.L.</given-names>
</name>
<name>
<surname>Müller</surname>
<given-names>D.J.</given-names>
</name>
</person-group>
<article-title>Genetic variation in CYP3A43 is associated with response to antipsychotic medication</article-title>
<source/>J. Neural. Transm.
          <year>2015</year>
<volume>122</volume>
<fpage>29</fpage>
<lpage>34</lpage>
<pub-id pub-id-type="doi">10.1007/s00702-014-1298-8</pub-id>
<pub-id pub-id-type="pmid">25150845</pub-id>
</element-citation>
</ref>
<ref id="B187-pharmaceutics-12-00013">
<label>187.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kim</surname>
<given-names>K.A.</given-names>
</name>
<name>
<surname>Joo</surname>
<given-names>H.J.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>H.M.</given-names>
</name>
<name>
<surname>Park</surname>
<given-names>J.Y.</given-names>
</name>
</person-group>
<article-title>Influence of ABCB1 and CYP3A5 genetic polymorphisms on the pharmacokinetics of quetiapine in healthy volunteers</article-title>
<source/>Pharmacogenet. Genom.
          <year>2014</year>
<volume>24</volume>
<fpage>35</fpage>
<lpage>42</lpage>
<pub-id pub-id-type="doi">10.1097/FPC.0000000000000020</pub-id>
</element-citation>
</ref>
<ref id="B188-pharmaceutics-12-00013">
<label>188.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Krishnaswamy</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Hao</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Al-Rohaimi</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Hesse</surname>
<given-names>L.M.</given-names>
</name>
<name>
<surname>von Moltke</surname>
<given-names>L.L.</given-names>
</name>
<name>
<surname>Greenblatt</surname>
<given-names>D.J.</given-names>
</name>
</person-group>
<article-title>UDP glucuronosyltransferase (UGT) 1A6 pharmacogenetics: II. Functional impact of the three most common nonsynonymous UGT1A6 polymorphisms (S7A, T181A, and R184S)</article-title>
<source/>J. Pharmacol. Exp. Ther.
          <year>2015</year>
<volume>313</volume>
<fpage>1340</fpage>
<lpage>1346</lpage>
<pub-id pub-id-type="doi">10.1124/jpet.104.081968</pub-id>
</element-citation>
</ref>
<ref id="B189-pharmaceutics-12-00013">
<label>189.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mei</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Feng</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Zhu</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Gao</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Fang</surname>
<given-names>F.</given-names>
</name>
</person-group>
<article-title>Genetic polymorphisms and valproic acid plasma concentration in children with epilepsy on valproic acid monotherapy</article-title>
<source/>Seizure
          <year>2017</year>
<volume>51</volume>
<fpage>22</fpage>
<lpage>26</lpage>
<pub-id pub-id-type="doi">10.1016/j.seizure.2017.07.005</pub-id>
<pub-id pub-id-type="pmid">28763744</pub-id>
</element-citation>
</ref>
<ref id="B190-pharmaceutics-12-00013">
<label>190.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>L.Y.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>M.C.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>S.Y.</given-names>
</name>
</person-group>
<article-title>Correlation of the UGT1A4 gene polymorphism with serum concentration and therapeutic efficacy of lamotrigine in Han Chinese of Northern China</article-title>
<source/>Eur. J. Clin. Pharmacol.
          <year>2014</year>
<volume>70</volume>
<fpage>941</fpage>
<lpage>946</lpage>
<pub-id pub-id-type="doi">10.1007/s00228-014-1690-1</pub-id>
<pub-id pub-id-type="pmid">24820767</pub-id>
</element-citation>
</ref>
<ref id="B191-pharmaceutics-12-00013">
<label>191.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chung</surname>
<given-names>J.Y.</given-names>
</name>
<name>
<surname>Cho</surname>
<given-names>J.Y.</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>K.S.</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>J.R.</given-names>
</name>
<name>
<surname>Lim</surname>
<given-names>K.S.</given-names>
</name>
<name>
<surname>Sohn</surname>
<given-names>D.R.</given-names>
</name>
<name>
<surname>Shin</surname>
<given-names>S.G.</given-names>
</name>
<name>
<surname>Jang</surname>
<given-names>I.J.</given-names>
</name>
</person-group>
<article-title>Pharmacokinetic and pharmacodynamic interaction of lorazepam and valproic acid in relation to UGT2B7 genetic polymorphism in healthy subjects</article-title>
<source/>Clin. Pharmacol. Ther.
          <year>2008</year>
<volume>83</volume>
<fpage>595</fpage>
<lpage>600</lpage>
<pub-id pub-id-type="doi">10.1038/sj.clpt.6100324</pub-id>
<pub-id pub-id-type="pmid">17687269</pub-id>
</element-citation>
</ref>
<ref id="B192-pharmaceutics-12-00013">
<label>192.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>X.Q.</given-names>
</name>
<name>
<surname>Cai</surname>
<given-names>W.K.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>G.L.</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>M.D.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>He</surname>
<given-names>G.H.</given-names>
</name>
</person-group>
<article-title>Effect of UGT2B7 genotypes on plasma concentration of valproic acid: A meta-analysis</article-title>
<source/>Eur. J. Clin. Pharmacol.
          <year>2018</year>
<volume>74</volume>
<fpage>433</fpage>
<lpage>442</lpage>
<pub-id pub-id-type="doi">10.1007/s00228-017-2395-z</pub-id>
<pub-id pub-id-type="pmid">29243113</pub-id>
</element-citation>
</ref>
<ref id="B193-pharmaceutics-12-00013">
<label>193.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Milosheska</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Lorber</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Vovk</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Kastelic</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Dolžan</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Grabnar</surname>
<given-names>I.</given-names>
</name>
</person-group>
<article-title>Pharmacokinetics of lamotrigine and its metabolite N-2-glucuronide: Influence of polymorphism of UDP-glucuronosyltransferases and drug transporters</article-title>
<source/>Br. J. Clin. Pharmacol.
          <year>2016</year>
<volume>82</volume>
<fpage>399</fpage>
<lpage>411</lpage>
<pub-id pub-id-type="doi">10.1111/bcp.12984</pub-id>
<pub-id pub-id-type="pmid">27096250</pub-id>
</element-citation>
</ref>
</ref-list>
</back>
<floats-group>
<fig id="pharmaceutics-12-00013-f001" orientation="portrait" position="float">
<label>Figure 1</label>
<caption>
<p>Schematic diagram showing neuronal CNS pathways involved in mania-inducing side effects caused by the administration of a serotoninergic antidepressant when <italic>HTR2A</italic> is mutated (see text for more details).</p>
</caption>
<graphic xlink:href="pharmaceutics-12-00013-g001"></graphic>
</fig>
<fig id="pharmaceutics-12-00013-f002" orientation="portrait" position="float">
<label>Figure 2</label>
<caption>
<p>Proposed algorithm for drug use orientation in pharmacological treatment of bipolar spectrum disorders.</p>
</caption>
<graphic xlink:href="pharmaceutics-12-00013-g002"></graphic>
</fig>
<table-wrap id="pharmaceutics-12-00013-t001" orientation="portrait" position="float">
<object-id pub-id-type="pii">pharmaceutics-12-00013-t001_Table 1</object-id>
<label>Table 1</label>
<caption>
<p>SNPs relevant for the pharmacodynamics of drugs used for treatment of bipolar spectrum disorders.</p>
</caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">Gene</th>
<th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">Protein</th>
<th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">SNPs</th>
<th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">Drugs</th>
<th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">Results</th>
<th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">Level of Evidence (1A Strongest)</th>
<th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">Ref.</th>
</tr>
</thead>
<tbody>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
<italic>ADCY1</italic>
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Adenylate cyclase 1</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">rs1521470</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">lithium</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Patients with the AA genotype and bipolar affective disorder may have a decreased response to lithium as compared to patients with the AG or GG genotypes.</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">3</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B88-pharmaceutics-12-00013">88</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
<italic>ADCY2</italic>
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">adenylate cyclase 2</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">rs1544938<break></break>rs4702484 </td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">antipsychotics</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Patients with the CC genotype may have increased response to antipsychotics compared to patients with the GG genotype.</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">3</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B89-pharmaceutics-12-00013">89</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">
<italic>ADRB2</italic>
</td>
<td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">Adrenoceptor beta 2</td>
<td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">rs1042713<break></break>rs8050896 </td>
<td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">risperidone paliperidone</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Patients with the GG or AG genotype may have increased likelihood of sexual adverse events when treated with risperidone as compared to patients with the AA genotype.</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">3</td>
<td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B90-pharmaceutics-12-00013">90</xref>,<xref ref-type="bibr" rid="B91-pharmaceutics-12-00013">91</xref>]</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Patients with the TT genotype may have an increased response to risperidone as compared to patients with the AA or AT genotypes.</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">3</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
<italic>AKT1</italic>
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">AKT serine/threonine kinase 1</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">rs2494732</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">risperidone paliperidone</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Patients with the TT may have an increased response to risperidone as compared to patients with the CC or CT genotype.</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">3</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B92-pharmaceutics-12-00013">92</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
<italic>ANKK1</italic>
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Ankyrin repeat and kinase domain containing 1</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">rs1800497</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">valproic acid aripiprazole risperidone paliperidone</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Patients with the AA genotype may have increased risk of side effects including hyperprolactinemia and weight gain, but decreased risk of tardive dyskinesia, as compared to patients with the AG or (GG: increased risk of tardive dyskinesia) genotype.</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">2B</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B93-pharmaceutics-12-00013">93</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
<italic>ASIC2</italic>
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Acid sensing ion channel subunit 2</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">rs11869731</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">lithium</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Patients with the CC genotype may have a better response to lithium.</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">3</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B94-pharmaceutics-12-00013">94</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">
<italic>BDNF</italic>
</td>
<td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">Brain derived neurotrophic factor</td>
<td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">rs6265<break></break>rs11030104</td>
<td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">antipsychotics<break></break>antidepressants</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Patients with the AA genotype and schizophrenia may show less resistance to treatment with antipsychotics as compared to patients with the AG or GG genotype.</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">3</td>
<td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B25-pharmaceutics-12-00013">25</xref>,<xref ref-type="bibr" rid="B75-pharmaceutics-12-00013">75</xref>,<xref ref-type="bibr" rid="B95-pharmaceutics-12-00013">95</xref>]</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Patients with the CC genotype and depressive disorder may be more likely to respond to paroxetine but less likely to respond to citalopram or antidepressants as compared to patients with the CT or TT genotype.</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">3</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
<italic>CACNG2</italic>
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Calcium voltage-gated channel auxiliary subunit gamma 2</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">rs2284018<break></break>rs2284017 </td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">lithium</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Patients with the CC or CT genotype may be more likely to respond to lithium.</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">3</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B96-pharmaceutics-12-00013">96</xref>,<xref ref-type="bibr" rid="B97-pharmaceutics-12-00013">97</xref>] </td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
<italic>CCL2</italic>
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">C-C motif chemokine ligand 2</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">rs4586</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">risperidone paliperidone</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Patients with the GG genotype and schizophrenia may have a poorer response when treated with risperidone as compared to patients with the AA or AG genotype.</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">3</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B98-pharmaceutics-12-00013">98</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
<italic>CNR1</italic>
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Cannabinoid receptor 1</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">rs1049353<break></break>rs806378</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">aripiprazole clozapine haloperidol olanzapine quetiapine risperidone</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Patients with the CC genotype and psychotic disorders may have an increased likelihood of weight gain as compared to patients with the CT and CC genotypes.</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">3</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B99-pharmaceutics-12-00013">99</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="3" style="border-bottom:solid thin" valign="middle">
<italic>COMT</italic>
</td>
<td align="center" colspan="1" rowspan="3" style="border-bottom:solid thin" valign="middle">catechol-O-methyltransferase</td>
<td align="center" colspan="1" rowspan="3" style="border-bottom:solid thin" valign="middle">rs4818<break></break>rs4680<break></break>rs13306278</td>
<td align="center" colspan="1" rowspan="3" style="border-bottom:solid thin" valign="middle">antipsychotics<break></break>SSRI</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Patients with the GG genotype may have a better response to treatment.</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">3</td>
<td align="center" colspan="1" rowspan="3" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B100-pharmaceutics-12-00013">100</xref>,<xref ref-type="bibr" rid="B101-pharmaceutics-12-00013">101</xref>]</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Patients with the AA genotype may have increased blood pressure when treated with antipsychotics as compared to patients with the GG genotype.</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">3</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Patients with the CC genotype may have increased likelihood of remission when treated with Selective serotonin reuptake inhibitors compared to patients with the TT or CT genotype.</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">2B</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
<italic>CPS1</italic>
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Carbamoyl-phosphate synthase 1</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">complete gene sequencing</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">valproic acid<break></break>Testing suggested by FDA and PMDA </td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Valproic acid is contraindicated in patients with known urea cycle disorders (UCDs), due to a risk for severe hyperammonemia. UCDs result from mutations in one of several genes, such as carbamoyl-phosphate synthetase 1 (CPS1) deficiency.</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">none</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B102-pharmaceutics-12-00013">102</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
<italic>DRD1</italic>
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Dopamine receptor D1</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">rs4532 </td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">lithium</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Patients with the TT genotype may have an increased response to lithium as compared to patients with the CC genotype.</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">4</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B103-pharmaceutics-12-00013">103</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
<italic>DRD2</italic>
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Dopamine receptor D2</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">rs1800497<break></break>rs1799978 </td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">antipsychotics</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Patients with the AA genotype may have increased risk of side effects including hyperprolactinemia and weight gain, but decreased risk of tardive dyskinesia, during treatment with antipsychotic drugs as compared to patients with the AG or GG genotype.</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">2B</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B93-pharmaceutics-12-00013">93</xref>,<xref ref-type="bibr" rid="B104-pharmaceutics-12-00013">104</xref>,<xref ref-type="bibr" rid="B105-pharmaceutics-12-00013">105</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
<italic>DRD3</italic>
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Dopamine receptor D3</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">rs6280</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">quetiapine</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">People with TT genotype may have increased clearance of quetiapine compared with people with genotypes CC or CT.</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">3</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B106-pharmaceutics-12-00013">106</xref>,<xref ref-type="bibr" rid="B107-pharmaceutics-12-00013">107</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
<italic>EPM2A</italic>
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">EPM2A, laforin glucan phosphatase</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">rs1415744 </td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">chlorpromazine clozapine<break></break>haloperidol olanzapine quetiapine risperidone </td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Patients with the CC genotype and schizophrenia may have increased response to chlorpromazine, clozapine, haloperidol, olanzapine, quetiapine, and risperidone compared to patients with the CT and TT genotypes.</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">3</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B108-pharmaceutics-12-00013">108</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
<italic>FAAH</italic>
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Fatty acid amide hydrolase</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">rs324420 </td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">aripiprazole clozapine haloperidol<break></break>olanzapine quetiapine risperidone</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Patients with the AA genotype and psychotic disorders who are treated with aripiprazole, clozapine, haloperidol, olanzapine, quetiapine, or risperidone may have an increased likelihood of weight gain of more than 7% of baseline body weight as compared to patients with the CC genotype.</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">3</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B109-pharmaceutics-12-00013">109</xref>,<xref ref-type="bibr" rid="B110-pharmaceutics-12-00013">110</xref>,<xref ref-type="bibr" rid="B111-pharmaceutics-12-00013">111</xref>,<xref ref-type="bibr" rid="B112-pharmaceutics-12-00013">112</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
<italic>FAM177A1</italic>
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Family with sequence similarity 177 member A1</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">rs79403677 </td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">lithium</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Patients with the GG genotype and bipolar affective disorder may have an increased response to lithium as compared to patients with the GT or TT genotypes.</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">3</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B88-pharmaceutics-12-00013">88</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
<italic>FAM178B</italic>
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Family with sequence similarity 178 member B</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">rs6728642 </td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">lithium</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Patients with the AA genotype and bipolar affective disorder may have a decreased response to lithium as compared to patients with the AG or GG genotypes.</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">3</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B88-pharmaceutics-12-00013">88</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
<italic>FKBP5</italic>
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">FKBP prolyl isomerase 5</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">rs1360780</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">clomipramine lithium<break></break>paroxetine venlafaxine</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Patients with the CC genotype may (1) have decreased response to antidepressants (2) have decreased, but not absent, risk for suicide ideation with paroxetine, venlafaxine, clomipramine, and lithium, as compared to patients with the CT or TT genotype.</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">2B</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B103-pharmaceutics-12-00013">103</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
<italic>GABRA1</italic>
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Gamma-aminobutyric acid type A receptor alpha1 subunit</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">rs2279020</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">carbamazepine phenytoin<break></break>valproic acid</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Patients with the GG genotype treated with antipsychotics may have increased risk for drug-resistance as compared to patients with the AA genotype.</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">3</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B113-pharmaceutics-12-00013">113</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
<italic>GADL1</italic>
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">glutamate decarboxylase like 1</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">rs17026688 </td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">lithium</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Allele T is associated with increased response to lithium when treated with lithium in people with bipolar disorder as compared to allele C.</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">none</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B90-pharmaceutics-12-00013">90</xref>,<xref ref-type="bibr" rid="B114-pharmaceutics-12-00013">114</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
<italic>GNB3</italic>
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">G protein subunit beta 3</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">rs5443 </td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">risperidone paliperidone<break></break>olanzapine</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Patients with the CC genotype and schizophrenia who are treated with olanzapine may have a decreased, but not absent, risk of weight gain as compared to patients with the CT or TT genotype.</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">3</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B115-pharmaceutics-12-00013">115</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
<italic>GRAMD1B</italic>
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">GRAM domain containing 1B</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">rs61123830 </td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">lithium</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Patients with the AA genotype and bipolar affective disorder may have a decreased response to lithium as compared to patients with the AG or GG genotypes.</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">3</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B88-pharmaceutics-12-00013">88</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
<italic>GRID2</italic>
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Glutamate ionotropic receptor delta type subunit 2</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">rs1875705 </td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">risperidone paliperidone</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Patients with the GG genotype may have an increased response to risperidone as compared to patients with the AA and AG genotypes.</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">3</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B116-pharmaceutics-12-00013">116</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="4" style="border-bottom:solid thin" valign="middle">
<italic>GRIN2B</italic>
</td>
<td align="center" colspan="1" rowspan="4" style="border-bottom:solid thin" valign="middle">Glutamate ionotropic receptor NMDA type subunit 2B</td>
<td align="center" colspan="1" rowspan="4" style="border-bottom:solid thin" valign="middle">rs1806201<break></break>rs1019385<break></break>rs1072388</td>
<td align="center" colspan="1" rowspan="4" style="border-bottom:solid thin" valign="middle">risperidone quetiapine<break></break>valproic acid clozapine</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Patients with the GG genotype who are treated with risperidone may have an increased likelihood of adverse reactions as compared to patients with the AA or AG genotype.</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">3</td>
<td align="center" colspan="1" rowspan="4" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B117-pharmaceutics-12-00013">117</xref>]</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Patients with the AA genotype who are treated with quetiapine may have an increased likelihood of neurological adverse reactions and sleepiness as compared to patients with the AG or GG genotype.</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">3</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Patients with the CC genotype and epilepsy may require a decreased dose of valproic acid as compared to patients with the AA or AC genotype.</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">3</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Patients with the GG genotype and schizophrenia may have a worse response when treated with clozapine as compared to patients with the AA or AG genotype.</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">3</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
<italic>GRM3</italic>
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Glutamate metabotropic receptor 3</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">rs724226 </td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">risperidone paliperidone</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Patients with the GG genotype who are treated with risperidone may have more improvement in symptoms as compared to patients with the AA genotype.</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">3</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B118-pharmaceutics-12-00013">118</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
<italic>GRM7</italic>
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Glutamate metabotropic receptor 7</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">rs2069062 </td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">risperidone paliperidone</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Patients with the CC genotype may have increased response to risperidone as compared to patients with the CG and GG genotypes.</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">3</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B116-pharmaceutics-12-00013">116</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
<italic>GSK3B</italic>
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Glycogen synthase kinase 3 beta</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">rs334558<break></break>rs6438552 </td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">lithium</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Patients with the AA genotype and bipolar disorder may be less likely to respond to lithium as compared to patients with the GG or AG genotype.</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">3</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B119-pharmaceutics-12-00013">119</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
<italic>HLA-A</italic>
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Major histocompatibility complex, class I, A</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">HLA-A*02:07:01<break></break>HLA-A*30:01:01<break></break>HLA-A*33:03<break></break>HLA-A*33:03:01<break></break>HLA-A*68:01:01:01 </td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">carbamazepine<break></break>valproic acid lamotrigine topiramate</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Increased risk of severe cutaneous adverse reactions.</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">2B</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B120-pharmaceutics-12-00013">120</xref>,<xref ref-type="bibr" rid="B121-pharmaceutics-12-00013">121</xref>,<xref ref-type="bibr" rid="B122-pharmaceutics-12-00013">122</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
<italic>HLA-A</italic>
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Major histocompatibility complex, class I, A</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">HLA-A*31:01:02 </td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">carbamazepine<break></break><italic>Testing recommended by HCSC and suggested by FDA and PMDA</italic></td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Increased risk of severe cutaneous adverse reactions.</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">1A</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B70-pharmaceutics-12-00013">70</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
<italic>HLA-B</italic>
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Major histocompatibility complex, class I, B</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">HLA-B*13:02:01<break></break>HLA-B*38:01:01 </td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">carbamazepine<break></break>valproic acid lamotrigine topiramate</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Increased risk of Stevens–Johnson syndrome, toxic epidermal necrolysis, and maculopapular exanthema.</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">3</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B123-pharmaceutics-12-00013">123</xref>,<xref ref-type="bibr" rid="B124-pharmaceutics-12-00013">124</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
<italic>HLA-B</italic>
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Major histocompatibility complex, class I, B</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">HLA-B*15:02:01 </td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">carbamazepine<break></break><italic>Testing required by FDA and suggested by PMDA</italic>
</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Increased risk of Stevens–Johnson syndrome and toxic epidermal necrolysis.</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">1A</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B123-pharmaceutics-12-00013">123</xref>,<xref ref-type="bibr" rid="B125-pharmaceutics-12-00013">125</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
<italic>HLA-C</italic>
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Major histocompatibility complex, class I, C</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">HLA-C*07:18<break></break>HLA-C*08:01</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">carbamazepine valproic acid lamotrigine topiramate</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Increased risk of Stevens–Johnson syndrome and toxic epidermal necrolysis.</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">3</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B122-pharmaceutics-12-00013">122</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
<italic>HLA-DQB1</italic>
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Major histocompatibility complex, class II, DQ beta 1</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">HLA-DQB1*06:09 </td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">carbamazepine valproic acid lamotrigine topiramate</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Increased risk of severe cutaneous adverse reactions.</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">none</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B122-pharmaceutics-12-00013">122</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
<italic>HLA-DRB1</italic>
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">major histocompatibility complex, class II, DR beta 1</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">HLA-DRB1*13:01:01 </td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">carbamazepine valproic acid lamotrigine topiramate</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Increased risk of severe cutaneous adverse reactions.</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">none</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B122-pharmaceutics-12-00013">122</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
<italic>HNF4A</italic>
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Hepatocyte nuclear factor 4 alpha</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">rs2071197 </td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">lamotrigine</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Patients with the AA genotype may have decreased concentrations of lamotrigine compared to patients with the AG and GG genotypes.</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">3</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B115-pharmaceutics-12-00013">115</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
<italic>HRH3</italic>
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Histamine receptor H3</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">rs3787429<break></break>rs3787430 </td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">risperidone paliperidone</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Patients with the TT genotype and schizophrenia may have a better response when treated with risperidone as compared to patients with the CC or CT genotype.</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">3</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B126-pharmaceutics-12-00013">126</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
<italic>HRH4</italic>
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Histamine receptor H4</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">rs4483927 </td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">risperidone paliperidone</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Patients with the TT genotype and schizophrenia may have a poorer response when treated with risperidone as compared to patients with the GT or GG genotype.</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">3</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B127-pharmaceutics-12-00013">127</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">
<italic>HTR1A</italic>
</td>
<td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">5-Hydroxytryptamine Receptor 1A</td>
<td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">rs6295<break></break>rs10042486<break></break>rs1364043 </td>
<td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">antidepressants<break></break>amisulpride olanzapine quetiapine risperidone</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Patients with the CC genotype may have a decreased likelihood of response to antidepressants as compared to patients with the GG or CG genotype.</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">3</td>
<td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B128-pharmaceutics-12-00013">128</xref>,<xref ref-type="bibr" rid="B129-pharmaceutics-12-00013">129</xref>,<xref ref-type="bibr" rid="B130-pharmaceutics-12-00013">130</xref>]</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Patients with the TT genotype and schizophrenia may have a better response when treated with antipsychotics, including amisulpride, olanzapine, quetiapine, and risperidone, as compared to patients with the CC or CT genotype.</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">3</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
<italic>HTR1B</italic>
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">5-hydroxytryptamine receptor 1B</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">rs130058</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">clomipramine liothyronine<break></break>lithium<break></break>nefazodone venlafaxine</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Patients with the AA genotype and depression who are treated with clomipramine, liothyronine, lithium, nefazodone, or venlafaxine may have an increased risk for suicidal ideation as compared to patients with the TT genotype.</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">3</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B25-pharmaceutics-12-00013">25</xref>,<xref ref-type="bibr" rid="B75-pharmaceutics-12-00013">75</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="3" style="border-bottom:solid thin" valign="middle">
<italic>HTR2A</italic>
</td>
<td align="center" colspan="1" rowspan="3" style="border-bottom:solid thin" valign="middle">5-Hydroxytryptamine Receptor 2A</td>
<td align="center" colspan="1" rowspan="3" style="border-bottom:solid thin" valign="middle">rs7997012<break></break>rs9567733<break></break>rs6314</td>
<td align="center" colspan="1" rowspan="3" style="border-bottom:solid thin" valign="middle">citalopram<break></break>antipsychotics<break></break>antidepressants</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Patients with the AA genotype who are treated with citalopram may be more likely to have improvement in symptoms as compared to patients with the GG genotype. </td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">2B</td>
<td align="center" colspan="1" rowspan="3" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B25-pharmaceutics-12-00013">25</xref>,<xref ref-type="bibr" rid="B75-pharmaceutics-12-00013">75</xref>]</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Patients with the AA genotype and first episode psychosis (FEP) may have a decreased risk for extrapyramidal symptoms when treated with antipsychotics as compared to patients with the AG or GG genotype.</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">3</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Patients with the AA genotype who are treated with antidepressants and other treatments may have a reduced response and reduced likelihood of remission as compared to patients with the AG or GG genotype.</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">3</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">
<italic>HTR2C</italic>
</td>
<td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">5-Hydroxytryptamine Receptor 2C</td>
<td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">rs1414334<break></break>rs3813929</td>
<td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">antipsychotics </td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Male patients with the C genotype and female patients with the CC genotype may have an increased risk of developing metabolic syndrome and weight gain.</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">2B</td>
<td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B131-pharmaceutics-12-00013">131</xref>,<xref ref-type="bibr" rid="B132-pharmaceutics-12-00013">132</xref>,<xref ref-type="bibr" rid="B133-pharmaceutics-12-00013">133</xref>,<xref ref-type="bibr" rid="B134-pharmaceutics-12-00013">134</xref>,<xref ref-type="bibr" rid="B135-pharmaceutics-12-00013">135</xref>] </td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Male patients with the C genotype who are treated with antipsychotics may have an increased risk of weight gain as compared to patients with the T genotype.</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">2B</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
<italic>KCNMA1</italic>
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Potassium calcium-activated channel subfamily M alpha 1</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">rs35793 </td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">quetiapine</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Allele G is associated with response to quetiapine.</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">none</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B136-pharmaceutics-12-00013">136</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
<italic>LEP</italic>
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Leptin</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">rs7799039<break></break>rs4731426</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">risperidone paliperidone olanzapine</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Patients with the GG genotype may have an increased likelihood of weight gain when taking antipsychotics.</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">3</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B137-pharmaceutics-12-00013">137</xref>,<xref ref-type="bibr" rid="B138-pharmaceutics-12-00013">138</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">
<italic>LEPR</italic>
</td>
<td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">Leptin receptor</td>
<td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">rs1137101 </td>
<td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">valproic acid<break></break>antipsychotics</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Patients with the GG genotype and epilepsy may have lower weight gain when treated with valproic acid as compared to patients with the AA or AG genotype.</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">3</td>
<td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B139-pharmaceutics-12-00013">139</xref>]</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Female patients with the GG genotype may have an increased likelihood of weight gain when treated with antipsychotics as compared to patients with the AA genotype.</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">3</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">
<italic>MC4R</italic>
</td>
<td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">Melanocortin 4 receptor</td>
<td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">rs489693<break></break>rs17782313 </td>
<td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">antipsychotics</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Patients with the CC genotype and disorders requiring antipsychotic treatment may have an increased risk of weight gain when treated with antipsychotics as compared to patients with the TT genotype.</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">2B</td>
<td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B140-pharmaceutics-12-00013">140</xref>,<xref ref-type="bibr" rid="B141-pharmaceutics-12-00013">141</xref>]</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Patients with the AA genotype may have an increased likelihood of weight gain and hypertriglyceridemia when taking antipsychotics as compared to patients with the AC and CC genotypes.</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">2B</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
<italic>MYO1H</italic>
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Myosin IH</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">rs7959663 </td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">lithium</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Patients with the CC genotype and bipolar affective disorder may have a decreased response to lithium as compared to patients with the CG or GG genotypes.</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">3</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B88-pharmaceutics-12-00013">88</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">
<italic>NR1D1</italic>
</td>
<td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">Nuclear receptor subfamily 1 group D member 1</td>
<td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">rs2314339<break></break>rs2071427</td>
<td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">lithium</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Patients with the CC or CT genotype and bipolar disorder may be more likely to respond to lithium as compared to patients with the TT genotype.</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">3</td>
<td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B142-pharmaceutics-12-00013">142</xref>,<xref ref-type="bibr" rid="B143-pharmaceutics-12-00013">143</xref>]</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Patients with the CC genotype and bipolar disorder may be less likely to respond to lithium as compared to patients with the TT genotype.</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">3</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">
<italic>NR1I2</italic>
</td>
<td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">Nuclear receptor subfamily 1 group I member 2</td>
<td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">rs7643645<break></break>rs2276707 </td>
<td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">risperidone paliperidone</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Patients with the AA genotype may have increased levels of the active metabolite of risperidone, 9-hydroxy-risperidone, as compared to those with the GG genotype.</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">3</td>
<td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B144-pharmaceutics-12-00013">144</xref>,<xref ref-type="bibr" rid="B145-pharmaceutics-12-00013">145</xref>,<xref ref-type="bibr" rid="B146-pharmaceutics-12-00013">146</xref>]</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Patients with the CC genotype and psychiatric disorders may have decreased clearance of risperidone compared to patients with the CT or TT genotypes.</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">3</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">
<italic>NTRK2</italic>
</td>
<td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">Neurotrophic tyrosine kinase receptor type 2</td>
<td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">rs1387923<break></break>rs2769605<break></break>rs10465180 </td>
<td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">lithium<break></break>valproic acid<break></break>clozapine</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Patients with the AA genotype and bipolar disorder may have increased response to lithium as compared to patients with the AG or GG genotype.</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">4</td>
<td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B144-pharmaceutics-12-00013">144</xref>]</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Patients with the CC genotype and schizophrenia who are treated with clozapine may have a decreased response to clozapine as compared to patients with the CT or TT genotype.</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">3</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
<italic>OR52E2</italic>
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Olfactory receptor family 52 subfamily E member 2</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">rs16909440</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">lithium</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Patients with the CC genotype and bipolar disorder may have a poorer response to treatment with lithium as compared to patients with the CT or TT genotype.</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">3</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B94-pharmaceutics-12-00013">94</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
<italic>OTC</italic>
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Ornithine carbamoyltransferase</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">complete gene sequencing</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">valproic acid<break></break><italic>Testing suggested by FDA and PMDA</italic>
</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Valproic acid is contraindicated in patients with known urea cycle disorders (UCD) due to a risk for severe hyperammonemia. UCDs result from mutations in one of several genes, such as ornithine transcarbamylase (OTC).</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">none</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B102-pharmaceutics-12-00013">102</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">
<italic>PDE4D</italic>
</td>
<td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">Phosphodiesterase 4D</td>
<td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">rs2164660<break></break>rs17382202 </td>
<td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">quetiapine</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Patients with the AA genotype may have an increased response to quetiapine as compared to patients with the AG or GG genotypes.</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">3</td>
<td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B90-pharmaceutics-12-00013">90</xref>]</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Patients with the CC genotype may have a decreased response to quetiapine as compared to patients with the CT or TT genotypes.</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">3</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
<italic>POLG</italic>
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">DNA polymerase gamma, catalytic subunit</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">complete gene sequencing</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">divalprovex<break></break>valproic acid<break></break><italic>Testing required by FDA and HCSC</italic>
</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Patients with the AA or AT may have an increased risk of hepatotoxicity as compared to patients with the CC genotype.</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">3</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B102-pharmaceutics-12-00013">102</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
<italic>PPA2</italic>
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Pyrophosphatase (inorganic) 2</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">rs2636719 </td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">risperidone paliperidone</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Patients with the CC genotype may have an increased response to risperidone as compared to patients with the AA or AC genotypes.</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">3</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B90-pharmaceutics-12-00013">90</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
<italic>RGS4</italic>
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Regulator of G protein signaling 4</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">rs2661319<break></break>rs951439 </td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">risperidone paliperidone</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Patients with the CT genotype treated with risperidone may have more improvement in symptoms as compared to the CC genotype or may have less improvement in symptoms as compared to the TT genotype.</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">3</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B147-pharmaceutics-12-00013">147</xref>,<xref ref-type="bibr" rid="B148-pharmaceutics-12-00013">148</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
<italic>RIMS1</italic>
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Regulating synaptic membrane exocytosis 1</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">rs502046 </td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">quetiapine</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Genotypes CC + CT are associated with decreased likelihood of discontinuation when treated with quetiapine.</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">none</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B149-pharmaceutics-12-00013">149</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">
<italic>SCN1A</italic>
</td>
<td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">Sodium voltage-gated channel alpha subunit 1</td>
<td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">rs2298771<break></break>rs3812718 </td>
<td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">carbamazepine phenytoin<break></break>valproic acid lamotrigine topiramate oxcarbazepine</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Patients with the CC genotype who are treated with mono or combination antiepileptic therapy may have an improved response.</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">3</td>
<td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B150-pharmaceutics-12-00013">150</xref>,<xref ref-type="bibr" rid="B151-pharmaceutics-12-00013">151</xref>,<xref ref-type="bibr" rid="B152-pharmaceutics-12-00013">152</xref>]</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Patients with the CC genotype who are treated with phenytoin may require a lower dose.</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">2B</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
<italic>SCN2A</italic>
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Sodium voltage-gated channel alpha subunit 2</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">rs17183814<break></break>rs2304016 </td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">carbamazepine valproic acid lamotrigine</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Patients with the GG genotype may be more likely to respond.</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">3</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B153-pharmaceutics-12-00013">153</xref>,<xref ref-type="bibr" rid="B154-pharmaceutics-12-00013">154</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
<italic>SLC18A2</italic>
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">solute carrier family 18 member 2</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">rs363224 </td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">antipsychotics</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Genotypes AC + CC is associated with increased risk of tardive dyskinesia when treated with antipsychotics.</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">none</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B155-pharmaceutics-12-00013">155</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
<italic>SLC1A1</italic>
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Solute carrier family 1 member 1</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">rs3780412 </td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">clozapine<break></break>olanzapine risperidone paliperidone</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Allele C is associated with increased risk of obsessive-compulsive symptoms when treated with clozapine, olanzapine, and risperidone.</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">none</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B156-pharmaceutics-12-00013">156</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
<italic>SLC22A8</italic>
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Solute carrier family 22 member 8</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">rs2276299 </td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">risperidone paliperidone</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Allele A is not associated with risk of hyperprolactinemia when treated with risperidone in children.</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">none</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B157-pharmaceutics-12-00013">157</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
<italic>SLC6A4</italic>
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Solute carrier family 6 member 4</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">SLC6A4 HTTLPR long form (L allele)<break></break>SLC6A4 HTTLPR short form (S allele)</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">antidepressants</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">HTTLPR short form (S allele)/HTTLPR long form (L allele) + HTTLPR short form (S allele)/HTTLPR short form (S allele) is associated with non-response when treated with antidepressants in people with mood disorders as compared to SLC6A4 HTTLPR long form (L allele)/HTTLPR long form (L allele).</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">2B, 3</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B75-pharmaceutics-12-00013">75</xref>,<xref ref-type="bibr" rid="B93-pharmaceutics-12-00013">93</xref>,<xref ref-type="bibr" rid="B100-pharmaceutics-12-00013">100</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
<italic>TAAR6</italic>
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Trace amine associated receptor 6</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">rs4305746 </td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">aripiprazole</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Patients with the AA genotype may have faster improvement in brief psychiatric rating scale (BPRS) scores when treated with aripiprazole as compared to patients with the GG genotype.</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">3</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B158-pharmaceutics-12-00013">158</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
<italic>TNFRSF11A</italic>
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">TNF receptor superfamily member 11a</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">rs2980976 </td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">risperidone paliperidone</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Patients with schizophrenia and the AA genotype may have a decreased response to risperidone as compared to patients with the AG or GG genotypes.</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">3</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B90-pharmaceutics-12-00013">90</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
<italic>TPH1</italic>
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Tryptophan hydroxylase 1</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">rs1799913 </td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">lithium</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Genotype TT is associated with decreased response to lithium in people with bipolar disorder.</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">none</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B159-pharmaceutics-12-00013">159</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
<italic>TPH2</italic>
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Tryptophan hydroxylase 2</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">rs1487278<break></break>rs2171363<break></break>rs17110747 </td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">quetiapine </td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Patients with the CC or CT genotype may respond better to antidepressant treatments as compared to patients with the TT genotype.</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">3</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B160-pharmaceutics-12-00013">160</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
<italic>TYMS</italic>
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Thymidylate synthetase</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">rs3786362 </td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">risperidone paliperidone</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Allele A is associated with increased risk of hyperprolactinemia when treated with risperidone.</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">none</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B114-pharmaceutics-12-00013">114</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
<italic>ZNF804A</italic>
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">zinc finger protein 804A</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">rs62200793 </td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">lithium</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Patients with the CC genotype and bipolar affective disorder may have a decreased response to lithium as compared to patients with the CT or TT genotypes.</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">3</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B88-pharmaceutics-12-00013">88</xref>]</td>
</tr>
</tbody>
</table>
</table-wrap>
<table-wrap id="pharmaceutics-12-00013-t002" orientation="portrait" position="float">
<object-id pub-id-type="pii">pharmaceutics-12-00013-t002_Table 2</object-id>
<label>Table 2</label>
<caption>
<p>SNPs relevant for pharmacokinetics of drugs used for treatment of bipolar spectrum disorders.</p>
</caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">Gene</th>
<th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">Protein</th>
<th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">SNPs</th>
<th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">Drugs</th>
<th align="right" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">Results</th>
<th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">Level of Evidence (1A Strongest)</th>
<th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">Ref.</th>
</tr>
</thead>
<tbody>
<tr>
<td align="center" colspan="1" rowspan="3" style="border-bottom:solid thin" valign="middle">
<italic>ABCB1</italic>
</td>
<td align="center" colspan="1" rowspan="3" style="border-bottom:solid thin" valign="middle">ATP binding cassette subfamily B member 1</td>
<td align="center" colspan="1" rowspan="3" style="border-bottom:solid thin" valign="middle">rs2032582<break></break>rs1045642<break></break>rs1128503 </td>
<td align="center" colspan="1" rowspan="3" style="border-bottom:solid thin" valign="middle">carbamazepine phenobarbital phenytoin valproic acid<break></break>amisulpiride aripiprazole olanzapine risperidone paliperidone</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Patients with the CC genotype may have decreased risk for non-response as compared to patients with the TT genotype.</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">3</td>
<td align="center" colspan="1" rowspan="3" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B164-pharmaceutics-12-00013">164</xref>,<xref ref-type="bibr" rid="B165-pharmaceutics-12-00013">165</xref>,<xref ref-type="bibr" rid="B166-pharmaceutics-12-00013">166</xref>,<xref ref-type="bibr" rid="B167-pharmaceutics-12-00013">167</xref>,<xref ref-type="bibr" rid="B168-pharmaceutics-12-00013">168</xref>]</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Patients with the AA genotype may have decreased concentrations of oxcarbazepine and worse response as compared to patients with the AG and GG genotypes.</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">3</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Patients with the AA genotype who responded to treatment with antipsychotics may require a decreased dose of antipsychotics as compared to patients with the CC genotype.</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">3</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
<italic>ABCG2</italic>
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">ATP binding cassette subfamily G member</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">rs2231142<break></break>rs3114020 </td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">risperidone paliperidone lamotrigine</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Patients with the CC genotype may have increased concentrations of lamotrigine compared to patients with the TT genotype.</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">3</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B169-pharmaceutics-12-00013">169</xref>,<xref ref-type="bibr" rid="B170-pharmaceutics-12-00013">170</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
<italic>APEH</italic>
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Acylaminoacyl-peptide hydrolase</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">rs3816877 </td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">valproic acid divalproex</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Genotype CC is associated with increased concentrations of valproic acid in people with Epilepsy as compared to genotype CT.</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">none</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B171-pharmaceutics-12-00013">171</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
<italic>CYP1A1</italic>
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Cytochrome P450 family 1 subfamily A member 1</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">rs2606345 </td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">valproic acid, divalproex</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Female patients with the AA genotype may have a poorer response when treated with antiepileptic drugs as compared to patients with the AC or CC genotype.</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">3</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B172-pharmaceutics-12-00013">172</xref>,<xref ref-type="bibr" rid="B173-pharmaceutics-12-00013">173</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
<italic>CYP1A2</italic>
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">cytochrome P450 family 1 subfamily A member 2</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">rs762551 </td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">antipsychotics chlorpromazinefluphenazine thioridazine trifluoperazine</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Patients with the AA genotype may have decreased QT interval when treated with antipsychotics, chlorpromazine, fluphenazine, thioridazine, and trifluoperazine as compared to patients with genotype CC or AC.</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">3</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B67-pharmaceutics-12-00013">67</xref>,<xref ref-type="bibr" rid="B174-pharmaceutics-12-00013">174</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="3" style="border-bottom:solid thin" valign="middle"><italic>CYP2C19</italic> * </td>
<td align="center" colspan="1" rowspan="3" style="border-bottom:solid thin" valign="middle">cytochrome P450 family 2 subfamily C member 19</td>
<td align="center" colspan="1" rowspan="3" style="border-bottom:solid thin" valign="middle">CYP2C19 * 1<break></break>CYP2C19 * 17CYP2C19 * 2<break></break>CYP2C19 * 3<break></break>CYP2C19 * 4</td>
<td align="center" colspan="1" rowspan="3" style="border-bottom:solid thin" valign="middle">citalopram escitalopram<break></break>sertraline<break></break>clomipramine</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Patients with the CYP2C19 * 1/* 1 genotype who are treated with citalopram or escitalopram may have an increased drug clearance/metabolism as compared to patients with CYP2C19 * 2, * 3, or * 4 allele and a decreased drug clearance/metabolism as compared to patients with CYP2C19 * 1/* 17 or * 17/* 17 genotype.</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">1A</td>
<td align="center" colspan="1" rowspan="3" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B67-pharmaceutics-12-00013">67</xref>,<xref ref-type="bibr" rid="B175-pharmaceutics-12-00013">175</xref>,<xref ref-type="bibr" rid="B176-pharmaceutics-12-00013">176</xref>,<xref ref-type="bibr" rid="B177-pharmaceutics-12-00013">177</xref>]</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Patients with the * 1/* 1 diplotype who are treated with sertraline may have lower dose-corrected drug plasma concentrations and increased clearance as compared to patients with one or two CYP2C19 no alleles (* 1/* 2 or * 2/* 2, * 2/* 3).</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">1A</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Patients with the CYP2C19 * 1/* 1 genotype may have 1) increased metabolism of clomipramine as compared to patients with CYP2C19 * 2 and * 3 alleles, 2) increased plasma levels of clomipramine as compared to patients with the CYP2C19 * 17/* 17 genotype.</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">2A</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">
<italic>CYP2C9</italic>
</td>
<td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">cytochrome P450 family 2 subfamily C member 9</td>
<td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">CYP2C9 * 1<break></break>CYP2C9 * 2<break></break>CYP2C9 * 3</td>
<td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">valproic acid divalproex<break></break>olanzapine </td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Patients with the * 1/* 1 genotype and bipolar disorder and other psychotic disorders may have increased dose of valproic acid compared to patients with the * 1/* 2 and * 1/* 3 genotypes.</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">3</td>
<td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B67-pharmaceutics-12-00013">67</xref>,<xref ref-type="bibr" rid="B178-pharmaceutics-12-00013">178</xref>,<xref ref-type="bibr" rid="B179-pharmaceutics-12-00013">179</xref>]</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Individuals with the * 1/* 1 genotype were less likely to experience hypotension when receiving olanzapine as compared to individuals with the * 1/* 3, * 2/* 3 or * 3/* 6 genotype.</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">3</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="5" style="border-bottom:solid thin" valign="middle"><italic>CYP2D6</italic> * </td>
<td align="center" colspan="1" rowspan="5" style="border-bottom:solid thin" valign="middle">cytochrome P450 family 2 subfamily D member 6</td>
<td align="center" colspan="1" rowspan="5" style="border-bottom:solid thin" valign="middle">CYP2D6 * 1<break></break>CYP2D6 * 10<break></break>CYP2D6 * 1xNCYP2D6 * 2<break></break>CYP2D6 * 2xNCYP2D6 * 3<break></break>CYP2D6 * 4<break></break>CYP2D6 * 5<break></break>CYP2D6 * 6<break></break>rs3892097</td>
<td align="center" colspan="1" rowspan="5" style="border-bottom:solid thin" valign="middle">paroxetine<break></break>fluvoxamine<break></break>risperidone<break></break>clomipramine<break></break>quetiapine valproic acid divalproex aripiprazole<break></break><italic>Testing suggested by FDA, EMA, DPWG and HCSC for aripiprazole, risperidone</italic>
</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Patients with the CYP2D6 * 1/* 1 genotype who are treated with paroxetine may have (1) a decreased clearance of paroxetine as compared to patients with more than two functional CYP2D6 alleles (* 1xN, * 2xN) and (2) an increased clearance of paroxetine as compared to patients with two non-functional CYP2D6 alleles (* 3, * 4, * 5, * 6) or * 10/* 10 genotype.</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">1A</td>
<td align="center" colspan="1" rowspan="5" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B67-pharmaceutics-12-00013">67</xref>,<xref ref-type="bibr" rid="B180-pharmaceutics-12-00013">180</xref>,<xref ref-type="bibr" rid="B181-pharmaceutics-12-00013">181</xref>,<xref ref-type="bibr" rid="B182-pharmaceutics-12-00013">182</xref>,<xref ref-type="bibr" rid="B183-pharmaceutics-12-00013">183</xref>]</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Patients with the CYP2D6 * 1/* 1 genotype who are treated with fluvoxamine may have 1) decreased steady-state plasma concentration-to-dose (C/D) ratio as compared to patients with the * 1/* 5, * 1/* 10, * 5/* 10, * 10/* 10 genotype, 2) decreased plasma concentrations, 3) decreased risk of developing gastrointestinal side effects as compared to patients with the * 5/* 10, * 10/* 10 genotype, and 4) decreased AUC, Cmax and half-life time of fluvoxamine as compared to patients with two non-functional CYP2D6 alleles (poor metabolizer phenotypes).</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">1A</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Patients with the * 1 allele may have increased metabolism/clearance of risperidone as compared to patients with two reduced function alleles (* 10), one reduced function and one non-functional (* 4, * 5, or * 14) allele, or two non-functional alleles.</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">2A</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Patients with the CC genotype (CYP2D6 * 1/* 1) treated with tricyclic antidepressants (1) may have a decreased likelihood of switching treatment indicating a reduced risk of side effects (2) may require an increased dose of drug as compared to patients with the TT genotype (CYP2D6 * 4/* 4).</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">1A</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Patients with the CYP2D6 * 1/* 1 genotype treated with clomipramine may have (1) a decreased, but not absent, risk for side effects as compared to patients with the CYP2D6 * 4 allele, (2) increased plasma concentration of clomipramine and desmethyl clomipramine as compared to patients with a duplication of a functional CYP2D6 gene, (3) decreased plasma concentration of clomipramine and desmethyl clomipramine as compared to patients with two non-functional CYP2D6 alleles.</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">1A</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">
<italic>CYP3A4</italic>
</td>
<td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">cytochrome P450 family 3 subfamily A member 4</td>
<td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">rs35599367<break></break>rs2242480</td>
<td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">risperidone carbamazepine </td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Patients with the AG genotype may have reduced clearance of risperidone compared to patients with the GG genotype.</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">3</td>
<td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B67-pharmaceutics-12-00013">67</xref>,<xref ref-type="bibr" rid="B184-pharmaceutics-12-00013">184</xref>,<xref ref-type="bibr" rid="B185-pharmaceutics-12-00013">185</xref>]</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Patients with the CC genotype (CYP3A4 * 1/* 1) may have increased concentrations of carbamazepine as compared to patients with the CT (* 1/* 1G) or TT (* 1G/* 1G) genotype.</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">3</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
<italic>CYP3A43</italic>
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Cytochrome P450 family 3 subfamily A member 43</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">rs680055 </td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">aripiprazole clozapine haloperidol olanzapine quetiapine risperidone </td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Genotype CG is associated with increased response to antipsychotics, aripiprazole, clozapine, haloperidol, olanzapine, quetiapine, or risperidone in people with schizoaffective disorder or schizophrenia as compared to genotype CC.</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">none</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B186-pharmaceutics-12-00013">186</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">
<italic>CYP3A5</italic>
</td>
<td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">cytochrome P450 family 3 subfamily A member 5</td>
<td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">rs776746<break></break>rs10264272 </td>
<td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">olanzapine<break></break>carbamazepine</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Individuals with the * 1A/* 1A genotype may have increased area under the curve (AUC) of olanzapine as compared to Individuals with the * 3A/* 3A genotype.</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">3</td>
<td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B67-pharmaceutics-12-00013">67</xref>,<xref ref-type="bibr" rid="B187-pharmaceutics-12-00013">187</xref>]</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Patients with the CC genotype (CYP3A5 * 3/* 3) may have decreased clearance and increased concentrations of carbamazepine, and require lower doses of the drug, as compared to patients with the CT (* 1/* 3) or TT (* 1/* 1) genotype.</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">3</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
<italic>EPHX2</italic>
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">epoxide hydrolase 2</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">rs59724122 </td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">lithium</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Patients with the CC genotype and bipolar affective disorder may have a decreased response to lithium as compared to patients with the CT or TT genotypes.</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">3</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B88-pharmaceutics-12-00013">88</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">
<italic>UGT2B7</italic>
</td>
<td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">UDP glucuronosyltransferase family 2 member B7</td>
<td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">rs7438284<break></break>rs7668258<break></break>rs12233719<break></break>rs28365063 </td>
<td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">valproic acid divalproex lamotrigine<break></break>oxicarbazepine</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Patients with the CC genotype and epilepsy who are treated with valproic acid may have decreased concentrations of valproic acid as compared to patients with the TT genotypes.</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">3</td>
<td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B188-pharmaceutics-12-00013">188</xref>,<xref ref-type="bibr" rid="B189-pharmaceutics-12-00013">189</xref>,<xref ref-type="bibr" rid="B190-pharmaceutics-12-00013">190</xref>,<xref ref-type="bibr" rid="B191-pharmaceutics-12-00013">191</xref>,<xref ref-type="bibr" rid="B192-pharmaceutics-12-00013">192</xref>,<xref ref-type="bibr" rid="B193-pharmaceutics-12-00013">193</xref>]</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Patients with the AA genotype and epilepsy may have decreased clearance of lamotrigine compared to patients with the GG genotype.</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">3</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn>
<p>* see CPIC<sup>®</sup> Guideline for selective serotonin reuptake inhibitors and CYP2D6 and CYP2C19.</p>
</fn>
</table-wrap-foot>
</table-wrap>
</floats-group>
</article>
</pmc-articleset>